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Résumé : Les nouvelles exigences du 
diagnostic clinique et de la thérapeutique, 
particulièrement en termes d’examens au chevet 
du patient et en médecine de précision, ont 
conduit à une demande croissante d’analyses à 
la fois multiplexées et présentant un rendement 
important, et ce d’un grand nombre de 
biomolécules au sein d’un échantillon unique. 
La thèse se concentre sur le développement de 
biosenseurs multiplexés basés sur le transfert 
d’énergie par résonance de type Förster résolu 
en temps de complexes de lanthanide vers des 
colorants organiques ou des boîtes quantiques. 
Je présente plusieurs techniques novatrices 
permettant la détection simultanée et 
multiplexée de protéines biomarqueurs du  
cancer (récepteur du facteur de croissance 
épidermique) ou de microARNs (hsa-miR-20a-
5p, hsa-miR-20b-5p et hsa-miR-21-5p) avec de 
très faibles limites de détection. J’ai utilisé 
différentes stratégies afin d’obtenir des 
détections multiplexées telles la détection 
multiplexée spectrale basée sur les différents 
spectres d’émission de différents luminophores, 
et la détection multiplexée temporelle basée sur 
les durées de vie distinctes des états excités des 
luminophores. Ces travaux ne sont pas 
seulement une recherche appliquée qui peut être 
utilisée en diagnostic clinique, mais constituent 
également une recherche fondamentale sur le 
FRET résolu en temps qui ouvre de nouvelles 
perspectives de détection et augmente 
considérablement le nombre de biomarqueurs 
pouvant être détectés. 
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Abstract: The new mission of clinical 
diagnostics and therapeutics, especially in 
point-of-care testing and precision medicine, 
has led to an increasing demand for multiplex 
and high throughput analyses of large numbers 
of biomolecules within a single sample. The 
thesis focuses on developing multiplexed 
biosensors based on time-resolved Förster 
resonance energy transfer from lanthanide 
complexes to organic dyes or quantum dots. I 
present several new techniques to 
simultaneously and multiplexed detect cancer 
related protein biomarkers (human epidermal 
growth factor receptor) or microRNAs (hsa- 
miR-20a-5p, 
hsa-miR-20b-5p and hsa-miR-21-5p) with very 
low limits of detections. I have used different 
strategies to achieve multiplexed detections 
such as spectral multiplexed detection based on 
different emission spectra of different 
luminophores, and temporal multiplexed 
detection based on distinguishable excited-state 
lifetimes of luminophores. The work is not only 
an applied research that can be used in clinical 
diagnostics but also a fundamental research of 
time-resolved FRET, which opens a new 
dimension of detection and greatly increases 
the number of biomarkers that can be detected. 
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1. Introduction  
“You can match a blood transfusion to a blood type — that was an important discovery. 
What if matching a cancer cure to our genetic code was just as easy, just as standard? 
What if figuring out the right dose of medicine was as simple as taking our 
temperature?”  
Barack Obama, January 30, 2015 
The picture drawn above is desirable and exciting, nevertheless, not easy to achieve. 
What is the genetic code? What is the relationship between the cancer and the genetic 
code? How to choose an efficient cure? After the completion of the Human Genome 
Project in 2003, the first question can possibly be answered, however, the problem how 
the genetic code effects the development of cancer has not been fully figured out, on the 
other hand, new -omics studies such as proteomics, transcriptomics and metabolomics 
also need to be taken into account [1–3]. The new mission of clinical diagnostics and 
therapeutics especially in point-of-care diagnostic and precision medicine — more 
challenging for scientists, analysts and  clinicians, but more beneficial for the patients 
— has led to increasing demand for multiplex and high throughput analyses of large 
numbers of biomolecules (proteins, nucleic acids, metabolites) within a single sample [4–
6]. A multiplexed detection of potential biomarkers can not only achieve superior 
accuracy for clinical diagnostics but also provide more information for precision 
medicine [7]. Förster Resonance Energy Transfer (FRET) based applications are one of 
the most promising techniques that can meet almost all the demands for a fast, simple, 
multiplexed diagnostic [8]. FRET gains its popularity in the diagnostics field due to the 
strong distance dependence in the working distances of biomolecular interactions, which 
is around 1-20 nm [9]. FRET is a spectroscopic term and can be regarded as an 
additional deactivation process of an excited molecule (FRET donor), from which the 
resonant energy is transferred non-radiatively to a ground-state molecule (FRET 
acceptor) [10, 11]. When two different target-recognition molecules are conjugated with 
FRET donor and acceptor fluorophores, respectively, the presence of the target results in 
a close proximity of FRET donor and acceptor to provide a measurable change in the 
photophysical properties of FRET pair. The vast majorities of the FRET based assays 
are homogeneous in nature and are often as simple as “mix and measure”, which has 
catalyzed their spread in clinical diagnostics. Section 2.1 provides the necessary 
background for FRET and a short review of FRET-based applications. 
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Due to the increased application of FRET, many different kinds of fluorophore materials 
available have been used as FRET donor, acceptor or both [12]. Among the almost 
infinitive choices of FRET donors, FRET based on lanthanide terbium complex (LTC) as 
energy donor has several unique advantages for multiplexed biomolecular detection [13–
18]. LTC belongs to the lanthanide complexes family, and due to the forbidden 
intraconfigurational f–f transitions of the central lanthanide ions (common form of Ln3+), 
the lanthanide complexes provide distinguished photophysical properties, compared to 
other fluorophores, such as the multiple, characteristic narrow emission bands, and 
extremely long excited-state lifetimes, which can extend up to several milliseconds [19, 
20]. LTC is the optimal choice as a FRET donor among the lanthanide complexes family. 
Aside from large Förster distances for efficient FRET and extremely long excited-state 
lifetimes, which allow for time-resolved measurements (Section 2.2.4), a hallmark 
advantage of the use of LTC as FRET donor is the multiplexing capability [14, 21]. The 
four main emission bands of Tb are much better separated and therefore superior for 
spectral multiplexing; the long and distinguished decay time of the sensitized acceptors 
due to different FRET efficiencies provide a great potential for temporal multiplexing.  
The photophysical features of LTC offer promising multiplexing capability as a FRET 
donor, nevertheless, FRET acceptors perfectly matched into the two multiplexed 
configurations (spectral and temporal multiplexing) are the other key factors. QDs are 
semiconductor nanocrystals confining the excitons in all three dimensions [22]. Due to 
the quantum confinement effect, the photoluminescence (PL) of QDs can be tuned by 
their sizes, which means one can synthesize a series of QDs of different sizes and thus 
emissions [22, 23]. Narrow and symmetric emission profiles with full width at half 
maximum (FWHM) approximating  25-35 nm can be achieved with high-quality QDs 
[24]. This feature of QDs is very suitable for spectral multiplexing due to greatly 
reduced optical crosstalk among different detection channels (utilizing optical bandpass 
filters for light separation). Compared to traditional organic dyes, the application of QDs 
in FRET-based biosensing provides many other advantages for the challenging 
diagnostic requirements, including high brightness, remarkable photostability and large 
effective Stokes shift. Coupling LTC and QD into the FRET construct can take the 
advantages from both sides [25]. In recent studies of our group and others, we have 
shown that LTC-to-QD FRET assays can fulfill the necessary requirements for 
diagnostic tests even in challenging media such as serum or plasma, and multiplexed 
FRET between LTC and different QDs was demonstrated to sense multiple biomolecules 
based on spectral multiplexing, and up to quintuplicate LTC-to-QD FRET has already 
been realized.  
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For the spectral multiplexing, traditional organic dyes are usually not the best choices. 
Because of the obvious optical crosstalk of different dyes caused by their broad emission 
profiles, a correction is always needed to achieve efficient multiplexing. On the other 
hand, these organic dyes show promising physical properties to perform temporal 
multiplexing. Due to the small sizes, most organic dyes provide a single active site for 
conjugation with biomolecules, and more importantly they can be approximated as a 
point when we estimate the distance of FRET donor and acceptor. Well-estimated and 
controllable FRET donor to acceptor distances can then be achieved in biological 
systems for the temporal-multiplexed detection. The origin of the photophysical 
properties of the PL probes being used as FRET donor or acceptors in this work 
including LTCs (Section 2.2), QDs (Section 2.3) and organic dyes (Section 2.4) are 
briefly explained, together with their advantages and limitations in different FRET 
based applications. 
In this work, I have focused on two classes of very important biomarkers: protein 
biomarkers and microRNA (miRNA) biomarkers. Protein biomarkers have been applied 
in diagnostics long ago both in academic research and clinical application [6, 26, 27]. 
Circulating protein cancer biomarkers are those tumor-derived secretory proteins 
circulating in the blood. We chose the epidermal growth factor receptor family as a 
model for investigating the applicability of multiplexed FRET in immunoassays. 
Compared to proteins, miRNAs are much younger members of the biomarker family, but 
have shown great potential as next generation biomarkers [28]. More than 2,500 
miRNAs have been found in humans and they are involved in a large scale of gene 
expression control by interacting with target messenger RNA [29]. Physiological 
homeostasis of cells and tissues is maintained by complex regulation, and therefore 
miRNA dysregulation can lead to diseases such as cancer or cardiovascular diseases [30, 
31]. Circulating miRNAs are found to be very stable and have shown their fingerprint 
expression spectra of specific cancer types or disease-stages. A brief review of biomarker 
development and the importances of protein and miRNA biomarkers and their detection 
techniques is shown in Section 2.5. 
Following the background of this work, three individual studies are presented. Each 
chapter is corroborated with introduction, materials and methods, results and 
discussion, and conclusion. 
The first study presents a duplexed assay of two epidermal growth factor receptors 
EGFR and HER2 based on time-gated FRET from LTC to two commercial available QDs. 
The antibody provides high specific binding to the antigen and high affinity as well, 
however, it can be less practical from a FRET perspective due to the relatively large 
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dimensions of the resulting antibody–antigen–antibody complex [32]. FRET may benefit 
from alternative antibodies with the same specificity but decreased sizes. The fragment 
antigen-binding (Fab) fragment is a region on antibody composed of one constant and 
one variable domain of each of heavy and light chain that determines the specificity of 
binding to the antigen. Fab fragments can be generated in the laboratory based on 
enzyme cleavage of the antibody. A single-domain antibody (sdAb) is an antibody 
fragment consisting of a single monomeric variable antibody domain, which is the 
smallest antibody available to date [33]. To be used in a FRET configuration, two 
antibodies, which bind to different epitopes of the antigen, are conjugated with LTC and 
QD, respectively. Different covalent bioconjugation methods such as the N-
hydroxysuccinimide ester-primary amine coupling and maleimide-thiol/cysteine 
coupling were performed and compared. Taking advantage of the relatively easy 
manipulation of sdAb with terminal modification such as cysteines using standard 
molecular biology techniques [34], we could also perform oriented labeling and compared 
it with random labeling. A detailed spectroscopic characterization of the LTC and QD 
conjugates was performed before and after conjugation with different types of antibodies 
(mAb, Fab fragment and sdAb) using stationary UV/Vis absorption spectroscopy and 
steady-state and time-resolved luminescence spectroscopy to estimate the number of 
antibodies per luminophore and to verify any alteration of the photophysical properties 
due to the biomolecule conjugation. Based on a systematic investigation of different 
FRET immunoassays using all kinds of antibodies and two QDs with different emission 
wavelengths (eFluor 605/650 nanocrystals), we found that several aspects such as the 
sizes of the antibodies, their orientations on the QDs, the binding sites of antibodies on 
the antigens and the photophysical properties of QDs, all of these parameters affected 
the performances of the FRET measurements and we suggest that they should be taken 
into consideration when one designs FRET based immunoassays. We also show 
promising results for a simultaneously duplexed assay of EGFR and HER2. The 
homogeneous assays provided sub-nM (few ng/mL) detection limits for both EGFR and 
HER2 in 50 μL samples and have been designed for their application on an approved 
clinical diagnostics fluorescence microplate reader. 
In the second study, I first applied the spectral-multiplexed FRET assay (a single type of  
LTC to different QDs) to miRNA detection. Duo to the very short lengths of miRNAs, it 
is not preferable to use the traditional sandwich-structured hybridization (which is 
similar to the immunoassay presented above, where two different antibodies LTC or QD 
conjugates bind to the different epitopes of a single antigen), instead, the miRNA was 
recognized by a single DNA probe. The recognition principle of the LTC and QD probes 
and the miRNA biomarkers is based on RNA/DNA base pairing and stacking. The single 
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miRNA sensor contained a single QD with a short DNA strand (QD-DNA, 7-8 bases) and 
a LTC with a longer DNA strand (LTC-DNA, 30-31 bases), and QD-DNA could specially 
bind to one part of the LTC-DNA with metastability, which means the binding between 
them were not stable under certain conditions (room temperature for example). When 
the miRNA target was present, it specially bound to the other part of the LTC-DNA, and 
the hybridization of miRNA and LTC-DNA could stabilize the binding between the short 
QD-DNA and LTC-DNA based on the so-called stacking effect, and lead to the proximity 
of LTC and QD to perform FRET. For the multiplexed miRNAs assay, I designed three 
LTC-DNAs, which were specific to three miRNAs, and conjugated three commerical QDs, 
QD605, QD655 and QD705 (Qdot 605/655/705 ITK™ Streptavidin Conjugate Kits), with 
three short DNAs, respectively. In order to demonstrate full multiplexing functionality 
of our assay we have detected the three miRNAs hsa-miR-20a-5p (miRNA-20a, mir-20a), 
hsa-miR-20b-5p (miRNA-20b, mir-20b), and hsa-miR-21-5p (miRNA-21, mir-21), two of 
which contain only two base pair mismatches. The stacking effect showed very high 
capability to distinguish terminal mismatches between miRNA-20a and miRNA-20b. 
The multiplexed assay did neither require any washing or separation steps nor the 
addition of enzymes, and as only simple hybridizations were involved, the assay could be 
performed within 30 min incubation. We also demonstrated precise multiplexed 
measurements of these miRNAs at different and varying concentrations and the 
feasibility of adapting the technology to point-of-care testing (POCT) in buffer 
containing 10 % serum. The second multiplexed sensor is an advanced version of the 
first sensor, and we demonstrated for the first time a successful temporal multiplexed 
FRET miRNA assay from a LTC to a single QD. We achieved this by applying different 
QD self-assemblies to control the distances of the FRET donor and acceptor and to 
obtain distinguishable PL decay curves. The QD we applied in these systems was the 
same commercial QD-streptavidin conjugate we used in the previous sensor, where the 
streptavidin covalently attached to the inner amphiphilic coating without a PEG linker, 
and this provided more freedom for the coassembly of other biomolecules to the QD. 
Terminally modifying DNA with a polyhistidine (His6) sequence can allow its rapid self-
assembly to the QDs via metal-affinity coordination, and more importantly, it provides 
more efficient FRET due to the direct attachment of polyhistidine to the inorganic 
surface of QD compared to streptavidin-biotin (sAv-biot) assembly and lead to 
distinguishable excited-state decay lifetime of QD for temporal multiplexing. DNA 
modified to display either a terminal biotin or an oligohistidine peptidyl sequence was 
assembled to a streptavidin/ amphiphilic QD and served as the capture molecule of QD 
to get proximity with the LTC. Two time-gated windows (0.1-1 ms and 4-8 ms) were 
used for collecting distinguishable contributions of two miRNAs in these two windows.  
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A rapid and homogeneous method to sensitively and highly selectively detect miRNA-
20a and miRNA-20b from a single 150 µL sample was realized based on a single LTC to 
a single QD FRET. We achieved both spectral- and temporal- multiplexing based on 
LTC-to-QD FRET. 
In the third study I first demonstrated a more straightforward way to control the FRET 
efficiency by investigating the donor and acceptor distance dependence of LTC-to-Cy5.5 
FRET efficiency using different lengths of dsDNAs, and achieved an excellent match 
between the estimated distances (based on the defined structure of dsDNAs) and the 
measured distances (based on the relationship of FRET efficiency and distance), and 
thus, we could simply control the FRET efficiency by control the distance of donor and 
acceptor fluorophores. With the distinguishable decay curves of the sensitized dyes from 
different lengths of dsDNAs, we could perform temporal multiplexing. Then we 
integrated it into target-primed rolling circle amplification (RCA) for temporal-
multiplexed and highly sensitive homogeneous ssDNA detection. RCA isothermally 
generates long ssDNA with a tandem sequence using random primers, a DNA 
polymerase and a circular amplification template formed by joining the 5'-PO4 and 3'-
OH ends of a linear padlock probe using the target nucleic acid as the ligation templates. 
Targets can be amplified 10,000-fold in a few hours using RCA [35, 36]. After the 
generation of RCA products, LTC labeled oligonucleotides and Cy5.5 labeled 
oligonucleotides (according to RCA products) hybridize with certain locations of RCA 
products and the detection is based on time-gated FRET from the LTC to Cy5.5. Based 
on the distance dependance of FRET efficiency, we designed the LTC and Cy5.5 probes 
to be separated with 10 bps, 13 bps and 18 bps sequences for ssDNA/miRNA-20a, 
ssDNA/miRNA-20b and ssDNA/miRNA-21, respectively, to perform temporal 
multiplexing. Isothermal amplification of RCA allows for a constant and low working 
temperature (≤37°C). This amplified FRET assay still did not require any washing or 
separation steps and provided a homogeneous FRET-RCA detection of ssDNA (miRNA 
analog) with a few fM limit of detection.  
A summary of the obtained results and findings together with an outlook into future 
developments is given in the last chapter. The appendix consists of the list of 
abbreviations, the detailed bioconjugation protocols, the mathematical correction model, 
the decay time fitting tables, other supplementary graphical information, and the 
bibliography.  
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2. Background 
2.1. Förster resonance energy transfer 
The discussion below presents some very basic knowledge of energy transfer 
mechanisms and mathematics needed to design and perform FRET experiments and 
analyze the data, and is mainly extracted from reference [37]. After a short review of 
FRET based bioapplication is presented.     
Förster resonance energy transfer (FRET) is among the four main mechanisms by which 
excitation energy can be transferred from a donor to an acceptor. These are resonance 
energy transfer, reabsorption, complex formation, and collision quenching. Reabsorption 
is the emission of a photon by the donor with the subsequent absorption of that photon 
by the acceptor, which usually occurs in radiation zone of the electrical field of the donor 
(> 1 μm). Complex formation is the creation of an excited-state complex of a donor and 
an acceptor that are in proximity. Collision quenching can occur when an excited 
molecule loses its excitation energy to another molecule by colliding with it. For either 
complex formation or collision quenching to occur the donor and acceptor must be in 
contact, in other words, the acceptor must be in the contact zone of the electrical field 
around the donor (< 1 nm). FRET is only valid in the near field zone, that is, roughly in 
the 1–20 nm range, within which the ideal dipole approximation can be applied.  In the 
near field, the distance between the center of the donor and that of the acceptor is 
usually much larger than the radius of donor or acceptor, so within the ideal dipole 
approximation, the electromagnetic interaction between donor and acceptor is a dipole–
dipole interaction, and all interactions due to higher multipoles can be ignored. 
2.1.1. Förster theory 
Förster demonstrated the resonance energy transfer from classical [38] and quantum 
mechanical theory [39]. In his classical theory of energy transfer he visualized a donor 
or an acceptor molecule as a group of coupled electrical oscillators. Resonance occurs 
when an oscillator capable of vibrating at a natural frequency interacts with an external 
system that forces this oscillator to vibrate at an external frequency. The acceptor will 
pick up significant energy only if its natural frequency and the frequency of the donor 
oscillators are equal or nearly equal. According to quantum mechanics, the donor or 
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acceptor adopts a number of different electronic states, and the energy transfer happens 
only when they share the same electronic transition and takes place from the state in 
which the donor is excited and the acceptor is not, to a state in which the acceptor is 
excited and the donor is not (Figure 2.1). So the shared electronic transition — in 
spectroscopic terms, spectral overlap between donor emission and acceptor absorbance 
— is necessary for FRET, and due to the dipole-dipole interaction, the donor and 
acceptor must be in close proximity, but not too close. 
 
Figure 2.1. Basic FRET principle. In the simplified energy level scheme (Jablonski diagram), the 
donor is excited (by   ) from an electronic ground state (D) to an excited state (D*), and then goes 
to to an excited electronic ground state by inner relaxation (dotted arrow), and finally it goes 
back to ground state by radiative decay (  ), nonradiative decay (   ), or FRET (     ). The 
FRET process happens when there are shared electronic transition between D* and A* 
(horizontal lines with dots on each end). After FRET, the acceptor is in an excited state (A*), 
followed by radiative or nonradiative decay to its ground state (A).) (Reprinted from reference 
[40]. Copyright 2013 Wiley-VCH Verlag GmbH & Co. KGaA) 
The rate of energy transfer      , is given by Equation 2.1,   
       
 
  
(
  
 
)
 
 2.1 
  
where   
             is the sum of the intrinsic radiative and nonradiative decay 
rates for the donor,    is the Förster distance, at which transfer and spontaneous decay 
of the excited donor are equally probable (        ), and   is the separation distance 
between donor and acceptor. The characteristic inverse sixth power dependence on 
distance can be easily noticed in the equation. 
The Förster distance depends on the spectral overlap integral between the emission 
spectrum of the donor and the absorption spectrum of the acceptor. Among the deviation 
of the equations of Förster distance   , the Equation 2.2,   
   
  
        
      
               2.2  
shows a separation among spectroscopic properties (the luminescence quantum yield of 
donor in the absence of acceptor    and the spectral overlap integral  ), geometric 
9 
 
property (the orientation factor   ), and environmental factor (refractive index of the 
medium  ). N is Avogadro's number. 
The spectral overlap integral   describing the degree of resonance between donor and 
acceptor is accessible with precise spectroscopy measurements and is given by: 
   ∫   ̅         
    2.3  
Where       is the acceptor molar absorptivity (or extinction coefficient) spectrum,   ̅    
is the donor emission spectrum normalized to unity and is given by:  
 ∫   ̅        2.4 
 
Figure 2.2. The overlap (gray area) of the area normalized emission spectrum of D (cf. Equation 
2.4) and the molar absorptivity spectrum of A (  ). The gray area is not the overlap integral J (cf. 
Equation 2.3), and only shows that there is overlap. The maximum of the overlap integral curve 
usually comes later than the one where donor emission spectrum and acceptor molar absorptivity 
spectrum intersect. (Reprinted from reference [40]. Copyright 2013 Wiley-VCH Verlag GmbH & 
Co. KGaA) 
The orientation factor    is given by 
                        
  2.5 
where     is the angle between the donor and acceptor transition dipole moments, and 
   and    are the angles between these dipoles and the vector joining the donor and the 
acceptor, respectively.    is in the range 0 to 4. For instance, 0 can occur for the 
perpendicular transition dipole moments, 1 for the parallel transition dipole moments, 
and 4 for the collinear transition dipole moments. When the molecules are free to rotate 
much faster than the depopulation of the donor, the average value of      ⁄ . Since the 
sixth root is taken to calculate the distance, variation of    does usually not result in 
major errors in the calculated distances except when    is close to 0, which would result 
in serious errors in the calculated distance [10]. 
The FRET efficiency is the quantum yield of the energy transfer transition, i.e. the 
fraction of energy transfer event occurring per donor excitation event [10], which is 
shown in the first part of Equation 2.6. Combination of Equations 2.1 and the first 
two parts of Equation 2.6 leads to the simple relation between the FRET efficiency and 
the distances. 
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 2.6 
Due to the    distance dependency, the FRET efficiency is very sensitive to the distance 
change between FRET donor and acceptor in a region between        and       , as out 
of this range, the FRET efficiency is either close to 0 for longer distances (due to low 
level of  electronic coupling) or close to 1 for shorter distances (due to too efficient FRET 
or other energy transfer mechanisms like complex formation and collision quenching  
may occur).  
FRET is originally a deactivation process of the excited donor, so when FRET happens, 
the photophysical properties such as the luminescence intensity ( ), quantum yield ( ), 
and lifetime of the donor (  ) get decreased. The FRET efficiency can be determined by 
different spectroscopy terms, for instance, the first expression of the Equation 2.7 is 
often used in time-resolved measurement, while the second expression is usually used in 
steady-state measurement. DA and D describe the value in the presence and in the 
absence of the acceptor, respectively.  
         
   
  
   
   
  
 2.7 
 
Detailed theory about FRET can be found in the following books and reviews [9–11, 41, 
42].  
2.1.2. FRET based application 
While the FRET theory has been demonstrated more than 70 years before, the large 
popularity of FRET based application started much later, which can be seen as a 
renaissance of FRET, and this has been triggered by the great advances in new 
fluorophores, and new optical methods and instrumentation [43]. But the reason that 
FRET has been selected instead of others is its intrinsic characteristics such as the 
strong distance dependence in the biological interaction range (1-20 nm). This reason 
together with the necessity of two participants have made FRET a very powerful tool of 
measuring a “change” and/or an “interaction” in biological systems, and studies include 
conformation changes, cell imaging, and in vitro diagnostics.   
Folding and conformation changes 
The function of proteins depends largely on their structures and structural changes. The 
static structures of enormous numbers of proteins have been determined mostly by X-
ray crystallography, and less but more currently by nuclear magnetic resonance 
spectroscopy and electron microscopy, however, there is little direct information on the 
dynamics of protein structure and function. The structure changes of proteins are 
ideally measured under physiological conditions, with which these techniques are 
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mostly incompatible. In contrast, FRET can examine biological samples under native 
conditions and provide real-time measurements [44]. The folding and conformation 
change in protein results in the changes of the relative location of the amino-acid 
residues, i.e. it results in the distance change between different residues, and by 
labeling the appropriate sites (where the conformation change introduces obvious 
distance differences) with FRET donor and acceptor respectively, one can get precise 
distance information by analyzing the photophysical changes due to FRET. A successful 
FRET measurement of structure changes greatly depends on the site-specific labeling of 
residues or bases in a biological system, because a nonspecific labeling leads to 
uncontrollable or multiple FRET pairs, which complicates the interpretation of the 
FRET data. Site-specific labeling can be achieved by different strategies such as 
chemical modification, genetically encoded fluorescent proteins or mutagenesis 
techniques [45–49].  
Besides for protein conformation investigation, FRET has also been used extensively to 
study the structure, configuration, and conformational changes of nucleic acids such as 
the Holliday junction (intermediate in homologous and site-specific recombination) and 
artificial 2D or 3D DNA nanostructures [50]. 
Cell imaging  
The numerous biological molecules and the complicated interactions in cells that are the 
basis of cellular functions, led to the need of specific interrogation techniques to assess 
molecular structure and interactions. FRET holds tremendous promise for monitoring 
intracellular biological processes in real time, with high spatial and temporal resolution 
[51]. Fluorescent proteins (FP) can be genetically encoded and delivered to cells in a 
nondestructive fashion, and FP-based FRET imaging methods have been instrumental 
in determining the compartmentalization and functional organization of living cells and 
for tracing the movement of proteins inside cells [52]. FRET-based biosensors can be 
delivered to cells as DNA plasmids and even guided to specific subcellular regions via 
specific amino acid-targeting sequences. To simultaneously monitor several separate 
processes with multiple FRET pairs or the dynamic interaction between several 
molecules with multistep FRET may provide the most promising field of using FRET in 
cell process investigation compared to other techniqus. 
In vitro diagnostics 
Developments in clinical diagnostics/prognostics and personalized medicine have set 
more challenging demands for in vitro diagnostics. The desire for high-throughput, real-
time, simple, and rapid assays for molecular in vitro diagnostics has been one of the 
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driving forces behind the increased interest in FRET [8]. There are a number of 
potential in vitro analytes of interest, including proteins, metabolites, drugs, toxins, 
nucleic acids, human cells, microbes, and other pathogens. FRET is applied to cancer 
related protein and miRNAs biomarkers detection in this work, and a more detailed 
overview is given in Section 2.5. The signal transduction mechanisms of FRET 
configurations (the presence of an analyte to the measurable change in the FRET signal) 
are diverse, but initially with a proximation or the opposite, which ultimately alter the 
FRET between the donor/acceptor molecules. The recognition molecules can take a 
variety of forms, for protein analytes, it can be antibodies or aptamers. The ability to 
generate antibodies to a wide range of target analytes and their resulting specific nature 
make them very attractive biorecognition elements for FRET-based biosensing and 
diagnostics. For nucleic acid analytes, the recognition is usually based on specific 
hybridization of complementary nucleic acids or newly developed non-classical nucleic 
acids such as the locked nucleic acid and peptide nucleic acid. As the biological 
mechanisms under these situations are usually much clearer, a vast number of newly 
developed materials with unique luminescence properties are being explored in order to 
improve the performance of the assays [53]. Lanthanides and QDs, two very promising 
materials used in FRET diagnotics are reviewed in detail in Sections 2.2 and 2.3. 
The different biological applications mentioned above can be studied by FRET on a 
single-molecule level or on ensemble population (or both). For most of in vitro 
diagnostics, the ensemble measurements, where averaged PL intensities (steady-state 
or time-resolved) are recorded, can fullfill the needs of precise detections, as only the 
total PL intensities are needed to relatively quantify the targets of interest. However, as 
the ensemble molecules may contain the subpopulations due to the imcomplete 
biomolecule labeling with donor and acceptor fluorophores, or a portion of the acceptor 
fluorophores, which are nonfluorescent and/or nonabsorbing due to photobleaching and 
blinking, the ensemble measurements may lead to underestimate FRET efficiencies, and 
this consequently affects the investigations of folding or conformation change of 
biomolecules. The single-molecule FRET (smFRET), which involves FRET of a single 
FRET pair, allows the identification of subpopulations of FRET pairs that would be 
indistinguishable in ensemble measurements [54]. The rapid development in both 
fluorescence spectroscopy and high-resolution fluorescence microscopy have raised the 
spatial resolution and detection sensitivity to the single-molecule level and have been 
highly important for many smFRET studies [55]. SmFRET coupled with single-molecule 
tracking are promising to be used to fully characterize single-molecule conformation, 
dynamics, and interactions within the complex intracellular medium [54, 56]. 
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2.2. Luminescent lanthanide  
2.2.1. Introduction 
Lanthanides refer to the 15 elements (ranging from lanthanum to lutetium) located at 
the sixth period and IIIB group in the periodic system of elements. Lanthanides with the 
chemical similar elements scandium and yttrium are also called the rare-earth metals, 
which is appropriate considering the difficulty in obtaining an element in its pure form 
instead of the scarcity on earth [57, 58]. The difficulty in obtaining a pure form of 
lanthanide is due to the similarity in their chemical properties, particularly oxidation 
states, and this can be explained by their electronic configuration [59, 60]. The general 
electronic configuration of of lanthanide atoms is denoted as [Xe]4fn5d0−16s2 (n = 0−14), 
where the lanthanides mainly differ in the population of the 4f-orbitals. The filled, 
energetically lower 5s- and 5p- orbitals are spatially located outside the 4f-obitals, which 
consequently shield the inner 4f-orbitals and lead to a reduced response to the 
environment and only small differences in chemical behavior among all lanthanide 
elements [59–61]. 
 
Figure 2.3. Left: Energy diagrams for Ln3+ in a LaCl3 lattice. (Reprinted from reference [62]. 
Copyright 2009 American Chemical Society) Right: Luminescent 4f−4f transitions of Eu3+ (5   - 
7
   transitions) and Tb3+ (5   - 
7
   transitions) and commonly observed emission wavelengths to 
emit red and green light, respectively. (Reprinted from reference [63]. Copyright 2014 American 
Chemical Society) 
The luminescence of lanthanides has been an instrumental factor in the discovery of 
several lanthanide elements, and in turn, their peculiar luminescent properties have 
been exploited in applications ranging from biomedical to sensing areas and 
luminescence imaging [64]. It is well known that lanthanide ions (with a common 
oxidation state to be trivalent) have very low molar extinction coefficients (in the order 
of only 1 M-1cm-1) [65], but when sensitized by, e.g., an organic ligand, the molar 
absorption coefficients can be comparable with that of organic fluorophores and they can 
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emit multiple, characteristic narrow (line-like or atom-like) emission bands, mostly in 
the visible and near infrared ranges; the excited state lifetimes of lanthanide are 
extremely long, which can extend up to several milliseconds [66, 67]. These luminescent 
properties can be explained by the [Xe]4fn electronic configurations and a vast number of 
energy levels related (Figure 2.3 left). The very low level of direct excitation of the 
lanthanide ions as well as their extremely long excited state lifetimes come from the so-
called Laporte selection rule and spin-multiplicity rule, with which most of the 
transitions of the Ln3+ ions involve redistribution of electrons within the 4f sub-shell 
(intraconfigurational f–f transitions) are parity-forbidden [68]. To get more excited, 
lanthanide ions usually require indirect excitation from a sensitizing structure, which 
can be an organic ligand containing a light absorbing chromophore structure and a 
moiety that coordinates the central ion [69, 70], or an inorganic crystal structure 
containing sensitizer such as Yb3+ ions [71]. Under these situations, the forbidden 
electric dipole transitions become partly allowed. Together with the parity-allowed 
magnetic dipole transitions, the lanthanide ions get greatly sensitized. The narrow, 
lanthanide-specific emission bands are a result of the sharp transitions between the 
well-defined J-levels (be degenerated from the electronic configuration based on 
Coulomb interaction and spin-orbit coupling, Figure 2.3 right) of lanthanide ions due to 
the shielding of the 4f orbitals by the filled 5p66s2 sub-shells [72]. The J-levels can be 
further split into sublevels (which can be seen as the fine structure of the main emission 
bands of the lanthanide ion) if the lanthanide ions are in a coordinating environment 
[66]. The above mentioned luminescent properties of the lanthanide based fluorophores 
result in the obvious advantages compared to others [63, 68]: 
a) display substantially reduced photobleaching as long as the energy can be 
transferred to the central ions  
b) enable easy spectral discrimination of the emitted light due to the strongly 
spectrally-shifted indirect excitation   
c) pack a multitude of lanthanide complexes in close vicinity without concentration 
quenching 
d) allow the use of time-resolved detection in bioassays and in luminescence 
microscopy due to the long lifetime 
e) perform multiplexing due to the multiple, well-separated emission lines.  
2.2.2. Lanthanide complexes and nanoparticles 
Lanthanide complexes  
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A lanthanide complex contains a sensitizing conjugated chromophore moiety (the 
antenna ligand) and a moiety that coordinates the central ion (lanthanide ion carrier 
chelate). In general, the antenna ligand is excited by UV light (less energy light may be 
not efficient to excite the lanthanide ion) to a singlet state and undergoes intersystem 
crossing to the lowest triplet state, which then excites the bound lanthanide ion by 
intramolecular energy transfer [73]. The overall quantum yield of a lanthanide complex 
is given by Equation 2.8 
    
         
   2.8 
Where    
  and    
    are the quantum yields resulting from indirect and direct excitation 
of the lanthanide ions, respectively, while     represents the efficiency with which 
electromagnetic energy is transferred from the ligand onto the lanthanide ion. The 
intrinsic quantum yield    
    essentially depends on the energy gap between the lowest 
lying excited state of the lanthanide ion and the highest sublevel of its ground multiplet 
[68]. The smaller this gap, the easier it gets depopulated by non-radiative deactivation 
processes, especially through vibrational quenching caused by O–H vibrations. So the 
lanthanide complex can improve the    
  by improving both factors (    and    
  ), 
namely the antenna ligand with a higher intramolecular energy transfer rate provides a 
higher     value, and the lanthanide ion carrier chelate protects the ions from the 
quenching effects of the aqueous matrix, and thus minimizes the non-radiative 
processes and improves the intrinsic quantum yield    
  .  
 
Figure 2.4. Chemical structure of the ligand of the lanthanide complex used in this work. 
(Reprinted from reference [20]. Copyright 2011 American Chemical Society) 
When the Ln3+ complexes exhibit bright luminescence (lanthanide complexes with both 
high molar extinction coefficient and overall quantum yield), applications ranging from 
biomedical to sensing areas and optical imaging become possible, which are beneficial 
with their very long excited state lifetimes (up to milliseconds). The long PL decay times 
allow for efficient suppression of short-lived auto fluorescence background from the 
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sample or from other fluorophores by using pulsed excitation and time-gated detection 
(i.e., measuring the long-lived PL intensity decay in a time-window that opens after the 
other fluorescent components have already decayed). The indirect excitation of 
lanthanide ions results in very large Stokes shift, thus, the separation of excitation and 
Tb emission wavelengths, which allows facile blocking of stray excitation light by filters 
and/or dichroic mirrors. Remarkably, the mostly studied complexes of Eu3+ and Tb3+ can 
exhibit quite intense visible line-like emission, as since long known from an 
exceptionally extended literature [14, 18, 62, 63, 67, 72, 74–77]. The photophysical 
properties of near infrared (NIR) lanthanide emitters such as Sm3+, Dy3+, Pr3+, Ho3+, 
Yb3+, Nd3+, and Er3+ trigger a massive interest based on the fact that longer-wavelength 
emissions are more efficient to penetrate the human tissue than visible light, so 
convenient medical diagnostic procedures can be conceived based on long-wave length 
emitters [21, 68, 78, 79]. 
Lanthanide-doped inorganic materials 
Lanthanides can also be incorporated into nanoparticles (NPs). The general idea to 
generate NPs for biological application is to take the advantages of  their tunable size 
and morphology, as well as surface bio-immobilization, and the properties unique 
between bulk materials and atomic or molecular structures. The lanthanide based NPs 
have the characteristic properties of the lanthanide luminescence such as long lifetimes 
and narrow emission bands, but compared to lanthanide complex, they gain extra and 
very exciting property, namely, upconverting (UC) luminescence, in which photons with 
higher energy are emitted after the absorption of photons with lower-energy. The UC 
process refers to nonlinear optical phenomenon, in which continuous absorption of two 
or more photons leads to shorter- wavelength radiation via long-lived intermediate 
states (anti- Stokes emission) [80], and representation of different UC processes are 
shown in Figure 2.5. In the core of the inorganic crystalline NPs the lanthanide ions 
are protected by the solid structure from the quenching effect of the environment, while 
in molecular lanthanide chelates the ions have much higher probability of nonradiative 
relaxation, with which the molecular UC has been considered to be almost impossible 
[81, 82]. 
The most common strategy of synthesizing UCNP is to dope two kinds of active 
lanthanide ions sensitizer and activator into the inactive host inorganic crystal 
structures. Under the excitation of photons with lower energy, both the sensitizer and 
the activator would be excited. With the non-radiative energy transfer from the 
sensitizer to the adjacent activator, sequential absorption of the activators to the higher 
excited states takes place. Radiative emission could be observed as the activator 
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returned to the ground state. Energy level matching together with an adequate distance 
between the sensitizer and activator is required to accomplish highly efficient energy 
transfer. Yb3+ is generally used as the sensitizer to endow the NPs with NIR excitation 
(980 nm) due to the large absorption cross-section and high efficiency to transfer the 
absorbed energy to activator Ln3+ including Er3+, Ho3+, Tm3+, and Pr3+ [83].  
 
Figure 2.5. Principal UC processes for (a) second harmonic generation, (b) simultaneous two-
photon absorption, (c) excited states absorption, (d) energy transfer UC, and (e) photon avalanche. 
(Reprinted from reference [80]. Copyright 2013 Royal Society of Chemistry) 
The Ln3+-doped upconversion NPs have evoked considerable interest in bio-imaging due 
to the unique near-infrared excitation nature, the high resistance to photobleaching, as 
well as the minimized photo blinking and cross-talked emissions [84]. The near-infrared 
(NIR) excitation is more friendly to organic tissues and offers a deeper penetration depth 
compared to the UV/Vis used with conventional photoluminescent probes. The 
possibility of the detection of upconversion emission either at red or even near-infrared 
wavelengths enables also the measurement of optically challenging physiological 
samples. Furthermore, the NIR excitation and large anti-Stokes emission result in a 
total elimination of the autofluorescence and scattered excitation lights which gain high 
signal-to-noise ratios compared to other photoluminescent probes such as quantum dots 
and organic dyes [85].  
The lanthanide-doped inorganic materials can also follow downconverting process, and 
in general, NIR emissions are generated via down-shifting processes such as the NIR 
emission of Nd3+ doped NPs, Nd3+-Yb3+ codoped NPs and Yb3+-Ln3+ (Ln = Er, Ho and Pr) 
codoped NPs. NIR emissions located in the “second transparent biological window”, 
where less biological tissue scattering is given, have also been developed to achieve 
highly sensitive in vivo bioimaging [83].  
Besides being doped in the inorganic structures, a large number of Ln3+ complexes can 
be incorporated into a single nanoparticle (either within the core-shell structure or 
18 
 
bound to ligands on the NP surface) to achieve enhanced photostability, brightness and 
improved biocompatability [86]. 
2.2.3. Tb complex as FRET donor 
We have shown that FRET is a very powerful tool in the biological applications, and it 
has offered new opportunities when being combined with lanthanide complexes as 
donors. Aside from large Förster distances for efficient FRET and extremely long 
excited-state lifetimes, which allow for time-resolved measurements, a major advantage 
of the use of luminescent terbium complex (LTC) as FRET donors is multiplexing 
capability. The emission bands of LTC are much better separated and therefore superior 
for spectral multiplexing; the long and distinguished sensitized decay time of acceptors 
due to different FRET efficiencies are promising for temporal multiplexing.   
LTCs have several remarkable advantages compared to other FRET donors, and we will 
discuss about this concerning the characterization of FRET parameters, the 
instrumentation and the multiplexed capability. 
Characterization of FRET parameters  
LTCs show promising properties over the several characteristics of FRET such as 
luminescence quantum yield, orientation factor, Förster distance and FRET efficiency. 
Quantum yield of donor    
The PL quantum yield of donor is the quantum yield of the Tb3+ ion (    ) and not the 
quantum yield of the complete LTC (     , because the    , not     , determines the 
strength of the donor’s electric field, thus, LTCs with high     can be designed for 
obtaining large Förster distance and more efficient FRET [14].  
Orientation factor     
The uncertainty of the orientation factor hampers us from the accurate determination of 
distances, but LTC greatly reduces this uncertainty. Tb possesses multiple emission 
transition dipole moments and therefore a dynamic averaging can be applied for the 
orientation factor [14]. When the acceptor is completely rigid and either parallel 
(·     ⁄ ) or perpendicular (·     ⁄ ) to the radius vector, then   ⁄       ⁄ . 
Simply assuming·     ⁄  under this situation results in error in    less than 12%. 
Furthermore, the reduced uncertainty also comes from the depolarization of the acceptor 
emission due to the long emission lifetime [9], making    very close to 2/3. Hence, the 
error in distances measured due to the orientation factor is often negligible. This, in 
turn, makes the distance determination generally more accurate than for classical FRET 
pairs because their orientation factor is often poorly known [87].  
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Förster distances     
The multiple LTC emission bands cover the spectral range from 450-700 nm, and in this 
range many fluorophores are excellent absorbers and therefore relatively large spectral 
overlap integrals can be achieved. Förster distances of LTC-to-dye can be 4-6 nm, and 
with QDs as acceptor, it can go up to 11 nm. The distance of the biological interactions 
can extend 20 nm, so larger Förster distances are generally recommended, though it 
does not mean a large Förster distance is always a good choice.  
Instrumentation 
As LTCs possess extremely long luminescence decay times of up to a few milliseconds, 
the complex TCSPC is no longer necessary, a much easier multichannel scaling can be 
used to measure the long PL decays of LTCs. Furthermore, the repetition rate of simpler 
and cheaper flashlamps instead of the much higher repetition rates of plused lasers can 
fullfil the demand of measurements [10]. The high accuracy of μs to ms lifetime 
measurement can often be achieved easier than that of very short lifetimes. In time-
gated PL intensities measurement, auto-fluorescence of the biological matrix (ns to μs 
lifetime) and emission from directly excited acceptors (ns lifetime) can be very efficiently 
suppressed by pulsed excitation and time-gated detection, therefore, the FRET 
measurements are not sensitive to concentration effects (e.g., excessively high 
concentrations of LTCs or acceptors) and incomplete bioconjugation (unlabeled 
biomolecules and/or free LTCs or acceptors) and can provide more robust and reliable 
results [14, 69].  
Multiplexed capability 
Multiplexing in biotechnology and life sciences refers to high throughput technologies 
capable of simultaneous identification and quantification of multiple distinctive species. 
Multiplexed molecular diagnostics impacts broadly on the bioinformatics areas of 
genomics, proteomics, metabolomics, cytomics and personalized medicine. 
One of the most important multiplexed domain in PL is the emission wavelength or 
color, namely, spectral multiplexing. The spectral multiplexing capacity of LTCs comes 
from the narrow and well-separated emission bands of LTCs, which make it easier to 
choose different acceptors emit in wavelength regions in between or beyond the LTC 
emission bands. Quantum dots are ideal acceptor candidates due to the size-tunable and 
narrow, symmetric emission profiles, because spectral separation based on the optical 
transmission filter is very efficient with the narrow and well-located QDs (located in the 
regions without LTC emission) (Figure 2.6). However, it becomes more complicated 
when different organic dyes are applied. Due to the broad emission profiles of most 
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organic dyes, one acceptor fluorophore emits in different detection channels (based on 
optical transmission filters), i.e. several acceptors emit in the same detection channel. 
When the spectral crosstalks happen, a deconvolution of contribution of individual 
acceptor fluorophore is necessary to achieve efficient multiplexing. More details of the 
PL properties of QD and organic dye and their respective advantages and disadvantages 
are shown in section 2.3 and 2.4. 
 
Figure 2.6. LTC donor-based spectral-multiplexed FRET using different organic dyes (left) and 
QDs (right). LTC-PL-spectra in black. Left: OregonGreen (blue), AlexaFluor555 (green), 
AlexaFluor568 (orange), Cy5 (red) and AlexaFluor700 (brown); right: Qdot525 (blue), Qdot565 
(green), Qdot605 (orange), Qdot655 (red),and QDot705 (brown). (Reprinted from reference [14]. 
Copyright 2014 Elsevier) 
The unavoidable spectral overlap can require complicated and tedious mathematic 
correction. Even with the narrower emission bands of QDs (as many as eight 
overlapping QD emission profiles have been deconvolved within a 200nm wavelength 
range [88]), the number of spectral multiplexing is still limited. Thus, the big 
challenge/opportunity in multiplexing is to find ways of creating additional 
distinguishable dimensions, such as mass spectra, PL decay lifetime and Raman spectra. 
The multiplexing based on lifetime (temporal multiplexing) is a very promising concept, 
but has not been extensively explored yet. Recently, researchers obtained tunability of 
microsecond region lifetimes of upconversion NPs and applied for multiplexing optical 
codes [89, 90]. LTCs based FRET are also well suited in temporal multiplexing. Using 
the extremely long PL lifetimes of LTC and different donor-acceptor distances for the 
same type of donor-acceptor pair would allow for designing different FRET-quenched 
and FRET-sensitized PL decay times, which could open another possibility of lifetime 
multiplexing. 
2.2.4. Time-resolved measurement 
We have discussed the advantages of using time-resolved measurement in lanthanide 
based biosensing or imaging due to their extremely long excited-state lifetimes. Not only 
lanthanides but every fluorophore has a characteristic PL lifetime, no matter if it is 
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longer than milliseconds or shorter than picoseconds. In other words, all of them can be 
studied by time-resolved measurements, which actually are neccessary for better 
understanding the photophysical properties of the fluorophores. While steady-state 
measurement gives an average and relative representation of the fluorescence emission 
(intensity vs wavelength), time-resolved measurement provides more dynamic 
information than is available from the steady-state data. Lifetime measurement is 
useful in elucidating changes in the environment of the fluorophores, in studying 
molecular interactions and in distinguishing static and dynamic quenching [10]. FRET 
is also best studied using time-resolved measurements. Determination of conformational 
changes as well as distance distributions within a biological FRET system can most 
often only be determined by time-resolved measurements [40]. Fluorescence Lifetime 
Imaging (FLIM), whose contrast is based on the lifetime of individual fluorophores 
rather than their emission spectra, is an increasingly used tool in cell biology. As the 
fluorescence lifetime does not depend on concentration, absorption by the sample, 
sample thickness, photo-bleaching and/or excitation intensity, it is more robust than 
intensity based methods [91, 92].  
Time-domain and frequency-domain methods are both widely used methods of 
measuring time-resolved photoluminescence (Figure 2.7). Time-domain or pulse 
fluorometry uses a short excitation pulse of light and gives the δ-pulse response of the 
sample, convoluted by the instrument response. Frequency-domain or phase fluorometry 
uses modulated light at variable frequency and gives the harmonic response of the 
sample (Fourier transform of the δ-pulse response). The two methods are theoretically 
equivalent and provide the same kind of information, however, they have their own 
advantages and drawbacks in methodologies [93]. Time-domain method permits 
visualization of the PL decay, but the deconvolution of the δ-pulse response of the 
sample from the instrument response is often necessary and requires the same 
instrumental parameters in recording the instrument response in the absence of the 
sample, especially for very short decay times [93]. No deconvolution is necessary with 
frequency-domain method because the data are directly analyzed in the frequency 
domain, however, the evaluation of the standard deviation of phase shift and 
modulation ratio may not be easy [93]. Time-resolved emission spectra are more 
straightforward with the time-domain method, while lifetime-based decomposition of 
spectra into components is simpler with frequency-domain method. 
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Figure 2.7. Principles of two time-resolved measurements. Pulse fluorometry (time-domain) uses 
a short excitation pulse of light and gives the δ-pulse response of the sample, convoluted by the 
instrument response. Phase fluorometry (frequency-domain) uses modulated light at variable 
frequency and gives the harmonic response of the sample. (Reprinted from reference [93]. 
Copyright 2001 Wiley-VCH Verlag GmbH & Co. KGaA) 
Within this work, we mainly demonstrate the time-resolved PL based on time-domain 
measurements, so the following discussion concerning the photon counting technique 
and the data analysis will focus on time-domain method.  
The mathematical description of a time-dependent luminescence decay (with i decay 
times) is the luminescence intensity ( ) as a function of time: 
   ∑                  2.9 
  is the time-resolved PL intensity,    is the amplitude of a certain lifetime    [40]. The 
lifetime can be determined by fitting the data to assumed decay models. In the time 
domain the data are usually presented as log photon counts versus time. In this 
logarithmic presentation, linear decay curve indicates that the decay is a single 
exponential. It should be noted that the shape of the excitation pulse and how this pulse 
is detected by the instrument are not negligible to decay curve of the short lifetimes, and 
the so-called instrument response function (IRF) should be taken into account when 
fitting the data [10]. 
Photon counting technique 
Different photon counting techniques can be applied to measure the lifetime such as 
Stroboscopic technique, time-correlated single-photon counting (TCSPC), streak camera 
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and upconversion methods, and TCSPC dominants the field until now. The current 
electronics are not fast enough to measure multiple photons per pulse when the 
lifetimes are in the ns range, but the fluorescence intensity at a certain time after an 
exciting pulse can be transferred to the probability of detecting a single photon at that 
time. After timing and recording the single photons following a large number of exciting 
pulses, the fluorescence intensity decay curve is reconstructed. To precisely represent 
the probability of a single photon at a certain time after an exciting pulse, the conditions 
of TCSPC are adjusted to detect much less than one photon per laser pulse, typically 1 
photon per 100 excitation pulses. If the count rate is higher, reconstructed decay curve is 
biased to shorter times due to the so called “pileup effect”. Complex and expensive 
electronic instruments are needed for TCSPC and for more valuable details please see 
reference [94]. 
For decay times longer than about 20 ns, a low pulse repetitive rate is needed, and the 
complexity of TCSPC is no longer necessary, in contrast, TCSPC is slow and inefficient 
due to a long time to detect each photon. Multichannel scaling (MCS) is preferred to 
measure the long PL decays. A multiscalar card functions as photon-counting detectors 
that sum the number of photons occurring within a time interval. Following the 
excitation pulse, photons arriving within a defined time interval (uniform or increased 
with time) are counted. The decay time of lanthanide complexes is usually determined 
by multichannel scaling. 
Data analysis 
There are many methods to analyze the TCSPC data. If possible, some assumptions of 
the decay model will help to choose the most appropriate one. For example, the 
maximum entropy method (MEM) is typically used to recover continuous lifetime 
distributions, which are involved in biological systems such as proteins, micellar 
systems and vesicles or membranes [93]. Otherwise, analysis consisting of a few distinct 
exponentials is accomplished mostly by nonlinear least squares [93]. In this method one 
finds the lifetime that results in the best fit between the measured data and the data 
calculated for the assumed lifetime. For a good fit, the deviations between the measured 
and calculated data, weighted by the standard deviations of each measurement are 
random, indicating the only source of difference is the random error in the data [10]. 
When multi-exponential decays are involved, one should take the physical model 
involving distinct exponentials into account and try with reasonable number of 
exponentials (usually no more than 4-exponentials).  
The necessity of measuring a precise PL decay time is determined by the research of 
interest. Distance distributions between donor and acceptor within a biological FRET 
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system as well as fluorescence lifetime imaging microscopy (FLIM) can only be 
determined by obtaining the lifetimes. Other cases, like the architectures designed for 
sensing applications, typically require well-defined changes in the PL intensity, not a 
precise lifetime measurement. For instance, time-gated PL intensity measurements 
have been used in high sensitivity detection of biomolecules [95], particularly for the 
applications based on probes with long PL decay times such as lanthanides [15, 19, 95–
98]. Briefly, the autofluorescence of biological samples (lifetime in ns to μs range) can be 
avoided by integrating the intensity of the lanthanide in a certain time-gated window 
and thus the limits of detection can be much lower. For the lifetime fitting and time-
gated intensity integrating, the expression of data is exactly the same, and one can 
select the method depending on the purposes to analyze the data. Generally, it is much 
easier to get the time-gated intensity than to obtain the precise lifetimes especially with 
multi-exponential decays. In this work, I applied both of the models to analyze the PL 
decay curves, with which more comprehensive information were provided. PL decay 
time fitting provided direct information of the lifetimes, and with time-resolved FRET in 
particular, the FRET efficiency can be calculated directly from the sensitized lifetime of 
the acceptor or quenched lifetime of the donor. Time-gated measurement cannot only be 
used to avoid the background signals, but also to expand biosensing to temporal 
multiplexed assays. 
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2.3. Quantum dots 
Colloidal quantum dots (QDs) are often used to describe nanocrystalline particles 
commonly synthesized from binary mixtures of III−V or II−VI semiconductor materials 
including ZnS, ZnSe, CdS, CdSe, CdTe, InP and etc. They provide unique electronic and 
optical properties that are distinguished from bulk semiconductor materials and also 
from the molecules due to the tight quantum confinement of electrons and holes in all 
three spatial dimensions [22, 23, 99–101]. The physically larger sizes of QDs compared 
to organic dyes and fluorescent proteins have not obstructed their blowout growth in 
biological applications based on the outstanding photophysical properties [25], especially 
after two semina articles applying QDs as biological labels into fluorescent microscopy 
were reported [102, 103]. 
2.3.1. Photophysical properties 
QDs possess a number of pertinent photophysical properties that make them ideal 
biosensing probes [25], these include: a) broad absorption profiles that increase nearly 
continuously toward the UV (excitation flexibility), b) narrow, size-dependent, and 
symmetric PL spectra spanning from the UV to the IR that are a function of the 
constituent materials (much better suited to spectral-multiplexed analyses and imagines 
than those of molecular fluorophores), c) large effective Stokes shifts (efficient 
separations of the excitation and emission lights), d) high brightness due to both high 
extinction coefficients and quantum yields (suitability for single particle visualization 
and tracking), e) remarkable photostability (strong resistance to photobleaching and 
chemical degradation, f) some provide high multiphoton action cross sections [104, 105] 
(excited in the near-infrared to have deeper tissue penetration compared to UV or visible 
light, and decreased autofluorescence from the biological matrix).  
 
Figure 2.8. Quantum confinement results in size-tunable QD PL. The colors of the energy levels 
represent the PL colors of different QDs. From left to right, the size of the QD becomes bigger, 
and the band gap energy becomes smaller. (Reprinted from reference [106]. Copyright 2013 
Wiley-VCH Verlag GmbH & Co. KGaA) 
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Most of these unique properties originate from the quantum confinement effect in 
semiconductors. The electronic structure of bulk semiconductor is characterized by a 
lower energy valence band, which is occupied by electrons and a higher energy 
conduction band which is empty. An important item needs to be introduced here to 
better understand the quantum confinement effect: the exciton. The excitation of an 
electron from the valence band to the conduction band leaves a positive hole in the 
valence band, and interaction between the electron and the hole creates an exciton 
(which can be imagined as a hydrogen with reduced mass) [107]. The valence band and 
conduction band arise from the linear combination of atomic orbitals associated with 
each constituent atom, and are typically separated by a band gap depending on the 
semiconductor materials. The valence band and conduction band can be regarded as 
continues energy levels due to the large density of electronic states [108]. But when the 
size of the semiconductor material becomes smaller and smaller to the nanometer-scale 
(close to the Bohr radius of the exciton), only a limited number of atoms are left 
(quantum dots with 2 to 10 nm diameters correspond to the diameters of 10 to 50 atoms, 
which results in as few as 100 to 100,000 atoms per QD), and the density of electronic 
states is not sufficient to form complete band structures and discrete energy levels exist 
at the band edges. Energy levels become more separated as the QDs become smaller, 
and thus, the band gap energy increases. The QD PL, which results from the radiative 
recombination of the exciton across that energy gap, has a hypsochromic shift when the 
QD becomes smaller, i.e. the QD PL can be tuned by its size [23] (Figure 2.8). The 
tunable wavelength range is mainly determined by the semiconductor material. CdSe 
and CdTe QDs have been most commonly applied in biology due to their preferable 
tunable wavelength ranges, which span the visible region of the spectrum [25]. The 
shape of the emission curve is depending on the size distribution of the QD. With high-
quality, monodisperse QDs, the PL emission is narrow and symmetric, approximating a 
Gaussian profile with full width at half maximum (FWHM) typically in the range of 25-
35 nm [24].  
In contrast to their narrow PL spectra, the absorption spectra of QDs are very broad, 
extending, and generally increasing in intensity at wavelengths shorter than the band 
gap energy. The excess energy above the energy gap is transferred very efficiently via 
nonradiative intraband transitions to the electron and hole, which yields band-edge PL 
regard less of the initial excitation wavelength. Generally, QDs have ca. ten times (or 
more) higher extinction coefficients than organic dyes [109]. 
The high quantum yield results from the shell-based passivation of the surface of the 
core nanocrystal of QDs by minimizing the so-called trap states, which spatially 
27 
 
separate the electron and the hole and inhibit radiative recombination of the exciton 
[110], and that is why the QDs mostly used in biological applications are core/shell 
structured. The photostability is a consequence of the quantum confinement of the 
exciton, which hinders photooxidation and also the inhibited chemical degradation due 
to the protection of the shell structure [111]. 
2.3.2. Biofunctionalization 
The preparation of high-quality, monodisperse and water-soluble QDs is highly 
important to achieve all the good properties mentioned above for the biological 
application [24].  Pyrolysis of organometallic precursors in the presence of hydrophobic 
coordinating ligands in organic media in the first place, followed by the ligand exchange 
or encapsulation of the native surface of QDs with smaller bifunctional, water soluble 
ligands or larger, amphiphilic block copolymers, can be used to prepare water-soluble 
QDs. With a good biocompatible QD in hand (which can be homemade or commercially 
available), the next issue is the biofunctionalization of the QDs, which enables certain 
biological applications, including recognition of biomarkers, targeting of cells and tissues, 
and delivery of drugs or in vivo diagnostic reagents [112]. Working on the intersection of 
biomolecules and NPs is not an easy task as people always ambitiously want to 
completely preserve the inherent structural or specific recognition properties of 
biomolecules as well as the unique properties of NPs. The “ideal” characteristics desired 
from a QD bioconjugation, which is also suitable for that of other NPs, are control over 
the ratio of biomolecule per QD, the orientation on the QD, the relative separation 
distance from the QD and attachment affinity, and it should also maintain the optimal 
function and activity of both QD and biomolecule (Figure 2.9).  Antibody (Ab) activities 
are dependent upon their binding sites having access to the environment. Nonspecific 
chemistry can result in heterogeneous attachment and impair activity in the final 
conjugate [112, 113].   
 
Figure 2.9. Schematic representation of the principle criteria for a universal controlled 
attachment of a protein to a NP. (Reprinted from reference [114]. Copyright 2006 Macmillan 
Publishers Ltd.)  
28 
 
The following paragraphs highlight approaches utilized to functionalize QDs with major 
types of biomolecules, including proteins, peptides, and oligonucleotides. 
Oligonucleotides and peptides can be synthesized with nucleophilic linkers (e.g., alkyl 
amines and thiols) or amino acid residues (e.g., N-terminus, lysine, and cysteine) at 
predetermined positions for labeling with succinimidyl ester, isothiocyanate, and 
maleimide derivatives of QDs. So the difficulty of oligonucleotide- or peptide- QD 
labeling is not controlling the labeling sites, but the orientations of the oligonucleotides 
and peptides on the QDs due to the flexibility of the structure of the peptides or 
oligonucleotides [115] (Figure 2.10) especially single strand oligonucleotides. As they 
tend to lay down on the surface of the QDs instead of staying vertical, the predictive 
distances are usually larger than the measured distances.   
 
Figure 2.10. Models of DNA - QD structures based on polyhistidine metal-affinity coordination 
(A) and streptavidin-biotin chemistry (B). With different conjugation strategies, the orientations 
of DNA on QDs are diverse. (Reproduced from reference [115]. Copyright 2010 American 
Chemical Society) 
In contrast, proteins are more difficult to label at unique positions due to the multitudes 
of accessible lysine residues with an amino side chain or glutamic and aspartic acid 
residues with carboxylic acid side chains. Cysteine residues, which typically have much 
lower abundance, are thus more promising to be labeled at specific sites, however, as 
cysteine residues are usually related to the second or third dimensional structure of the 
proteins, a labeling based on cysteine residues may decrease the activity of the protein 
[116, 117]. High-affinity self-assembly methods based on the coordination of alkylthiol, 
metallothionein and polyhistidine to QDs can provide the best control over conjugate 
valence and a defined point of attachment to the QD [24, 118, 119]. Unlike peptides or 
single strand oligonucleotides, which have flexible structures, the proteins have defined 
structures under physiologic conditions, which means a fixed labeling site sets a fixed 
orientation for the protein and, by extension, a fixed position for an acceptor/donor.  
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2.3.3. QD as FRET donor/acceptor 
QDs can serve as both FRET donor and acceptor. QDs are typically used as FRET 
donors due to the unique optical properties mentioned before. For instance, one can 
choose the adequate QD, which has better spectral overlap with a particular acceptor 
dye, to improve FRET efficiency. The broad absorption spectra and large Stokes shift 
found in QDs is also of benefit for FRET studies, as it allows excitation of mixed QD 
donor populations at one wavelength, far removed from their emissions and also 
facilitates selection of an excitation wavelength that corresponds to the acceptors 
absorption minima, thus reducing direct excitation background signals. The ability to 
excite multiple QD donors using a single excitation wavelength, combined with their 
narrow and symmetric emission (which makes deconvolution of multiple fluorescent 
signals simpler), makes them attractive labels for multiplex applications.  
While FRET from QD to organic dyes is popular, the opposite direction, where an 
organic dye is used as donor and QD is used as acceptor, is very unfavorable. FRET is a 
process where the resonant energy is transferred from an excited-state donor to a 
ground-state acceptor. Most organic dyes are excited by UV or visible light, and when 
they are excited, QDs are always directly excited at the same time than the dye donor 
due to their broad absorption spectra (cover the range from UV to the first exciton peak). 
However, the relatively long excited-state lifetime of a QD (>10 ns) compared to that of a 
typical organic dye (< 5 ns)  leads to a large fraction of QDs that remain in their excited-
states and therefore, they cannot effectively serve as acceptors for a proximal excited 
dye [16].  
Although the configurations of dye-to-QD are generally unfavorable, QDs can serve as 
excellent FRET acceptors for some unique classes of donors such as lanthanides, 
chemiluminophores, bioluminescent proteins and upconverting NPs [16], among which 
three different strategies are involved to inhibit  or decrease direct excited-state QDs: a) 
the avoidance of light excitation (chemiluminesence and bioluminescent), b) the usage of 
near-infrared excitation, which is not efficient enough to excite the QDs (upconverting 
NPs), c) a much shorter excited-state lifetime of QDs compared to that of long lifetime 
fluorophores (lanthanides). We have shown in Section 2.2.3 the unique PL properties of 
LTCs, and a combination of LTC donor and QD acceptor has several unique advantages 
for multiplexed biomolecular detection. The combination of the multiple emission bands 
of LTCs and with large molar absorption coefficients of QDs in a broad absorption 
spectra provide large Förster distances (6-11 nm). Exceptionally long excited-state 
lifetimes (ms) of LTCs enable time-gated detection void of autofluorecence background 
and directly excited QDs. The narrow, symmetric, and tunable emission bands of QDs 
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provide unrivaled potential for spectral multiplexing. It is simpler to choose QDs with 
PL maximum falling either between the various lanthanide emission lines, or beyond 
the longest wavelength emission line, than to choose that of organic dyes. 
However, it is important to note some of the unpleasant physical properties of QDs 
relevant to FRET based application. Thicker shells or polymer coatings of QDs (designed 
to provide better biocompatibility) increase the minimum separation between the 
optically active QD core and a suitable donor/acceptor partner, and such QDs offer 
inherently lower FRET efficiencies (the increase in Förster distance with improved 
quantum yield generally will not outperform the thicker shell). So the preparation of 
QDs with thinner shells (or even without the shell) or shorter ligands, but with 
competitive photophysical properties can potentially lead to more promising FRET 
applications [120].  
Another complixity is the distribution of FRET donor to acceptor distance, which is 
usually defined from the center of QD to the FRET donors or acceptors. Take the case of 
LTC-to-QD FRET configuration as an example. The relatively large surfaces of QDs 
provide multiple labeling sites of LTC donors on the QD surface. Although QDs are 
synthesized to have similar dimensions along each axis and are normally approximated 
as spherical, QDs are not truly spherical (some of them are close to spherical shape, 
while some of them are more elongated, tetrahedral or even star-shaped QDs) due to 
their core/shell structure and ligand exchange or encapsulation [121]. So even with a 
more confined construct, where the LTCs are attached covalently to the organic surface 
of the QD, the distances of central QD and multiple LTCs are not unique. A distance 
distribution derived from the shape of the QD is easy to imagine. It becomes more 
complicated when the LTCs are separated from the QD surface by the biomolecules, as 
the FRET distances also depend on the orientation of the biomolecules. Bioconjugation 
strategies with a confined orientation and limited freedom of lateral movement can 
improve the capacity to tune the separation distances between the central QD and the 
surrounding fluorophores, which is important to tune the FRET efficiency. For instance, 
QD-DNA conjugates assembled using polyhistidine metal-affinity coordination have 
structures with the DNA extending out nearly radially from the QD surface within an 
area, and thus the fluorophores on the DNA will be located at a uniform set of 
centrosymmetric distances from the central QD [115]. 
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2.4. Organic dyes 
Organic dyes (traditional or newly developed) are still dominating the fluorescence field 
and make us “love to hate” due to their intrinsic advantages and limitations. These 
relatively small dyes (compared to the size of the PL NPs such as QDs) are also the 
majority of donor/acceptor materials currently used in FRET applications due to 
commercial availability, cost-effectiveness, extensive characterization of FRET 
properties, easy bioconjugation through various chemistries available [12, 122]. This 
section only discusses some general considerations of utilizing organic dyes (especially 
when compared to QDs) in FRET based applications. 
2.4.1. Dye as FRET donor/acceptor 
When the biological mechanism underlying a FRET application is clear, researchers 
tend to look for new developed fluorophores with more promising FRET performances, 
like the increasing utilization of QDs in homogeneous immuno- or hybridization assays. 
In contrast, when it goes to the other side when the biological phenomena needs to be 
investigated or be explained, the traditional dyes are usually the first type of FRET 
material applied. Various strategies available for site-specific covalent and noncovalent 
labeling of proteins in living cells with organic dyes and with the well established 
methods for delivery of organic dyes into cells make them preferable choices for 
intracellular investigation [25]. FRET biosensors with organic dye pairs have led to a 
deeper understanding of a number of biological phenomena such as protein-protein 
interactions, inter- and intracellular processes. Enzymes, substrates, and cell surface 
receptors labeled with organic dye pairs have been used both in vitro and in vivo to 
monitor various biochemical processes, such as 3’, 5’ cyclic monophosphate production, 
phosphodiesterase activity, β-lactamase activity, integrin binding, conformational and 
electrical processes in ion channels [12].  
Dye–dye FRET combinations have had tremendous impact in the areas of nucleic acid 
analysis. One of the next generation sequencing techniques Illumina sequencing utilizes 
a common donor and four different acceptors (one for each of the DNA bases) attached to 
common DNA primers, they created four well-separated spectral emission windows that 
were excited at only a single wavelength [123]. Dye-labeled primers and FRET-based 
multiplexing strategies are the backbone of modern nucleic acid analysis [25], for 
instance, most of the miRNA detection techniques using qRT-PCR generate the FRET 
signal via the coupling of a fluorogenic dye and a quencher moeity to the oligonucleotide 
products after PCR. The FRET  probes used to monitor DNA amplification in PCR are 
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either cleaved in the reaction (TaqMan probes), incorporated into amplified DNA 
(Scorpion primers), or undergo a conformation change in the presence of a 
complementary DNA target (molecular beacons) [124]. Interestingly, use of DNA 
scaffolds incorporating FRET donor/acceptor dyes has led to a more fundamental 
understanding of the orientational dependence of the dyes on FRET efficiency [125]. 
2.4.2. Limitations and opportunities 
Despite all the advantages of organic dyes, there are inherent limitations, which 
complicate the FRET based experiment design and can lead to poor analytic 
performances. The broad absorption/emission profiles and small Stokes shifts often lead 
to direct excitation of the acceptor, complicating subsequent analysis, as a background of 
directly excited acceptor fluorescence must be accounted for in any analysis of FRET 
sensitized acceptor fluorescence [12, 120]. The challenge of multiplexing with molecular 
fluorophores also extends to their emission spectra. Compared to QDs, dye emission is 
broad due to the red tail associated with relaxation to an excited vibrational state, often 
approaching or exceeding 75 nm in spectral width. This consequently makes the spectra-
multiplexing based on different organic dyes very complicate due to the optical crosstalk 
in different detection channels. Besides the broad excitation and emission spectra, some 
organic dyes have a high rate of photobleaching, may be sensitive to pH, and have a 
propensity to self-quench when highly substituted on biomolecules. All of these negative 
aspects can inhibit to achieve robust, reliable FRET assay with organic dyes. 
It may seem that organic dyes totally fail in the competition with QDs considering the 
multiplexed FRET capacity, however, this is unilateral. Recall that FRET is a strong 
distance dependent process (raised to the sixth power), and the FRET efficiency can be 
tuned by the separation distances of FRET donor and acceptor. If different PL decay 
times can be distinguished (i.e., different τDA=τAD due to different FRET efficiencies 
resulting from different D-A distances for the same D-A pair), then temporal 
multiplexing could be achievable and this will add another dimension of multiplexing 
[14]. Although a theoretical construction of a temporally multiplexed FRET sensor is 
relatively easy, the practical development of such biosensors is much more challenging 
due to the difficulty in precisely controlling the distances between FRET donor and 
acceptor in biological systems, and it becomes much more complicated when NPs like 
QDs are used as the FRET acceptors due to the uncertainty of the orientation of 
biomolecule on the QD and their relative separation distance from the QD, which has 
been discussed in Section 2.3.3. In contrast, traditional organic dyes show greatly 
promising physical properties to perform temporal multiplexing. Due to the small sizes, 
most organic dyes provide a single active site for conjugation with biomolecules, and, 
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more importantly, they can be approximated as a point when we estimate the distance 
of FRET donor and acceptor. Site-specific (terminal or internal) modification of 
oligonucleotides with different kinds of organic dyes (Alexa Fluor, Cy, ATTO) are 
commercially available in most of the oligonucleotide synthesis companies, and site-
specific labeling of proteins can be achieved by different strategies such as chemical 
modification, genetically encoded fluorescent proteins or mutagenesis technique. Well-
estimated and controllable FRET donor to acceptor distances can then be achieved in 
biological systems for the temporal-multiplexed detection. Furthermore, the typically 
intrinsic mono-exponential decays of organic dyes enable straightforward identification 
of a single decay from a mixture of multiple decay curves.  
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2.5. Biomarker 
2.5.1. Introduction 
The consensus definition of a biomarker (defined by the National Institutes of Health 
Biomarkers Definitions Working Group in 1998) is “a characteristic that is objectively 
measured and evaluated as an indicator of normal biologic processes, pathogenic 
processes or pharmacologic responses to a therapeutic intervention” [126]. The countless 
biomarkers can be classified based on different parameters such as the types of the 
biomarkers (metabolites, carbohydrates, steroids, and lipids, peptides, proteins and 
nucleic acid and cells) [127], the potential application (diagnostic biomarkers, staging of 
disease biomarkers, disease prognosis biomarkers, predictive biomarkers, surrogate 
biomarkers, pharmacodynamics biomarkers, etc.) [128, 129], and others. While 
biomarkers involved in different diseases such as cancer, metabolic disorders, 
inflammatory disorders, and diseases of nervous system and cardiovascular system, the 
focus of this work is on cancer related biomarkers such as proteins and miRNAs. 
Cancer seriously threats the human health across the world. There are some basic 
clinical conceptions on cancer biomarkers discovery [26, 130, 131]. Cancer development 
is a result of complicated interactions between the cancer cells and the surrounding 
microenvironment, and various molecules such as cell surface antigens and receptors, 
cell-anchored and secreted enzymes, cytokines, and extracellular matrix molecules 
involve in the communication between cancer cells and the surrounding. The complexity 
of cancer development may be the reason that most single biomarkers have not reached 
the level of cancer specificity and sensitivity required for routine clinical use, and thus, 
biomarker discovery is moving away from the ideal single, cancer-specific biomarker to 
multiple biomarkers [132–135].  
The field of biomarker discovery is to identify candidate biomarkers, which are 
differentially expressed between the normal and diseased states, and the process is 
more beneficial of unbiased approaches or hypothesis-free approaches [136]. The 
biomarkers verification and validation is to confirm the differential abundance of 
candidates in human plasma, to assess and establish diagnostic accuracy [26]. 
Diagnostic accuracy refers to the degree with which results of a test concur with what 
would be considered the current gold standard of clinical assessment (another 
established biomarker or a clinical outcome) of the interrogated question. Accuracy can 
be expressed through diagnostic sensitivity (the likelihood that a diseased sample will 
test positive) and specificity (the likelihood that an unaffected sample will test negative) 
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[137]. These parameters are not intrinsic to the test and are determined by the clinical 
context in which the test is employed [26]. Biomarkers verification and validation 
processes,  as well as the applicability of valid biomarkers strongly rely on the 
development of targeted quantification approaches or hypothesis-driven analytical 
techniques [136] such as immunoassay or sequence-specific nucleic acid hybridization 
assay. Analytical accuracy refers to a number of metrological parameters (precision, 
accuracy, limits of detection, analytical range, reagent stability, reproducibility, etc.) 
that determine the performance of an assay on the level of technical specification. The 
complexity of developing robust and accurate analytical methods is mainly due to the 
very low abundance of many biomedical relevant biomarkers and the very high amounts 
of plasma proteins such as albumin in human samples. Both high analytical accuracy 
and diagnostic accuracy are necessary for an informative diagnostic assay. 
2.5.2. Protein biomarkers 
Protein biomarkers are among the most important and classic biomarkers, which offer a 
significantly great degree of differentiated information of cancers. Cancer occurs in all 
parts of the body, but for practical purposes, the biomarkers available in body fluids (in 
most cases the blood and urine) have been the first choice of investigation as most of 
such specimens can be obtained by non-invasive or minimally invasive techniques, 
though a combination and/or comparison of the tissue samples is usually recommended 
to provide more comprehensive information [26, 136, 138–140]. Circulating protein 
cancer biomarkers are those tumor-derived secretory proteins circulating in the blood. 
Proteomics is a key technology for the discovery of biomarkers for pharmaceutical and 
diagnostic research. Various proteomic platforms can be applied from the unbiased 
discovery setting to the targeted quantification in the validation stage (which can be 
further used in clinical practice). Unbiased approach that involves untargeted 
identification of differentially expressed proteins between two analyzed groups is 
preferred, especially in the cases when molecular mechanisms underlying the disease 
initiation or progression are not available. Currently, mass spectrometry based protein 
profiling results in a substantial increase of novel biomarker candidates [128, 140]. 
Following the discovery of new biomarker candidates is the validation stage where 
targeted quantification approaches with immunoassays to be the mainstay of testing-
need to be used. The ability to generate antibodies to a wide range of proteins and their 
specific nature make them the most important recognition elements for targeted 
quantification approaches. They use antibodies directed against the protein of interest. 
Besides the most widely used traditional immunoassay called enzyme-linked 
immunosorbent assay (ELISA), numerous other immunoassays based on radioactive 
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isotopes, photo-/ chemi-/ bio-luminescence probes or even labeling free method such as 
surface plasmon resonance have been developed to provide more sensitive and specific 
measurements (targeting to the complexity of body fluids), and to perform simultaneous 
quantitative analysis of multiple potential biomarkers (targeting to the trend of 
biomarker discovery from single to multiple biomarker).  
Despite years of intensive analysis, only a small number of proteins have been validated 
as cancer biomarkers [141, 142]. The list of FDA-approved protein tumor markers 
currently used in clinical practice is show in Table 2.1. 
While proteins are more diverse and therefore potentially more informative, challenges 
for developing new protein-based biomarkers include the complexity of protein 
composition in blood, the diversity of post-translational modifications, the low relative 
abundance of many proteins of interest, the sequence variations among different 
clinically relevant species, and the difficulties in developing suitable high-affinity 
detection agents have made the discovery and development of new protein-based 
biomarkers with proper characteristics an expensive and time-consuming task [143]. 
2.5.3. miRNA biomarkers 
Compared to protein biomarkers, miRNA biomarkers are quite young members in the 
biomarker family, but have shown their great potentials [28]. MiRNAs are small non-
coding RNA molecules of 19-25 nucleotides in length. They involve in tissue-specific 
gene expression control by acting as post-transcriptional repressors through binding to 
3’-untranslated regions of target messenger RNA [144, 145] (Figure 2.11). MiRNAs are 
specifically modulated by the tumor, for instance, serum levels of miR-141 [146], have 
been used to discriminate patients with advanced prostate cancer from healthy 
individuals, the ratio of miR-126 and miR-182 in urine samples can be used to detect 
bladder cancer [147]. The discovery of many different miRNAs specific for breast, 
colorectal, esophageal, gastric, liver, lung, ovarian, and pancreatic cancers, have 
strongly driven the implementation of miRNAs as potential cancer biomarkers [148, 
149]. Analysis of extracellular miRNAs circulating in the blood became highly relevant 
when circulating miRNAs were found to be extremely resistant against RNases because 
of their protection inside the membrane structure of microvesicles (e.g., exosomes, 
microparticles, and apoptotic bodies) or associated with RNA-binding proteins (e.g., 
Argonaute2 and nucleophosmin) [150, 151] (Figure 2.11). Furthermore, the sequences 
of most miRNAs are conserved among different species. The possibility of direct 
detection in easily-accessible plasma samples has opened up new clinical avenues for 
miRNAs to be used as a next generation of biomarkers for diagnosis and prognosis [152–
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157]. The major challenge of applying miRNAs as biomarkers concern their physical 
properties, such as the very short lengths, the low expression levels and extremely 
similar sequences of the miRNAs within a family, which have been the main stumbling 
blocks to achieve precise quantification. 
Table 2.1. List of some FDA-approved protein tumor markers currently used in clinical practice 
(modified from reference [137]).  
Biomarker  Clinical use 
Cancer 
type  Specimen  Methodology 
Nuclear Mitotic Apparatus 
protein (NuMA, NMP22) 
Diagnosis and monitoring of 
disease (professional and 
home use) Bladder Urine 
Lateral flow 
immunoassay 
Estrogen receptor (ER) 
Prognosis, response to 
therapy Breast FFPE tissue IHC 
Progesterone receptor (PR) 
Prognosis, response to 
therapy Breast FFPE tissue IHC 
HER-2/neu Assessment for therapy Breast FFPE tissue IHC 
CA15-3 
Monitoring disease response 
to therapy Breast 
Serum, 
plasma Immunoassay 
CA27.29 
Monitoring disease response 
to therapy Breast Serum Immunoassay 
Circulating Tumor Cells 
(EpCAM, CD45, 
cytokeratins 8, 18+, 19+) 
Prediction of cancer 
progression and 
survival Breast  Whole blood  
Immunomagnetic 
capture/ immune-
fluorescence 
Fibrin/ fibrinogen 
degradation product (DR-
70) 
Monitoring progression of 
disease 
Colorecta
l Serum Immunoassay 
Human hemoglobin (fecal 
occult blood) 
Detection of fecal occult blood 
(home use) 
Colorecta
l Feces 
Lateral flow 
immunoassay 
c-Kit 
Detection of tumors, aid in 
selection of patients 
Gastroint
estinal 
stromal 
tumors FFPE tissue IHC 
AFP-L3% 
Risk assessment for 
development of disease 
Hepatoce
llular Serum 
HPLC, microfluidic 
capillary 
electrophoresis 
Carcino-embryonic antigen 
Aid in management and 
prognosis 
Not 
specified 
Serum, 
plasma Immunoassay 
ROMA (HE4+CA-125) Prediction of malignancy Ovarian Serum Immunoassay 
OVA1 (multiple proteins) Prediction of malignancy Ovarian Serum Immunoassay 
HE4 
Monitoring recurrence or 
progression of disease Ovarian Serum Immunoassay 
CA-125 
Monitoring disease 
progression, response to 
therapy Ovarian 
Serum, 
plasma Immunoassay 
CA19-9 Monitoring disease status 
Pancreat
ic 
Serum, 
plasma Immunoassay 
Pro2PSA 
Discriminating cancer from 
benign disease Prostate Serum Immunoassay 
Free PSA 
Discriminating cancer from 
benign disease Prostate Serum Immunoassay 
Total PSA 
Prostate cancer diagnosis 
and monitoring Prostate Serum Immunoassay 
p63 protein  Aid in differential diagnosis  Prostate  FFPE tissue IHC 
Alpha-fetoprotein (AFP) Management of cancer 
Testicula
r 
Serum, 
plasma, 
amniotic 
fluid Immunoassay 
Thyroglobulin Aid in monitoring Thyroid 
Serum, 
plasma Immunoassay 
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Figure 2.11. MiRNA biogenesis and ADAR-mediated editing during miRNA maturation. ADAR: 
family of adenosine deaminase; miRISC: miRNA induced silencing complex. (Reprinted from 
reference [144]. Copyright 2016 Macmillan Publishers Ltd.) 
There has been increasing understanding of their biological functions and some clear 
evidences of their fingerprint expression spectra of specific cancer types or disease-
stages, nevertheless, miRNA biomarkers require the same stringent validation 
processes as protein biomarkers to demonstrate their diagnostic specificity and 
selectivity in order to be used for clinical diagnostics. MiRNA expression profiling allows 
for an identification of miRNAs as key regulators of diseases, and the expression levels 
of the disease-specific miRNA are also the main task of the miRNA biomarker discovery. 
There are three major global miRNA profiling platforms in use today: microarray, 
quantitative reverse transcription-polymerase chain reaction (qRT-PCR) and next 
generation sequencing (NGS) [145, 158–161]. In microarrays, the terminal 3’-OH of the 
miRNA is firstly ligated with a fluorophore-conjugated nucleotide using T4 RNA ligase, 
and then gets captured by the array, by scanning the fluorescence information of the 
array, the miRNA profile can be built. qRT-PCR relies on reverse transcription of 
miRNA to complementary DNA (cDNA), followed by qPCR with real-time monitoring of 
reaction product accumulation in a highly parallel, high-throughput form, and due to 
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the PCR amplification, qRT-PCR allows detecting very small quantities of miRNAs. The 
general approach of NGS for miRNA profiling begins with the preparation of a cDNA 
library from the RNA sample of interest, followed by the parallel sequencing of millions 
of individual cDNA molecules from the library[145]. Each platform has one 
distinguishable advantage, such as the high throughput of microarray, the high 
sensitivity of qRT-PCR, the detection of both novel and known miRNAs and precise 
identification of miRNA sequences of NGS.   
However, common or individual limitations exist in these techniques. The sequence 
variability among miRNAs have made all the three technologies to be miRNA sequence-
specifically biased, which is derived from the enzymatic miRNA-labelling step in 
microarrays, primer annealing in qRT-PCR and enzymatic step of small RNA cDNA 
library preparation in NGS, respectively. The limited specificity and quantification of 
microarrays, the low throughput of qRT-PCR and the money and time-consuming NGS 
are the main drawbacks of these techniques.  
New miRNA detection techniques based on splint ligation, rolling circle amplification 
(RCA) or new NPs emerge and are intended to address some or at least one of the 
challenges. Among these well-established or new emerged techniques, FRET has been 
largely used as a powerful signal transduction tool to detect (directly or indirectly) short 
miRNA sequences. Three of the four qRT-PCR detection chemistries available, namely, 
TaqMan probes, Molecular Beacons and Scorpions depend on FRET to generate the 
fluorescence signal via the coupling of a fluorogenic dye and a quencher moeity to the 
oligonucleotide products after PCR. FRET-based RCA methods for nucleic acid detection 
almost exclusively use molecular beacons (a hairpin DNA functionalized with a 
fluorescent FRET donor and a fluorescence quencher as acceptor) as RCP-hybridizing 
FRET probes. These RCA-based assays can be performed with a constant and low 
temperature and offer very high sensitivity competitive to PCR. Unfortunately, they 
could not provide multiplexing, and have not been largely applied to miRNA detections. 
Therefore, real-time, homogeneous, and high-throughput and high-order multiplexed 
assays in a single sample are highly desired for FRET-based miRNA detection 
technologies in order to solve all the problems mentioned above within a single 
biosensing approach. 
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3. Multiplexed Protein Assay 
3.1. Introduction 
The rapid development of clinical diagnostics and therapeutics such as point-of-care 
testing and personalized medicine [4–6], together with the trend of biomarker discovery  
moving away from the ideal single, cancer-specific biomarker to multiple biomarkers 
[132–134], have led to increasing demand for a multiplex and high throughput analysis 
of large numbers of biomolecules within a single sample. For instance, EGFR and HER2 
are cell surface receptor tyrosine kinases that transduce growth signals through 
dimerization with HER family receptors, and they are involved in the regulation of 
fundamental cellular functions, and an aberrant regulation of the receptors has been 
implicated in a broad range of human malignancies such as lung and breast cancers 
[162–164]. Non-small-cell lung cancer (NSCLC) tumors that overexpress both EGFR and 
HER2 are more sensitive to EGFR tyrosine kinases inhibitors than are tumors that 
overexpress EGFR but are HER2 negative. Therefore, a simultaneous detection of EGFR 
and HER2 in NSCLC tumors may have a prognostic value in NSCLC (e.g. decreased 
values of both EGFR and HER2 mean an objective tumor response) and a predictive 
value (targeting the group of patients who are likely to benefit from EGFR tyrosine 
kinases inhibitors) [165]. The status of HER2 is an essential step in the breast cancer 
diagnostic, but EGFR expressions levels are diverse. EGFR overexpression has been 
associated to the basal-like breast carcinomas [166], while low EGFR levels in patients 
with metastatic breast cancer are associated with a shorter overall survival [167]. 
Serum levels of the HER2 and EGFR change significantly between primary diagnosis 
and the onset of metastatic disease, however in opposite directions [168]. So the 
combined determination of EGFR and HER2 also delivers relevant information for 
breast cancers. A multiplexed detection of potential biomarkers can not only achieve 
superior accuracy for clinical diagnostics and provide more information for personalized 
medicine [7]. We have shown recently the successful clinical diagnostics of cancer 
biomarkers such as total prostate specific antigen (TPSA) and human epidermal growth 
factor receptor (EGFR) based on time-gated LTC-to-QD FRET sandwich immunoassays 
[32, 34]. However, a multiplexed detection from a single sample has not been 
demonstrated so far. 
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The performance of the single sensor assay is the precondition to make the multiplexing 
work. To optimize the single sensor assays of EGFR and HER2, we performed a 
systematic investigation of different immunoassays based on all kinds of antibodies such 
as monoclonal full size antibody (mAb), fragment antigen-binding (Fab) fragment and 
single domain antibody (sdAb). Several aspects, such as the sizes of the antibodies, the 
binding sites of antibodies on the antigens, their orientations on the QDs, and the 
photophysical properties of QDs, all of which potentially affected the performances of 
the FRET measurements, were systematically studied. By estimating simplification of 
the conjugating methods, comparing the labeling ratios of different bioconjugates and 
FRET assay performances (FRET efficiencies, limits of detection), we could find the best 
FRET pairs for EGFR and HER2 sensing. Then we challenged our multiplexed assay to 
simultaneously sense EGFR and HER2 from both the biological and photophysical point 
of views. EGFR and HER2 come from the same receptor family and, as they are 
structurally related, this aspect sets high demands for the specificity of the antibodies. 
We accomplished promising results for simultaneous duplexed assay of EGFR and 
HER2 based on monoclonal antibodies. The homogeneous assays provided sub-nM (few 
ng/mL) detection limits for both EGFR and HER2 in 50 μL samples.   
3.2. Materials and methods 
3.2.1. Materials  
Recombinant Human EGFR (#344-ER-050) and HER2 (#1129-ER-050) were purchased 
from R&D system. Nanobodies against EGFR (EgA1 and EgB4) were produced as 
described elsewhere [169]. Nanobodies against HER2 (11A4-Cysteine-tag and 18A12-
Cysteine-tag) were produced as described elsewhere [170, 171]. IgGs against EGFR 
(Cetuximab and Matuzumab) were provided by Merck Serono. IgGs against HER2 
(Trastuzumab and Pertuzumab) were provided by Roche/Genentech. Fab fragments 
were prepared using Pierce Mouse IgG1 Fab and F(ab’)2 preparation kit (Thermo Fisher 
Scientific). Fragments were verified using SDS-PAGE (Appendix 7.2.1). Quantum dots 
(eFluor650/605 Nanocrystal Conjugation Kit–Sulfhydryl Reactive) were provided by 
Affymetrix/eBioscience. LTC (Lumi4-Tb-NHS and Lumi4-maleimide) was provided by 
Lumiphore. Sodium tetraborate decahydrate (Na2B4O7.10H2O), Trizma® hydrochloride, 
phosphate buffered saline (1x PBS), and sodium bicarbonate (NaHCO3), hydrochloric 
acid (HCl), sodium hydroxide (NaOH), hydroxylamine hydrochloride (HONH2·HCl), Tris 
(2-carboxyethyl) phospine hydrochloride (TCEP), dimethyl sulfoxide (DMSO), N,N -
Dimethylformamide (DMF), bovine serum albumin (BSA) were purchased from Sigma-
Aldrich. Sodium chloride (NaCl), disodium hydrogen phosphate dihydrate 
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(Na2HPO4.2H2O), sodium dihydrogen phosphate dihydrate (NaH2PO4.2H2O) were 
purchased from Duchefa. All chemicals were used as received. Newborn calf serum was 
provided by Cezanne/Thermo Fisher Scientific. Water was purified by Purelab Option-Q 
equipped with bio-filter (ELGA Labwater Veolia water ST1, Antony, France) to produce 
nuclease free water.   
3.2.2. QD bioconjugates 
eFluor650/605 Nanocrystal Conjugation Kit–Sulfhydryl Reactive (provided by 
eBioscience in lyophilized form) was used for all QD conjugations. Prior to conjugation, 
protected sulfhydryl groups (N-Succinimidyl S-Acetylthioacetate) were introduced to 
anti-EGFR sdAb EgB4 (no sulfhydryl groups available) at 5× molar excess using SATA 
kit (#26102, Thermo Fisher Scientific). The sulfhydryl groups were deprotected by 
diacylation according to the manufacturer protocol. For anti-EGFR antibodies 
Cetuximab, Matuzumab, anti-HER2 antibodies Trastuzumab, Pertuzumab and anti-
HER2 nanobodies 11A4 and 18A12 (special for oriented labeling based on the terminal 
cysteine tags), there are no additional steps before being conjugated to QDs.  
Sulfhydryl-activated antibody or nanobody solutions (in concentration excess compared 
to the QD solutions) were prepared in 1× PBS and conjugated to QDs according to 
manufactures instructions. Unbound proteins were separated by washing 3 - 4 times in 
100 kDa molecular weight cutoff (MWCO) spin columns (Millipore) with 100 mM sodium 
tetraborate buffer (pH 8.3) as the wash buffer. QD concentrations were determined by 
absorbance measurements using molar absorptivities of 1.1×106 M-1cm-1 (at 641 nm) for 
QD650 and of 2.5×105 M-1cm-1 (at 594 nm) for QD605 as provided by the manufacturer. 
Antibodies were quantified by absorbance measurements at 280 nm using extinction 
coefficient of 1.4 g-1Lcm-1, 2.4 g-1Lcm-1, 2.2 g-1Lcm-1, and 2.0 g-1Lcm-1 for antibodies 
(Cetuximab, Matuzumab, Matuzumab Fab, Trastuzumab, Pertuzumab and Pertuzumab 
Fab), EgA1 (or EgB4), 11A4 and 18A12, respectively. The labeling ratios were 
determined by linear combination of the respective absorbance values of QDs and 
antibodies within the QD antibody conjugates.  
3.2.3. LTC bioconjugates  
Lumi4-Tb-NHS was used of random labeling for antibodies Cetuximab, Matuzumab, 
Trastuzumab, Pertuzumab and sdAb EgA1. Lumi4-Tb-NHS was dissolved to 8 mM in 
anhydrous DMF and mixed (in concentration excess to the antibody solutions) with the 
antibodies samples in 100 mM carbonate buffer at pH 9.0. The mixtures were incubated 
while rotating at 25 RPM (Intelli-Mixer, ELMI) for 2 hrs at room temperature. For LTC 
conjugate purification, the samples were washed 4 - 6 times with 100 mM TRIS-Cl pH 
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7.2 using 50 kDa MWCO spin columns for MAb, 10 kDa MWCO spin columns (Millipore) 
for Fab, and 3 kDa MWCO spin columns for sdAb.  
Lumi4-maleimide was used for oriented labeling for sdAb 11A4. Lumi4-maleimide was 
dissolved to 8 mM in anhydrous DMF. 11A4 was first reduced by excess TCEP for 30 
min at room temperature in reducing buffer (50mM sodium phosphate, 150 mM NaCl, 
pH=6.5) and then excess TCEP was washed 3 times with labeling buffer (50mM sodium 
phosphate, 150 mM NaCl, pH=7.4) using 3 kDa MWCO spin columns (Millipore). Reduced 
11A4 was mixed with excess Lumi4-maleimide for 3 hrs at room temperature in labeling 
buffer. For Lumi4-11A4 purification, the samples were washed 4 - 6 times with 100 mM 
TRIS-Cl pH 7.4 using 3 kDa MWCO spin columns. Lumi4-11A4 was then charged by 
TbCl3 for 1 hr and being stored at 4 °C. 
LTC concentrations were determined by absorbance measurements at 340 nm using a 
molar absorptivity of 26,000 M-1cm-1 as provided by the manufacturer. Antibodies were 
quantified by absorbance measurements at 280 nm. The labeling ratios were determined 
by linear combination of the respective absorbance values of LTC and antibodies within 
the LTC-antibody conjugates. 
3.2.4. Photophysical properties 
Absorption spectra (Lambda 35 UV/Vis System, PerkinElmer) and emission spectra 
(FluoTime 300, PicoQuant) were recorded in Tris(hydroxymethyl)-aminomethane (TRIS-
Cl, Sigma Aldrich) buffer with a pH of 7.4 and sodium-tetraborate buffer with a pH of 
8.5 (Sigma Aldrich) for LTC and QD samples, respectively. PL decay curves were 
acquired directly from the FRET immunoassay samples on an EI fluorescence plate 
reader (Edinburgh Instruments) using 4000 detection bins of 2 μs integration time and 
nitrogen laser (VSL 337 ND, Spectra Physics) excitation (337.1 nm, 20 Hz). Optical 
transmission filter bandpass wavelengths were (494±10) nm (Semrock) for the LTC 
detection channel, (660±7) nm (Semrock) for the QD650 detection channel and (607±5) 
nm (Delta) for the QD605 detection channel. 
3.2.5. Homogeneous FRET immunoassays 
The LTC and QD antibody conjugates were each dissolved in 50 μL TRIS-Cl-buffer 
containing 0.5 % bovine serum albumin (BSA, Sigma-Aldrich). 50 μL EGFR or HER2 
antigen samples with varying concentrations were added to the 100 μL solutions 
containing both the LTC and QD conjugates. Time-gated (0.1 – 0.9 ms) PL intensity 
measurements were acquired on a KRYPTOR compact plus fluorescence plate reader 
(Cezanne/Thermo Fisher Scientific) using 500 detection bins of 2 μs integration time and 
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nitrogen laser excitation (337.1 nm, 20 Hz, 100 pulses). Optical transmission filter 
bandpass wavelengths were the same as were used in the EI fluorescence plate reader. 
All FRET-assays were measured in black 96-well microtiter plates with an optimal 
working volume of 150 μL. Each sample containing EGFR or HER2 antigen samples 
were prepared three times and the samples without EGFR or HER2 were prepared ten 
times. All samples were measured in triplicates. After sample preparation the microtiter 
plates were incubated for 180 min at 37 °C before measurements on the KRYPTOR and 
EI fluorescence plate readers. 
3.3. Results and discussion 
3.3.1. Antibody Conjugations 
The “ideal” characteristics desired from a QD bioconjugation for FRET immunoassay 
applications should be controlled over the ratio of biomolecule per QD (decide the overall 
brightness of the FRET system and the sensitivity of FRET immunoassay), the 
orientation on the QD (decide the activity of antibody and distance between FRET donor 
and acceptor) and the relative separation distance from the QD (decide the FRET 
efficiency), and it should also maintain the optimal function and activity of both QD and 
Ab [112]. Ab activities are dependent upon their binding sites having access to the 
environment. Nonspecific chemistry can result in heterogeneous attachment and impair 
activity in the final conjugate. The conditions used for mAbs conjugation often provoke 
mAbs unfolding and provide random orientation of mAbs on the surface of QDs [116]. 
Compared to mAb, sdAb appears to be much easier to be controlled over the orientation 
as it can be manipulated with terminal modification such as cysteines using standard 
molecular biology techniques [34]. Anti-HER2 sdAb 18A12 was conjugated with QDs 
through the sulfhydryl-reactive conjugation chemistry of an additional cysteine residue 
(provide sulfydryl group) integrated within the C terminal of the 18A12 and maleimide 
group available on QD. This approach allowed us to develop sdAb-QD comprising larger 
amount of sdAbs coupled with a QD in a highly oriented manner. To better compare the 
effects of oriented and random conjugation on QD, we introduced random sulfydryl 
groups by transferring free amino groups available on 18A12 with N-succinimidyl S-
acetylthioacetate, and follow the same approach above to conjugate sdAbs with QD in a 
random manner. The application of sdAbs prompts another important aspect of QD 
coupling: the relative separation distance. As FRET is highly distance-dependent, we 
fully investigated this aspect by comparing the effects of sdAb with full size mAb (ca. 
150 kDa) and Fab (ca. 50 kDa) fragments for both EGFR and HER2 sensing. 
45 
 
Furthermore, to achieve simultaneous multiplexed detection of EGFR and HER2, we 
conjugated different Abs with both QD605 and QD650. 
The random labeling of LTC was in a straightforward manner via coupling of NHS-
activated LTC to available primary amines of the Abs, while the oriented labeling was 
performed on anti-HER2 sdAb 11A4 via coupling of Lumi4-maleimide to an additional 
cysteine residue integrated within the C terminal of the 11A4.  
An overview of LTC and QD conjugation methods including conjugation reagents, 
reaction groups and special treatments for each conjugate are summarized in Table 3.1. 
Labeling ratios of the LTC and QD conjugates were determined by UV/vis absorption 
spectroscopy and are shown in Table 3.2. As the sizes of the Abs are in the order of 
mAb > Fab > sdAb, theoretically the LTC/Ab labeling ratio decreases and Ab/QD 
labeling increases with decreasing Ab size, and this can be confirmed by the labeling 
ratios shown in Table 3.2. For LTC conjugates, the LTC/sdAb labeling ratios are around 
2, while the LTC/mAb labeling ratios are 4 - 14, depending on the number of free amino 
group available on the Abs. For QD conjugates, the sdAb/QD labeling ratios are 10 - 20, 
and the average of mAb/QD labeling ratios is 5. 
 
Figure 3.1. Principle of the homogeneous EGFR/HER2 duplexed immunoassay. The combination 
of LTC-labeled antibody and QD-labeled antibody allows the formation of LTC-antibody-
EGFR/HER2-QD-antibody sandwich complexes, which results in FRET from several LTC to the 
central QD. Time-gated detection of FRET-sensitized QD PL is used for a sensitive quantification 
of soluble EGFR/HER2 in buffer. Random and oriented labelings of the antibody are taken into 
considerations. 
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LTC 
conjugates 
Reaction 
group 
Labeling 
reagent 
Special 
treatment 
QD 
conjugates 
Reaction group 
Labeling 
reagent 
Special treatment 
anti-HER2 
nanobody 
11A4-LTC1 Sulfhydryls  
L4-
Maleimide 
Nanobody 
reducing 
before 
conjugation 
and TbCl3 
charging after 
conjugation 
18A12-
eQD650 (O) 
Sulfhydryls  
eFluor650 
Nanocrystal  
--- 
18A12-
eQD650 (R) 
Sulfhydryls  
eFluor650 
Nanocrystal  
Introducing Sulfhydryls to Primary 
amines using SATA  
18A12-
eQD605 (O) 
Sulfhydryls  
eFluor605 
Nanocrystal  
--- 
18A12-
eQD605 (R) 
Sulfhydryls  
eFluor605 
Nanocrystal  
Introducing Sulfhydryls to Primary 
amines using SATA  
                  
anti-HER2 
antibody 
Tras- LTC 
Primary 
amines 
L4Tb-NHS --- 
Pert-
eQD605 (R) 
Sulfhydryls  
eFluor605 
Nanocrystal  
--- 
Pert-
eQD650 (R) 
Sulfhydryls  
eFluor650 
Nanocrystal  
--- 
Pert Fab-
eQD605 (R) 
Sulfhydryls  
eFluor605 
Nanocrystal  
Fragmentation of IgG 
Pert Fab-
eQD650 (R) 
Sulfhydryls  
eFluor650 
Nanocrystal  
Fragmentation of IgG 
                  
anti-EGFR 
nanobody 
EgA1- 
LTC  
Primary 
amines 
L4Tb-NHS --- 
EgB4-
eQD605 
(R)2 
Sulfhydryls  
eFluor605 
Nanocrystal  
Introducing Sulfhydryls to Primary 
amines using SATA  
EgB4-
eQD650 (R) 
Sulfhydryls  
eFluor650 
Nanocrystal  
Introducing Sulfhydryls to Primary 
amines using SATA  
                  
anti-EGFR 
antibody 
Mat- LTC 
Primary 
amines 
L4Tb-NHS --- 
Cet- 
eQD650 (R) 
Sulfhydryls  
eFluor650 
Nanocrystal  
--- 
Cet- LTC 
Primary 
amines 
L4Tb-NHS --- 
Mat-
eQD605 (R) 
Sulfhydryls  
eFluor605 
Nanocrystal  
--- 
Mat-
eQD650 (R) 
Sulfhydryls  
eFluor650 
Nanocrystal  
--- 
Mat Fab-
eQD605 (R) 
Sulfhydryls  
eFluor605 
Nanocrystal  
Fragmentation of IgG 
Mat Fab-
eQD650 (R) 
Sulfhydryls  
eFluor650 
Nanocrystal  
Fragmentation of IgG 
 
Table 3.1. An overview of LTC and QD conjugation methods. Note 1 – 2, typical protocols see Appendix 7.2.2 
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LTC 
conjugates 
LTC/AB QD conjugates AB/QD 
11A4-LTC 1.4 
18A12-eQD650 (O) 19.7 
18A12-eQD650 (R) 17.3 
18A12-eQD605 (O) 9.8 
18A12-eQD605 (R) 3.1 
        
Tras- LTC 13.5 
Pert-eQD605 (R) 2.5 
Pert-eQD650 (R) 8.1 
Pert Fab-eQD605 (R) 3.4 
Pert Fab-eQD650 (R) 17.0 
        
EgA1- LTC  2.2 
EgB4-eQD605 (R) 22.0 
EgB4-eQD650 (R) 18.1 
    
        
Mat- LTC 4.1 Cet-eQD650 (R) 4.3 
Cet- LTC 7.7 
Mat-eQD605 (R) 3.6 
Mat-eQD650 (R) 6.5 
Mat Fab-eQD605 (R) 14.1 
Mat Fab-eQD650 (R) 35.9 
 
Table 3.2. LTC and QD conjugating ratios for the different sandwich immunoassays. 
Figure 3.2. Optical properties of the FRET assay components. Left: Molar absorptivity spectra 
of LTC (black, multiplied by 250), QD605 (orange, multiplied by 4) and QD650 (red). For the 
calculation of the overlap integrals between LTC donor emission and QD acceptor absorption, the 
area-normalized LTC emission spectrum (green) is also shown. Right: PL intensity spectra of 
LTC (green), QD605 (orange), and QD650 (red) antibody conjugates normalized to unity at their 
respective maxima. The gray spectra in the background define the transmission of the optical 
band-pass filters within the LTC (494 ± 10 nm), QD605 (607 ± 5 nm), and QD650 (660 ± 7 nm) 
detection channels. 
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3.3.2. EGFR single sensor development 
The homogeneous FRET immunoassays contained 50 μL of each Ab conjugate (LTC and 
QD) at constant concentrations and 50 μL of EGFR at increasing concentrations. The 
assays were measured on a KRYPTOR compact plus (Cezanne/Thermo Fisher Scientific) 
clinical fluorescence plate reader, which simultaneously detected the time-gated PL 
intensities (integration of the PL intensities within the time window from 0.1 to 0.9 ms 
after pulsed excitation) in the LTC donor (ILTC) and the QD acceptor (IQD) channels. FR 
(IQD/ILTC) was used for the determination of the biomarker concentration, and to fully 
compare FRET performances of different configurations, we normalized the FR to unity 
at [EGFR] = 0. 
Figure 3.3 showed the assay calibration curves of EGFR concentration-dependent 
measurement of rel. FR for all combinations of LTC-to-QD FRET pairs. All assay curves 
showed a strong increase of rel. FR (caused by QD FRET-sensitization from the LTC 
donors, as shown in the PL decay curves from the different QD detection channels) with 
increasing EGFR concentrations from 0.075 nM until ca. 9 nM EGFR, which is the 
concentration range, where the Abs (QD and/or LTC conjugates) became saturated by 
EGFR biomarkers and higher EGFR concentrations do not provide additional FRET, 
and in contrast, FRET ratios decrease due to the “hook-effect” [172]. It is expected that 
the more LTC per QD, the more efficient sensitization of QD from LTC (also means a 
higher sensitivity of the immunoassay) will be observed. This can be confirmed by 
comparing the Cetuximab-LTC/Matuzumab-QD650 system with Matuzumab-
LTC/Cetuximab-QD650 system (the opposite labeling direction). With the same 
biological recognition (meaning the same Ab activities and nearly the same donor to 
acceptor distance), the rel. FR of Cetuximab-LTC/Matuzumab-QD650 system increases 
faster (more sensitive) than that of Matuzumab-LTC/Cetuximab-QD650 system thanks 
to the higher LTC/Ab and Ab/QD in the Cetuximab-LTC/Matuzumab-QD650 system 
(shown in Table 3.2). This can be also demonstrated by comparing the curves of Fab-QD 
and mAb-QD containing systems, where the Fab-QD containing system showed steeper 
slope than mAb-QD containing system.  
By comparing the PL decay curves of QDs of Cetuximab-LTC/Matuzumab Fab-QD650 
system and EgA1-LTC/EgB4-QD650 system (Figure 3.3 Top two), we could see clearly 
the latter, which is based on sdAb, provides much faster decay than the antibody based 
system  because of their very small sizes, which decreases the relative distance of LTC 
and QD and increases FRET efficiencies. But as is shown in two of the bottom figures in 
Figure 3.3, the relative sensitization of sdAb systems is less than that of antibody 
systems, and this is mainly due to the nonspecific binding between the sdAb and the 
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buffer matrix, as was demonstrated in our previous study [34], the bovine serum 
albumin (BSA) used in the buffer introduced non-specific binding between EgA1-LTC 
and EgB4-QD, which consequently increases the background FRET signals without the 
presence of EGFR and decrease the sensitivity of the FRET assay based on sdAbs.  
The limits of detection (LODs; Table 3.3) of homogeneous FRET assays for all 
combinations of different Ab pairs are in the sub-nM (few ng/mL) EGFR range. The 
differences of LODs are correlative to results of the concentration-dependent 
measurements, where the LODs are lowest for the Fab-QD conjugates, followed by the 
mAb-QD conjugates and then sdAb-QD. All of these LODs are below the recommended 
cut-off level of 45 ng/mL of EGFR in breast cancer [166, 168] and well in the 
concentration range for revealing relevant clinical information. 
 
Figure 3.3. QD650 PL decay curves of pure Ab-QD (violet), pure LTC-Ab (dark blue), and both 
conjugates with increasing EGFR concentrations (0 – black, 0.9 nM – red, 2.25 nM – blue, 4.5 nM 
– magenta, and 9 nM – green) for the LTC-Cet/Mat Fab-QD650 (A) and LTC-EgA1/EgB4-QD650 
(B) FRET pairs. Time-gated PL intensity ratios of homogeneous EGFR immunoassays of Ab 
based (C, dark blue: LTC-Cet/Mat Fab-QD605; green: LTC-Cet/Mat Fab-QD650; blue: LTC-
Cet/Mat-QD605; black: LTC-Mat/Cet-QD650; red: LTC-Cet/Mat-QD650; magenta: LTC-Cet/Mat 
Fab-QD650 measured in serum samples) and sdAb based (D, black: LTC-EgA1/EgB4-QD650; red: 
LTC-EgA1/EgB4-QD605) systems. Relative time-gated (0.1-0.9 ms) PL intensity ratios (ChA/ChD 
ratio normalized to unity at [EGFR] =0) as a function of EGFR concentration. Increasing EGFR 
concentrations led to a strong increase of FRET ratio for all antibody combinations. 
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  LOD (nM) LOD (ng/mL) fmol 
Mat-LTC and Cet-eQD650 0.04 8.3 2.1 
Cet-LTC and Mat-eQD650 0.02 4.4 1.1 
Cet-LTC and Mat-eQD605 0.07 13.9 3.5 
Cet-LTC and Mat-eQD650 (serum) 0.04 7.1 1.8 
Cet-LTC and Mat Fab-eQD650 0.01 2.9 0.7 
Cet-LTC and Mat Fab-eQD605 0.02 4.8 1.2 
EgA1-LTC and EgB4-eQD650 0.12 23.9 6.0 
EgA1-LTC and EgB4-eQD605 0.11 22.9 5.7 
 
Table 3.3. Limits of Detection (LODs) of the EGFR single sensor assays for all combinations of 
antibody pairs. 
3.3.3. HER2 single sensor development 
We continued to the optimization of HER2 single sensor assay by introducing oriented 
conjugation of sdAbs 11A4 and 18A12 to LTC and QD, respectively (Figure 3.4). The 
oriented conjugation based system showed better FRET signals and lower LODs 
compared to the random labeling system as expected, mainly due to the terminal 
modifications, which greatly preserved the best activities of sdAbs and more controllable 
conjugation process [117]. By comparing the FRET performances of sdAb containing 
systems with mAb or Fab containing systems, we found that different to EGFR sensing 
profile, the sdAb containing systems, especially those with oriented conjugations of QDs, 
did provide better FRET sensitization and lower LODs compared to mAb or Fab 
containing systems. This partly benefit of the almost negligible non-specific binding 
between BSA and 11A4-LTC and 18A12-QDs (which caused a big problem in the EGFR 
sensing). Moreover, not like the two anti-EGFR antibodies which bound to the same 
domain of EGFR, it was reported that pertuzumab and trastuzumab bind to different 
domains of HER2 [163], so we had the reason to believe that the sdAb based system 
provided shorter distances of FRET donor (LTC) and acceptor (QD) compared to the 
mAb or Fab based systems, which also contributed to the better FRET signals. 
The limits of detection (LODs; Table 3.4) of homogeneous FRET assays for all 
combinations of different Ab pairs are in the sub-nM (few ng/mL) HER2 range. The Fab 
containing systems showed similar LODs with mAb containing systems, while the sdAb 
containing systems especially with oriented conjugation provided lower LODs, which 
were also below the recommended cut-off level of 15 ng/mL of HER2 in breast cancer  
[166, 168]. A graphic comparison of the limits of detection with different single sensor 
assays is shown in Figure 3.5.  
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Figure 3.4. QD650 PL decay curves of pure Ab-QD (green), pure LTC-Ab (magenta), and both 
conjugates with increasing HER2 concentrations (0 – black, 3 nM – red, 6 nM – blue) for the 
LTC-Tras/Pert-QD650 (A) and LTC-11A4/18A12-QD650 oriented labeling system (B) FRET pairs. 
Time-gated PL intensity ratios of homogeneous EGFR immunoassays of Ab based (C, red: LTC-
Tras/Pert-QD605; magenta: LTC-Tras/Pert Fab-QD605; blue: LTC-Tras/Pert Fab-QD650; black: 
LTC-Tras/Pert-QD650) and sdAb based (D, black: LTC-11A4/18A12-QD605 (oriented); red: LTC-
11A4/18A12-QD605 (random); blue: LTC-11A4/18A12-QD650 (oriented); magenta: LTC-
11A4/18A12-QD650 (random)) systems. Relative time-gated (0.1-0.9 ms) PL intensity ratios 
(ChA/ChD ratio normalized to unity at [HER2] =0) as a function of EGFR concentration. 
Increasing HER2 concentrations led to a strong increase of FRET ratio for all antibody 
combinations. 
 
  LOD (nM) LOD (ng/mL) fmol 
Tras-LTC and Pert-eQD650 0.09 18.5 4.6 
Tras-LTC and Pert-eQD605 0.15 30.2 7.5 
Tras-LTC and Pert Fab-eQD650 0.11 22.5 5.6 
Tras-LTC and Pert Fab-eQD605 0.12 23.0 5.8 
11A4-LTC (O) and 18A12-eQD605 (O) 0.04 8.0 2.0 
11A4-LTC (O) and 18A12-eQD605 (R) 0.12 24.4 6.1 
11A4-LTC (O) and 18A12-eQD650 (O) 0.05 9.1 2.3 
11A4-LTC (O) and 18A12-eQD650 (R) 0.08 15.5 3.9 
 
Table 3.4. Limits of Detection (LODs) of the HER2 single sensor assays for all combinations of 
antibody pairs. 
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Figure 3.5. An graphic comparison of the limits of detection of EGFR/HER2 single sensor assays 
with all combinations of antibody pairs and QDs. * Assay is performed in serum. 
So far we have demonstrated several very important factors needed to be taken into 
consideration when we develop new FRET biosensors based on immunoassays, such as 
the relative orientation and distance of two antibodies after binding to the biomarker, 
the sizes of antibodies, the bioconjugation method (random or oriented labeling) and the 
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accessibility of the antibodies to biomarker after conjugation. All these parameters affect 
the FRET performance in different ways and should be optimized to obtain the best 
sensitivity. 
3.3.4. EGFR and HER2 Duplexed Assay  
After a full investigation of single sensors for EGFR and HER2 detections, we processed 
to the EGFR and HER2 duplexed assay. An optimal choice among the different sensors 
would be an antibody-based sensors for both EGFR and HER2 considering the non-
specific binding issue of sdAb based sensors, as was demonstrated in the single sensor 
development. We chose the pair Cetuximab-LTC/ Matuzumab-QD605 and Trastuzumab-
LTC/ Pertuzumab-QD650 for EGFR and HER2, respectively.  
Two aspects should be taken into consideration when developing multiplexed FRET 
biosensors: optical crosstalk (due to the overlap between the different QD emission 
spectra) and biological crosstalk (due to the low specificity of Ab). We first designed 
orthogonal experiments to check the specificities of four Abs to their corresponding 
antigens where we used different configurations Cetuximab-LTC/ Matuzumab-QD650, 
Cetuximab-LTC/ Pertuzumab-QD650, Trastuzumab-LTC/ Pertuzumab-QD650, 
Trastuzumab-LTC/ Matuzumab-QD650, Pertuzumab-LTC/ Matuzumab-QD650 to sense 
EGFR and HER2 separately (Figure 3.6).  
Figure 3.6. Specificity of EGFR/HER2 antibodies. Black bars: no EGFR/HER2, red bars: EGFR 
from 0.75 nM to 3 nM, blue bars: HER2 from 0.75 nM to 3 nM. 
Cetuximab-LTC/ Matuzumab-QD650 and Trastuzumab-LTC/ Pertuzumab-QD650 
perform very high specificities to EGFR and HER2, respectively, which was expected as 
the combination of two different monoclonal Abs in FRET immunoassay greatly 
decrease the possibility of nonspecific binding to other antigens and ensure high 
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specificity. The fact that Cetuximab-LTC/ Pertuzumab-QD650 pair showed FRET 
signals to neither EGFR nor HER2 demonstrated Cetuximab and Pertuzumab have 
high specificity to EGFR and HER2, respectively. However, it was not expected that 
both the Trastuzumab-LTC/ Matuzumab-QD650 and Pertuzumab-LTC/ Matuzumab-
QD650 pairs gave FRET signals to HER2, meaning that Matuzumab can not only bind 
to EGFR but also to HER2 though with different affinities. The cross-reactivity to 
Matuzumab caused biological crosstalk in the EGFR/HER2 duplexed assay, where all 
Ab probes and different amounts of the two antigens were present into a single sample. 
The combination of the two antigens covered all possible scenarios and can be explained 
in two different ways. For EGFR detection, we prepared three different assays and eight 
control samples (Figure 3.7 A). The three assays contained EGFR at increasing 
concentrations from 0 to 3.0 nM with three different (0 nM, 1.2 nM and 3.0 nM) but 
consistent concentrations of HER2. Eight control samples were with two of EGFR 
concentrations at 0 nM and 3.0 nM under four of HER2 concentrations at 0.3 nM, 0.6 
nM, 1.8 nM, and 2.4 nM. For HER2 detection, all the samples above can be explained as 
two different assays and fifteen control samples (Figure 3.7 B). The two assays always 
contained HER2 at increasing concentrations from 0 to 3.0 nM with two different (0 nM 
and 3.0 nM) but consistent concentrations of EGFR. Fifteen control samples were with 
three of EGFR concentrations at 0 nM, 1.2 nM and 3.0 nM under five of HER2 
concentrations at 0.3 nM, 0.6 nM, 1.2 nM, 1.8 nM, and 2.4 nM. As shown in Figure 3.7 
A, EGFR can be correctly detected almost completely independent of the concentrations 
of HER2 in the samples. The presence of HER2 showed a very small contribution to the 
EGFR detection channel under lower concentrations of EGFR (0 - 1.2 nM), and the 
contribution turned to even negligible under higher concentrations of EGFR (eg. 1.8 - 3.0 
nM). The detection of HER2 in Figure 3.7 B showed the presence of EGFR strongly 
influenced the quantification of HER2 due to the biological crosstalk. The lower the 
concentration of EGFR, the more free Matuzumab-QD605 presented in the sample can 
compete with the Pertuzumab-QD650 to bind HER2, and the lower the signals obtained 
in the HER2 detection channel. However, the effects of the presence of EGFR to HER2 
detection can be quantified, as under the same concentration of HER2 (e.g. 0 nM, 1.2 nM 
and 3.0 nM), the FRET ratio increased nearly linearly with increasing concentrations of 
EGFR. Using the close to precise quantification of EGFR in its own detection channel 
(Figure 3.7 A), the FRET ratio under these concentrations can be easily calculated, 
which can be used later to calculate the quantitative curves of HER2 under a certain 
concentration of EGFR. So far, the HER2 can be detected even with the interference of 
EGFR. To estimate the LOD of the EGFR, the calibration curve being used was the one 
measured in the absence of HER2 and the FRET ratio values were calculated from the 
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FRET ratio of EGFR free samples in the presence of different concentrations of HER2 
plus three times their standard deviation (n = 30), and the average LOD was estimated 
as 0.35 nM. The LOD of HER2 was estimated as the FRET ratio of HER2 free samples 
in the presence of different concentrations of EGFR plus three times their standard 
deviation (n = 30) and the calibration curves of HER2 were measured under the 
corresponding conditions of EGFR, and the average LODs were estimated as 0.06 nM. 
We finally calculate the concentration recoveries of each sample to estimate the 
precision of our quantification. As shown in Figure 3.7 C the various concentrations of 
the EGFR and HER2 could be detected with quite high precision at low nM 
concentrations. It should be noted that the low concentrations of EGFR were 
overestimated especially when HER2 were in high values, and this is again due to the 
biological crosstalk between HER2 and Matuzumab.  
 
Figure 3.7. Duplexed immunoassay (all samples containing LTC-Cet, LTC-Tras, Mat-QD605, 
and Pert-QD650) calibration curves of EGFR (A, FRET-ratio of QD605 and LTC PL intensities) 
and HER2 (B, FRET-ratio of QD650 and LTC PL intensities) for increasing HER2 (A) and EGFR 
(B) concentrations, respectively. Figure C shows the sample recoveries of duplexed assay for the 
quantification of EGFR (black) and HER2 (red) within 19 different samples. Dotted lines 
represent the known concentrations and data points represent the measured concentrations.  
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3.4. Conclusion 
We have successfully prepared five antibody-LTC conjugates and fifteen antibody-QD 
conjugates based on either N-hydroxysuccinimide esters (NHS)-primary amines 
coupling or maleimide-thiol/cysteine coupling. The NHS-actived LTC can interact with 
all accessible primary amines on the mAb or sdAb (without terminal Cysteine 
modification), which were referred to random conjugations, and the number of LTC per 
antibody was mainly determined by the primary amines available thus determined by 
the size of the antibody and the proportion of primary amine containing amino-acid 
residues (mainly lysine). Generally, mAb can have more LTCs than sdAb per molecule. 
The sdAb can be relatively simple to be manipulated with terminal modification such as 
cysteines by standard molecular biology techniques than mAb, which allowed us to 
perform oriented conjugation via maleimide-thiol/cysteine coupling. Thus, the labeling 
ratio of  sdAb-LTC was determined by the number of modified cysteines, which was 1:1 
in our case. Although exceptions existed (18A12-eQD605 (R), Pert Fab-eQD605 (R) and 
Mat Fab-eQD650 (R)), the labeling ratios of antibodies per QD were mainly determined 
by the sizes of the antibodies, with which labeling ratios of sdAb/QD and Fab/QD 
conjugates were between ten to twenty, and labeling ratios of mAb/QD were around five. 
The single sensor immunoassays, including eight statistical assays for EGFR and eight 
statistical assays for HER2, showed increased FRET signals as a function of their 
respective antigen molecules. The best FRET pair for EGFR sensing was Cet-LTC and 
Mat Fab-eQD650, which was contributed by comprehensive effects from the decreased 
size of the antibody (which possibly offer higher FRET efficency and more FRET pairs), 
optimal binding sites of the two antibodies (which bound to the same domain of the 
antigen) and a negligible non-specific interaction among the LTC and QD probes and/or 
the buffer matrix.   The best FRET pair for HER2 sensing was 11A4-LTC and 18A12-
eQD650, both of which were used for oriented labeling strategies. This better 
performance was due to a decreased antibody size, an increased antibody activity 
derived from the oriented terminal labeling and, again, the almost negligible non-
specific interaction among the LTC and QD probes and/or the buffer matrix. Comparing 
the performance of two QDs, the eQD650 was preferred due to its larger Förster 
distance, which allowed more efficient FRET.  
We have chosen a very challenging biological model (EGFR and HER2, two structurally 
related receptor molecules from the same family) to test the multiplexing capacity of the 
LTC-to-QD FRET immunoassay. Although the potential optical crosstalks from different 
acceptor detection channels have been avoided by applying QDs as acceptors, we had 
unfortunate biological crosstalk between anti-EGFR antibody Matuzumab and HER2 
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antigen. Luckily, we could quantify the effects of the crosstalk and achieved 
quantification of both antigens with good precision.   
The very low EGFR and HER2 concentrations (well in the concentration range for 
revealing relevant clinical information) measured on a KRYPTOR diagnostic plate 
reader system demonstrate the direct applicability of our antibody-based LTC-to-QD 
FRET immunoassays for fast and sensitive biomarker detection in both point-of-care 
and high throughput in vitro diagnostics. 
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4. Multiplexed MiRNA Assay 
4.1. Introduction 
In the previous chapter, we have shown that LTC-to-QD FRET immunoassays can fulfill 
the necessary requirements for diagnostic tests even in challenging media such as 
serum, and a multiplexed detection of different protein biomarkers from a single sample 
has been demonstrated. Here, we extended the technique to miRNA detection. Although 
the importance of miRNA has led to the development of many different detection 
technologies, the standard technologies of miRNA detection are quantitative reverse 
transcription-polymerase chain reaction (qRT-PCR) and next generation sequencing 
(NGS) [158–160]. Although these technologies can provide sensitivity down to a few 
miRNA copies, they are time-consuming (NGS and qRT-PCR), require high costs (NGS), 
are limited concerning high throughput (qRT-PCR), and do not provide facile 
multiplexing from a single sample (NGS and qRT-PCR). In other words, a miRNA 
detection strategy that is ideally suited for clinical diagnostics does not exist to date. An 
ideal diagnostic miRNA assay should be single-step (e.g., no washing and separation 
steps), sensitive (detection of low concentrations), specific (e.g., discrimination of very 
similar sequences in complex mixtures), rapid (liquid phase binding kinetics and quick 
measurement), reproducible (low coefficients of variation), robust (stable sensing 
properties of bioconjugates), storable (e.g., stable lyophilized bioconjugates within an 
assay kit format), easy to use (without complicated preparation procedures), versatile 
(generic format for many miRNAs as well as DNA, facile bioconjugate 
production/purification), and multiplexed (simultaneous measurement of several 
miRNAs). 
LTC-to-QD FRET-based DNA hybridization assays have been recently demonstrated, 
but these utilized only a single QD color and the proof-of-principle system did not 
measure any free targets from a sample solution [13]. Moreover, hybridization assays for 
the detection of short (ca. 22 nucleotides) miRNAs are strongly limited in sensitivity 
because strand displacement assays (e.g., using molecular beacons) need to overcome 
energy barriers [173], and hybridization of two donor and acceptor oligos to a single 
short miRNA strand is not very stable at low concentrations. The advantages of QDs for 
FRET or fluorescence may become very useful for the detection of miRNA or other 
nucleic acids and recently several QD-based quantitative miRNA detection technologies 
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have been developed [174–184]. However, none of these methods provided homogeneous 
single-step assays, only few could multiplex from a single sample, and high selectivity 
and sensitivity could only be realized by using enzymes (ligases, polymerases, or 
nucleases), amplification strategies, and complicated sensor designs. A multiplexed 
“mix-and-measure” technology would be highly desirable for quantitative miRNA 
diagnostics. 
 
Figure 4.1. Photoluminescence multiplexing in three dimensions. x-axis: lifetime; y-axis: color; z-
axis: PL intensity.  
In this chapter, we first present an enzyme-free, simple, rapid, and homogeneous 
multiplexed assay-technology for the sensitive detection of multiple miRNAs in a single 
small-volume buffer or serum-based sample measured at room temperature. The assay 
is based on time-gated FRET from the LTC to different commercial QDs (Figure 4.1). It 
does neither require any washing or separation steps nor the addition of enzymes and 
has been designed for its application on the approved clinical diagnostics fluorescence 
microplate reader (KRYPTOR), as was mentioned before. In order to demonstrate full 
multiplexing functionality of our assay, we have detected the three miRNAs hsa-miR-
20a-5p (miRNA-20a), hsa-miR-20b-5p (miRNA-20b), and hsa-miR-21-5p (miRNA-21) in 
a single 150 μL sample at constant temperature, all with ca. 1 nM detection limits. We 
also demonstrate precise multiplexed measurements of these miRNAs at different and 
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varying concentrations and the feasibility of adapting the technology to point-of-care 
testing (POCT) in buffer containing 10 % serum.  
Then we continue to achieve higher order multiplexing. Besides the triplexed miRNAs 
detection above, in recent studies of our group and collaborators, we demonstrated 
multiplexed FRET between LTC and different organic dyes or QDs to sense multiple 
biomarkers using the principle of one-step FRET from one type of LTC to different 
acceptor molecules or particles (spectral multiplexing), and up to quintuplicate LTC-to-
QD or LTC-to-dye FRET have already been realized, however, the number is still 
limited due to the limited separated emission bands of LTC and crowded spectral 
domain of acceptors, especially when different organic dyes were applied, an optical 
crosstalk correction was always needed to achieve efficient multiplexing. If different PL 
decay times can be distinguished (i.e., different τDA=τAD due to different FRET 
efficiencies resulting from different D–A distances for the same D–A pair), then 
temporal multiplexing could be achievable and this will add another dimension of 
multiplexing (Figure 4.1). The FRET efficiency depends on the separation between the 
donor and acceptor fluorophores, raised to the sixth power. Although a theoretical 
construction of a temporal multiplexed LTC-based FRET sensor is relatively easy, the 
practical development of such biosensors is much more challenging due to the difficulty 
in precisely controlling the distances between FRET donor and acceptor in biological 
systems, and it becomes much more complicated when NPs like QDs are used as the 
FRET acceptor due to the uncertainty of the orientation of biomolecule on the QD and 
its relative separation distance from the QD. In the second study of this chapter, we 
demonstrated for the first time a successful temporal multiplexed FRET miRNA assay 
by applying different QD self-assemblies to control the distances of the FRET donor and 
acceptor and to obtain distinguishable PL decay curves. DNA modified to display either 
a terminal biotin or an oligohistidine peptidyl sequence was assembled to a streptavidin/ 
amphiphilic QD and served as the capture molecule of QD to get proximity with a LTC. 
A rapid and homogeneous method to sensitively and highly selectively detect miRNA-
20a and miRNA-20b from a single 150 µL sample was performed.  
4.2. Materials and methods 
4.2.1. Materials  
Lumi4-Tb-NHS was provided by Lumiphore, Inc.. Peptide−oligonucleotides were 
synthesized by Biosynthesis (Taxas, USA). All other oligonucleotides were purchased 
HPLC purified from Eurogentec. All sequences and modifications of nucleic acids used 
in this study are summarized in Table 4.1. Qdot® 605/655/705 ITK™ Streptavidin 
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Conjugate Kits and Zeba Spin Desalting Columns (7 kDa MWCO) were purchased from 
Thermo Fisher Scientific. Tris(hydroxymethyl)-aminomethane, bovine serum albumin, 
and HEPES were purchased from Sigma-Aldrich. NaCl was purchased from Duchefa. 
All chemicals were used as received. Newborn calf serum was provided by 
Cezanne/Thermo Fisher Scientific. Water was purified by Purelab Option-Q equipped 
with bio-filter (ELGA Labwater Veolia water ST1, Antony, France) to produce nuclease 
free water. 
4.2.2. LTC and QD DNA conjugates  
QD-DNA conjugates were obtained by mixing QD605-sAv/QD655-sAv/QD705-sAv with 
biotin-labeled oligonucleotides in hybridization buffer (20 mM Tris-Cl, 500 mM NaCl, 
pH 8.0) just before use. LTC-DNA conjugates were obtained by mixing Lumi4®-Tb-NHS 
(lyophilized product dissolved to 8 mM in anhydrous DMF) in concentration excess to 
amino-functionalized oligonucleotides in 100 mM carbonate buffer at pH 9.0. The 
mixtures were incubated while rotating at 30 RPM (Intelli-Mixer, ELMI) overnight at 
room temperature. The LTC-DNA conjugates were purified 3 times by Zeba Spin 
Desalting Columns (7 kDa MWCO). LTC concentrations were determined by absorbance 
measurements at 340 nm using a molar absorptivity of 26,000 M-1cm-1 as provided by 
the manufacturer. DNA was quantified by absorbance measurements at 260 nm. 
Labeling ratios (Table 4.1) were determined by linear combination of the respective 
absorbance values of LTC and oligo within the LTC-oligo conjugates. 
4.2.3. Photophysical properties  
Absorption spectra (Lambda 35 UV/Vis System, PerkinElmer) and emission spectra 
(FluoTime 300, PicoQuant) were recorded in HEPES (100 mM, pH 7.4) and 
hybridization buffer for LTC and QD samples, respectively. PL decay curves were 
acquired on a fluorescence plate reader (Edinburgh Instruments) using 4000 detection 
bins of 2 μs integration time and nitrogen laser (MNL 100, LTB Lasertechnik Berlin) 
excitation (337.1 nm, 20 Hz). Optical transmission filter bandpass wavelengths were 
(494±10) nm (Semrock) for the LTC detection channel, (607±5) nm (Delta) for the QD605 
detection channel, (660±7) nm (Semrock) for the QD655 detection channel and (716±20) 
nm (Semrock) for the QD705 detection channel. 
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Table 4.1. Oligonucleotide properties and LTC-to-oligo conjugation ratios. 
Probe Sequence 5'-3' Modification 
LTC/DNA 
ratio Tm  (°C) 
capture 20a (8 bps ) 
(Model 1) AACGGACT 3' C3 biotin / 
with reporter 
20a: 21.8 
capture 20a (6 bps ) 
(Model 1) AACGGA 3' C3 biotin / 
  
capture 20a (8 bps ) 
(Model 2) AACGGACT 5' TEG biotin / 
with reporter 
20a: 21.8 
capture 20b (8 bps ) TAGCTCGA 5' TEG biotin / 
with reporter 
20b: 20.3 
capture 20b (8 bps)* TAGCTCGA 
5' 
H6SLGAAAGSG
C 
/  
capture 21 (8 bps ) AGTTGTGG 3' TEG biotin / 
with reporter 
21: 19.3 
capture 21 (7 bps ) AGTTGTG 3' TEG biotin /   
capture 21 (6 bps ) AGTTGT 3' TEG biotin /   
reporter 20a (Model 
1) 
AGTCCGTT-
CTACCTGCACTATAAGCACTTTA 5' C6 amino 0.81 
with miRNA-
20a: 61.8 
reporter 20a (Model 
2) 
CTACCTGCACTATAAGCACTTTA-
AGTCCGTT 3' C6 amino 0.83 
with miRNA-
20a: 61.8 
reporter 20b 
CTACCTGCACTATGAGCACTTTG-
TCGAGCTA 3' C6 amino 0.85 
with miRNA-
20b: 65.0 
reporter 21 
CCACAACT-
TCAACATCAGTCTGATAAGCTA 5' C6 amino 0.88 
with miRNA-
21: 57.6 
Target Sequence 5'-3'       
miRNA-20a UAAAGUGCUUAUAGUGCAGGUAG / / 
with reporter 
20a: 61.8 
miRNA-20b  CAAAGUGCUCAUAGUGCAGGUAG / / 
with reporter 
20b: 65.0 
miRNA-21  UAGCUUAUCAGACUGAUGUUGA / / 
with reporter 
21: 57.6 
Note: Melting temperatures (Tm) were calculated by using Oligo Analyzer version 3.1 (Integrated 
DNA Technologies). Predictions are accurate for oligos from 8 to 60 bases in length, in neutral 
buffered solutions (pH 7 - 8) with monovalent cation (Na+) concentrations from 1.2 M down to 1.5 
mM, divalent cation (Mg2+) concentrations from 600 mM down to 0.01 mM, and triphosphates 
(dNTPs) concentrations up to 120% of the divalent cation concentration. Tm values for DNA/DNA 
duplexes were calculated using parameters set to oligonucleotide concentration at 20 nM, Na+ ion 
at 500 mM, Mg2+ ion at 0 mM, dNTPs at 0 mM. The modifications were not taken into 
consideration for Tm calculation. 
4.2.4. Homogeneous FRET miRNA assays  
Spectral-multiplexed assay 
Time-gated (0.1 – 0.9 ms) PL intensity measurements were acquired on a KRYPTOR 
compact plus clinical fluorescence plate reader (Cezanne/Thermo Fisher Scientific) using 
the same LTC and QD detection channel bandpass filters as mentioned above. All 
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FRET-assays were measured in black 96-well microtiter plates with an optimal working 
volume of 150 μL. All samples are prepared in hybridization buffer and contained 0.5 
nM of each QD-DNA (prepared by mixing 0.5 nM QD-sAv and 20 nM biotinylated DNA 
just before the addition of the other constituents), 20 nM of each LTC-DNA, and 
increasing concentrations of miRNAs. The single sensor assays contained only one type 
of QD-DNA and LTC-DNA. After sample preparation they were incubated in the 
microtiter plates for 30 min. at room temperature (22 °C) before measurements. In the 
single sensor assays each measurement consisted of 100 excitation flashes at 20 Hz 
repetition rate (5 s per measurement). In the multiplexed assays each measurement 
consisted of 50 excitation flashes at 20 Hz repetition rate (2.5 s per miRNA, 7.5 s for 
three miRNAs). For statistical analysis and the estimation of LODs all samples were 
prepared 3 times and measured in triplicates (n = 9) apart from the zero-concentration 
samples (without miRNA targets), which were prepared 10 times and measured in  
triplicates (n = 30). Samples of miRNA assays with varying target concentrations in 
buffer and buffer containing 10 % newborn calf serum were prepared 3 times and 
measured once (n = 3). The serum was added after pre-incubation of sensor and targets 
for 15 min. 
Temporal-multiplexed assay  
All FRET assays were prepared in hybridization buffer (20 mM Tris-Cl, 500 mM NaCl, 
0.1% BSA, pH 8.0) and contained 50 μL of QD-DNA (prepared by mixing QD and 
biotinylated DNA or polyhistidine-DNA for 30 min before the addition of the other 
constituents, 40 DNAs per QD) and 50 μL of LTC-DNA at constant concentrations to 
which 50 μL of miRNA target at different concentrations was added. The single sensor 
assays contained 0.5 nM of one type of QD-DNA and 20 nM of LTC-DNA and increasing 
concentrations of miRNAs (from 2 nM to 25 nM), and all samples were prepared once. 
The duplexed assays contained two types of QD-DNAs and LTC-DNAs (half of the 
concentrations of each probe used in the single sensor assays, 0.25 nM of each QD-DNA 
and 10 nM of each LTC-DNA) and different concentrations of the two miRNAs (from 2 
nM to 10 nM). For duplexed statistical analysis and the estimation of LODs all samples 
were prepared 3 times (n = 3) apart from the zero-concentration samples (without 
miRNA targets), which were prepared 10 times (n = 10). Samples of miRNA assays with 
varying target concentrations were prepared 2 times (n = 3). 
After sample preparation they were incubated in black 96-well microtiter plates for 30 
min at room temperature (22 °C) with an optimal working volume of 150 μL. PL decay 
curves were acquired on a fluorescence plate reader (Edinburgh Instruments) using 
4000 detection bins of 2 μs integration time and nitrogen laser (MNL 100, LTB 
64 
 
Lasertechnik Berlin) excitation (337.1 nm, 20 Hz). Optical transmission filter bandpass 
wavelengths were (494±10) nm (Semrock) for the LTC detection channel, (607±5) nm 
(Delta) for the QD detection channel.  
4.3. Results and discussion 
4.3.1. Spectral-multiplexed assay 
Sensing principle 
                    
 
Figure 4.2. The scheme of the multiplexed miRNA assay. The multiplexed miRNA assay is 
composed of three different QDs (QD655, QD605 and QD705 from left to right) that are 
conjugated with short DNA strands. These QD-DNAs are complementary (red, yellow, and brown 
color codes) to parts of three different LTC-conjugated DNA strands (LTC-reporter 20a, 20b, and 
21). Addition of the miRNAs 20a, 20b, and 21 leads to the formation of stable miRNA-LTC-
reporter double-stranded RNA/DNAs, which can then hybridize to the short QD-DNAs due to the 
combination of base pairing and stacking. Only this combination leads to stable double-stranded 
RNA/DNAs, in which LTC and the different QDs are in close proximity to enable three different 
FRET processes (FRET 1, 2, and 3). Note: The LTC-reporter-miRNA double strands of 20a and 
20b have only 2 base pair mismatches (magenta color code). Arrows point in 5’ to 3’ direction of 
the RNAs or DNAs. 
The recognition principle of the LTC and QD FRET probes and the miRNA biomarkers 
is based on RNA/DNA base pairing and stacking. As shown in Figure 4.2 the triplexed 
miRNA sensor is composed of three different QDs, with PL maxima at 605, 655, and 
705 nm, respectively, that are conjugated with short DNA strands (6 to 8 nucleotides). 
These short DNA sequences are complementary to parts of three different reporter 
DNAs that are conjugated with LTC. However, the complementary sequences are too 
short to form stable double-strands by base pairing between the QD-DNA and the LTC-
DNA (melting temperature Tm ~ 20 °C) and therefore LTC and QD are separated in 
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solution (no FRET). The LTC-reporter DNAs were designed to provide a second 
sequence that is complementary to the three miRNAs miRNA-20a, miRNA-20b, and 
miRNA-21, respectively. Hybridization of the LTC-reporters to their respective miRNAs 
leads to stable double-stranded RNA/DNA (Tm ~ 60 °C) with a short overhang on the 
LTC-side. Due to RNA/DNA nick-based stacking this overhang can stably hybridize to 
the complementary QD-DNA [185], which leads to the formation of three miRNA-specific 
double-stranded RNA/DNAs with distinguishable LTC-to-QD FRET pairs for PL-based 
detection (FRET 1 to 3). Sequences, modifications, labeling ratios and Tm values of all 
used oligonucleotides are summarized in Table 4.1. The extremely long PL lifetimes of 
LTC (milliseconds) allow efficient time-gated (TG) FRET detection from the same LTC 
to different QDs [186]. The TG PL detection (PL intensity integrated from 0.1 to 0.9 ms 
after the excitation pulse: ITG) was performed in four different color detection channels 
to efficiently distinguish the FRET-sensitized QDs and the FRET-quenched LTC and to 
allow ratiometric measurements, in which the TG PL intensities of the QD-acceptors 
ITG(QD) are divided by the TG PL intensities of the LTC-donors ITG(LTC): 
 FRET ratio = ITG(QD) / ITG(LTC) 4.1 
  
 
Figure 4.3. Optical properties of the FRET assay components. Left: Molar absorptivity spectra of 
LTC (blank, multiplied by 200), QD605-sAv (orange), QD655-sAv (red) and QD705-sAv (brown). 
For the calculation of the overlap integrals between LTC donor emission and QD acceptor 
absorption, the area-normalized LTC emission spectrum (green) is also shown. Right: PL 
intensity spectra of LTC-oligo conjugate (green), QD605-sAv (orange), QD655-sAv (red) and 
QD705-sAv (brown) normalized to unity at their respective maxima. The gray spectra in the 
background define the transmission of the optical band-pass filters (494±10) nm (Semrock) for 
the Tb detection channel, (607±5) nm (Delta) for the QD605 detection channel, (660±7) nm 
(Semrock) for the QD655 detection channel and (716±20) nm (Semrock) for the QD705 detection 
channel.   
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Stacking effect and specificity 
Because the specific formation of the different double-stranded RNA/DNA FRET 
complexes (FRET 1, 2, and 3) is based on both base pairing and stacking, a careful 
design and optimization of sequence lengths and orientations of the QD and LTC-DNAs 
was necessary to provide maximum selectivity and sensitivity for all three miRNA 
biomarkers. Too short QD-DNAs resulted in too weak base pairing and stacking 
interactions to form stable double-stranded RNA/DNA FRET complexes. Too long 
sequences led to stable hybridization of QD and LTC-DNA even without miRNA targets. 
The orientation (5’ to 3’ or vice versa) of the QD and LTC-DNAs was particularly 
important for the 20a and 20b sensors because of their sequence homology, which led to 
a strong orientation-dependent selectivity for miRNA-20a and 20b. Optimization of 
stacking effects using capture DNAs on the QDs with different lengths (Figures 4.4 and 
4.5) and of the orientation of these capture DNAs pointing in 3’-to-5’ direction from the 
QD or vice versa (Figures 4.6 and 4.7) led to the selection of QD-DNAs with 8 bases for 
QD655 (miRNA-20a) and QD605 (miRNA-20b) with the 5’ end conjugated to the QD and 
to 7 bases for QD705 (miRNA-21) with the 3’ end conjugated to the QD.  
 
Figure 4.4. Comparison of “double-stranded LTC-to-QD FRET RNA/DNA” (bottom left) 
formation for the detection of miRNA-20a using a 6-bases and an 8-bases long capture DNA on 
the QD (top left). 6 base pair formation does not lead to a stable double strand as shown by 
constant background FRET ratio signals with increasing miRNA-20a concentration (red data 
points in the graph on the bottom right). 8 base pairs lead to the formation of increasing amounts 
of stable double strands with increasing miRNA-20a concentrations as shown by the increasing 
FRET ratio signals (black data points in the graph on the bottom right). It should be noted that 
the black data point (8 base pairs) for zero miRNA-20a concentration already shows a higher 
FRET ratio signal than the red data point (6 base pairs). This is caused by the formation of few 
FRET-complexes even without the addition of miRNA. However, the strongly increasing FRET 
ratio with the addition of miRNA-20a provides a high sensitivity (slope of the curve) and 
therefore the FRET background is not interfering with the miRNA concentration dependent 
measurement.   
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Figure 4.5. Comparison of “double-stranded LTC-to-QD FRET RNA/DNA” (bottom left) 
formation for the detection of miRNA-21 using a 6-bases, 7-bases, and 8-bases long capture RNA 
on the QD (top left). 6 base pair formation does not lead to a stable double strand as shown by 
constant background FRET ratio signals with increasing miRNA-21 concentration (blue data 
points in the graph on the bottom right). 8 base pairs lead to the formation of stable double-
stranded FRET RNA/DNA independent of the miRNA-21 concentration as shown by the constant 
high FRET ratio (black data points in the graph on the bottom right). 7 base pairs lead to the 
formation of increasing amounts of stable double strands with increasing miRNA-21 
concentrations as shown by the increasing FRET ratio signals (red data points in the graph on 
the bottom right). It should be noted that the red data point (7 base pairs) for zero miRNA-21 
concentration already shows a higher FRET ratio signal than the blue data point (6 base pairs). 
This is caused by the formation of few FRET-complexes even without the addition of miRNA. 
However, the increasing FRET ratio with the addition of miRNA-21 provides a high sensitivity 
(slope of the curve) and therefore the FRET background is not interfering with the miRNA 
concentration dependent measurement. 
 
Figure 4.6. Using the sensor from Figure 4.4 with a QD-DNA in 3’ to 5’ direction from the QD 
(top left) leads to the formation of increasing amounts of stable double strands with increasing 
concentrations of both miRNA-20a and miRNA-20b as shown by the increasing FRET ratio 
signals (black and red data points in the graph on the bottom right). This lack of selectivity is 
most probably caused by the sequence homology of miRNA-20a and 20b, which leads to the same 
adjacent base pairs at the nick of QD-DNA with the two miRNAs. The base pair mismatches (red 
base pairs on the bottom left) are situated on the far end from the QD (close to the 3’ end of the 
LTC-reporter DNA).  
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Figure 4.7. Inverting the QD-DNA from the sensor from Figure 4.4 (5’ to 3’ direction from the 
QD – top left) leads to the formation of increasing amounts of stable double strands with 
increasing concentrations of only miRNA-20a as shown by the increasing FRET ratio signals 
(black data points in the graph on the bottom right). Although the red data points also slightly 
increase, the selectivity for miRNA-20a is significantly higher (much steeper slope of the black 
compared to the red curve) than for miRNA-20b. This strongly improved selectivity is most 
probably caused by the close distance of the base pair mismatches (red base pairs on the bottom 
left) to the QD-DNA/miRNA nick. Note: The LTC-reporter DNA also had to be inverted so that 
the LTC was conjugated on the 5’ end for this selectivity-optimized miRNA sensor. 
 
Figure 4.8. Similar to the sensor from Figure 4.7 a QD-DNA in 5’ to 3’ direction from the QD 
(top left) and an inverted LTC-reporter DNA with a miRNA-20b complementary sequence with 
base pair mismatches close to the QD-DNA/miRNA nick (bottom left) was selected for the 
detection of miRNA-20b. As shown by the significantly different slopes of the concentration 
dependent FRET ratio curves (bottom right) the sensor provides much higher selectivity for 
miRNA-20b compared to miRNA-20a. 
It should be noted that the optimization and choice of oligos were carried out for the 
assays to be performed at room temperature. However, the sensing approach can be 
implemented to a wider temperature range between ca. 10 and 37 °C. Lower and higher 
temperatures will result in stable FRET complexes even without miRNA and unstable 
FRET complexes even with miRNA, respectively [187]. For the calculation of Tm values 
we did not take into account changes due to attachment of the capture DNA to oligos, 
which may lead to an increased Tm [176]. However, even if the Tm values were slightly 
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larger this was not problematic for our assays because our empiric optimization led to 
enhanced FRET sensitization in the presence of miRNA targets. 
FRET pairs selection 
The next step of assay design was the selection of LTC-QD FRET pairs for the different 
miRNAs. Considering the Förster distances (9.0 nm for QD605, 10.7 nm for QD655, and 
11.1 nm for QD705) [17] and the detection filter transmission bandwidth and LTC PL 
spectral crosstalk to the QD detection channels (Figure 4.3) it was expected that the 
LTC-to-QD705 FRET pair (largest Förster distance and lowest LTC spectral crosstalk) 
would provide the highest sensitivity, followed by LTC-to-QD655 and LTC-to-QD605. 
MiRNA concentration dependent measurements of the FRET ratios for all combinations 
of LTC-to-QD FRET pairs and miRNA sensors confirmed this assumption and also 
showed that the miRNA-20b sensor provided the highest sensitivity for all LTC-to-QD 
FRET pairs, followed by miRNA-20a and miRNA-21 (Figure 4.9). Therefore the 
multiplexed sensor combined the strongest FRET pair with the weakest target-probe 
interaction and vice versa (Figure 4.2). 
Single sensor performance 
The performance of the single sensors is shown in Figure 4.10. In these assays the 
samples contained only one LTC-QD probe and one target at increasing concentrations. 
The FRET ratios of all three sensors increase nearly linearly with increasing miRNA 
concentrations between 0.5 and 10 nM, which was caused by QD FRET-sensitization 
from the LTC donors, as shown in the PL decay curves from the different QD detection 
channels (Figure 4.10 bottom graphs). Above this concentration range (the linear 
dynamic range for our probe concentration) the FRET ratios slowly leveled off and 
remained at a saturated value (plateau) after ca. 20 nM (data not shown), which was 
expected because this represents the concentration of the LTC-DNA and QD-DNA for 
target binding (saturation of the probe by the target). Within the FRET ratio curves 
(Figure 4.10 top graphs) it becomes obvious that the LTC-QD705 probe shows ca. one 
order magnitude lower FRET ratio intensities compared to LTC-QD655 and LTC-QD605 
(although the relative FRET ratio increases are very similar). This behavior is caused by 
the much lower spectral crosstalk of LTC in the QD705 detection channel compared to 
QD655 and QD605 (Figure 4.3 for spectral information and light green curves in the 
bottom graphs of Figure 4.10 for intensity information). The FRET ratio (Equation 4.1) 
is calculated by the time-gated QD intensities divided by the time-gated LTC intensities. 
The latter ones are very similar for all LTC-QD systems (same LTC concentration for all) 
but due to the lower LTC spectral crosstalk the QD705 intensities are significantly 
lower compared to QD655 and QD605. Another reason is the weaker probe-target 
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interaction for miRNA-21 compared to miRNA-20a and 20b (vide supra), which also 
resulted in lower FRET ratio intensities (less FRET sensitization) and higher LODs 
although the LTC-QD705 FRET probe provides higher sensitivities for each miRNA 
when directly compared to the other two probes (Figure 4.9). Limits of detection (LODs) 
were estimated as the FRET ratio values on the calibration curves (Figure 4.10 top 
graphs) calculated from the FRET ratio of samples without miRNA plus three times 
their standard deviation (n = 30). The LODs were 0.12 nM, 0.06 nM, and 0.40 nM for 
miRNA-20a, miRNA-20b, and miRNA-21, respectively.   
 
Figure 4.9. The optimized sensor designs for the three miRNAs were tested with all three QDs. 
The miRNA concentration-dependent relative FRET ratios (normalized to unity for the 
background FRET ratio without any miRNA in the samples) show that the sensors can be 
applied to any of the three LTC-to-QD FRET pairs (increasing ratios with increasing 
concentrations). They also show that the sensitivity (slope of the curves) is highest for miRNA20b 
(red dots), followed by miRNA-20a (black squares), and then miRNA-21 (blue triangles). LTC-to-
QD705 (C) showed the highest sensitivity for all miRNAs and was therefore selected for the 
detection of the “weakest” binder, namely miRNA-21. LTC-to-QD605 (A)  and LTC-to-QD655 (B)  
showed very similar sensitivities for miRNA-20b but LTC-to-QD655 showed slightly better 
sensitivity for miRNA-20a. Therefore QD655 was selected for miRNA-20a and QD605 for 
miRNA-20b. 
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Figure 4.10. Performance evaluation of the single miRNA sensors (A: miRNA-20a, B: miRNA-
20b, C: miRNA-21). The top graphs show the FRET ratios (Equation 4.1) and rel. FRET ratios 
(FRET ratios normalized to unity at [miRNA]=0) as a function of miRNA concentration. The 
nearly linear increase of these calibration curves is mainly caused by QD FRET-sensitization via 
long-lived (ms) excited states of LTC. This sensitization becomes obvious in the PL decay curves 
of the different QD detection channels (bottom graphs), in which the long-lifetime parts of the 
decay curves strongly increase with increasing miRNA concentrations (0 nM: black, 1 nM: orange, 
2 nM: dark green, 4 nM: blue, 6 nM: cyan, 10 nM: magenta) as indicated by the black arrows. 
Control experiments with only LTC-DNA and 6 nM miRNA (light green) and only QD-DNA and 
6nM miRNA (color of the QD, dark-yellow for QD605 for better visibility) showed the background 
of LTC PL (spectral crosstalk in the QD detection channels) and directly excited QD PL. 
Multiplexed sensor performance 
Encouraged by the excellent performance of the single sensor assays we proceeded to an 
optimization for multiplexed miRNA detection, when all three probes and different 
amounts of the three miRNA targets were present into a single sample. We therefore 
prepared four different assays and three control samples (Figure 4.11). The first assay 
contained all three miRNAs at increasing concentrations from 2 to 10 nM. The second to 
fourth assay contained the same increasing concentrations but only of one of the three 
miRNAs. The three control samples contained high concentrations (10 nM) of two 
different miRNAs (20a+20b, 20a+21, or 20b+21).  As shown in Figure 4.11 A and 4.11 
B miRNA-20a and miRNA-20b can be correctly detected almost completely 
independently of the concentrations of the other miRNAs in the samples. The presence 
of miRNA-20b shows a very small contribution to the miRNA-20a detection channel 
(difference between red and black data points) and vice versa (difference between dark-
yellow and black data points), whereas the presence of miRNA-21 does not influence at 
all the detection of miRNA-20a and miRNA-20b. The detection of miRNA-21 in Figure 
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4.11 C shows a different picture because the presence of both miRNA-20a and miRNA-
20b strongly influences the quantification of miRNA-21. As discussed above the absolute 
FRET ratio values (left ordinates in Figure 4.10) are much lower for miRNA-21. This 
strong difference in absolute intensities leads to a significant spectral crosstalk of 
QD655 and QD605 into the QD705 detection channel (which is not obvious from the 
intensity-normalized spectra from Figure 4.3).  
 
Figure 4.11. Multiplexed miRNA assays for the detection of miRNA-20a (A), miRNA-20b (B), 
and miRNA-21 (C and D). All assays contain all three sensors at constant concentrations and the 
different miRNAs at varying concentrations (as indicated on the abscissae). Black squares: all 
miRNAs; red dots: only miRNA-20a; dark-yellow upward triangles: only miRNA-20b; brown 
downward triangles: only miRNA-21. Open symbols present samples with 10 nM (1.5 pmol) of 
each miRNA-20a and miRNA-20b (green diamonds), miRNA-20b and miRNA-21 (blue upward 
triangles) and miRNA-20a and miRNA-21 (purple downward triangles). For miRNA-20a and 
miRNA-20b there are only minor differences between assays with single or multiple miRNAs. 
Quantification of miRNA-21 (C) is strongly influenced by the other two miRNAs and must 
therefore be corrected (D) to allow a specific and correct quantification of miRNA-21. The 
mathematical correction model is explained in Appendix 7.3.2.       
Using the miRNA concentration-dependent (linearly increasing) FRET ratios generated 
by the miRNA-20a and miRNA-20b sensors in the miRNA-21 detection channel (red and 
dark-yellow data points in Figure 4.11 C) and the precise and selective quantification 
of these two miRNAs in their own detection channels (Figure 4.11 A and 4.11 B), the 
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FRET ratio contribution of these two sensors to the miRNA-21 detection channel can be 
easily subtracted (Appendix 7.3.2 for the complete mathematical model). As shown in 
Figure 4.11 D the mathematical correction leads to a similar selectivity for miRNA-21 
as for the other two miRNAs. The LODs for the three miRNAs within the multiplexed 
assays (with all three sensors present) were estimated as the FRET ratio values on the 
calibration curves calculated from the FRET ratio of samples without miRNA plus three 
times their standard deviation (n = 30). To evaluate conditions in which all of the 
targets are present in the samples, the calibration curves for the different miRNAs 
(similar to those in Figure 4.11 A, B, and D) were measured in the absence and in the 
presence of the other miRNA targets and the average LODs were estimated as 1.3 nM, 
0.9 nM, and 0.7 nM for miRNA-20a, miRNA-20b, and miRNA-21, respectively (Table 
4.2 for all values that led to the averaged LODs).  
Table 4.2. Limits of detection (LODs) of the triplexed miRNA assay (all three probes are present 
in the samples) for the three different miRNAs under different conditions (with or without the 
presence of other targets). 
 
* If X=20a then Y=20b and Z=21; if X=20b then Y=20a and Z=21; if X=21 then Y=20a and Z=20b. 
In a final evaluation step of our homogeneous multiplexed miRNA detection technology 
we challenged the assays with varying concentrations of the different miRNAs and with 
ambitious sample conditions. We therefore prepared nine different samples that 
contained between 2 and 10 nM of the three miRNAs at varying concentrations (as 
found in real samples) in buffer and in samples containing 10 % serum. In clinical 
diagnostics circulating miRNA is usually detected from blood or serum extracted RNA 
samples using commercially available extraction kits [178]. Detection directly in whole 
blood, serum, or plasma would avoid such extraction steps and lead to a simpler and 
faster assay format. Circulating miRNAs circumvent degradation by endogenous 
ribonucleases, most probably through protection by their association to exosomes or 
protein and lipid complexes [156], and direct detection of circulating miRNAs may be 
possible. Such degradation cannot be avoided for exogenous miRNA and therefore our 
probes were pre-incubated with the miRNA targets to form DNA/RNA FRET complexes 
before their addition to the serum samples. The aim of our serum-based experiments 
was to demonstrate the biological, chemical, and photophysical stability of our probe-
LODs
miRNA 20a 20b 21 20a 20b 21
X * 0.67 0.21 0.48 100 32 72
X +10 nM Y 1.38 1.46 0.64 207 220 95
X +10 nM Z 0.53 0.30 0.43 80 45 65
X +10 nM Y+Z 2.50 1.54 1.38 375 231 207
Average 1.27 0.88 0.73 190 132 110
nM fmol
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target complexes and their sensitive and precise quantification in serum samples. 
Further investigations and in particular clinical studies using patient samples are 
necessary to verify if our approach can be used for direct measurements in serum and if 
the miRNA concentration range in such samples is sufficient to be quantified by our 
technique or if extraction of RNA from whole blood is required for their detection. 
The FRET ratio calibration curves for the buffer and serum-based assays were 
determined by using an average of single miRNA and multiple miRNA curves because 
the latter showed small deviations from the single target calibration functions 
(Appendix 7.3.2 Figure 7.4 and Figure 7.5). The calibration curves show a strong 
influence of serum on the LTC-QD705-miRNA-21 system, for which the FRET ratio 
intensity decreased ca. 5-fold, whereas the other two sensors do not show significant 
changes between buffer and serum-based experiments. This is again related to the 
weaker probe-target interaction for miRNA-21. The increased nuclease activity (due to 
the addition of serum) further reduces the miRNA-21 probe-target binding efficiency 
whereas the other two probe-target complexes are unaffected. Nevertheless, the most 
important aspect is the relative increase of the FRET ratio, which is not significantly 
affected by the addition of serum and therefore all three miRNAs can still be measured 
in a triplexed serum-containing assay.  As shown in Figure 4.12 the various 
concentrations of the different miRNAs in both buffer and serum-based samples could be 
detected with quite high precision at low nM concentrations. MiRNA-20b can be 
measured with the highest precision with only minor deviations from the known 
concentration values. The combination of high miRNA-20b and low miRNA-20a 
concentrations led to an overestimation of miRNA-20a (due to miRNA-20b contributions 
in the mi-RNA-20a channel), which automatically led to an underestimation of miRNA-
21 concentrations (overcorrection). Nevertheless, the concentration trends were 
extremely well detected, in particular when considering the simplicity of our correction 
model and the very challenging homogeneous assay (only 30 min. of incubation, no 
washing and separation steps, and only 2.5 s of measurement per miRNA) with three 
different miRNAs (of which two have a strong sequence homology). It can be expected 
that automation of sample preparation and the application of more sophisticated models 
[15] can further improve the detection sensitivity.    
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Figure 4.12. Triplexed homogeneous miRNA assay results for samples containing all three 
miRNAs at different concentrations between 2 nM and 10 nM in buffer (A) and in 10 % serum (B). 
Red: miRNA-20a; dark-yellow: miRNA-20b; brown: miRNA-21. Dash-dotted lines represent know 
concentrations. Error bars of the measured data points resulted from triplicate measurements 
per sample and averaging from two different calibration curves (Appendix 7.3.2). 
4.3.2. Temporal-multiplexed assay 
The recognition principle of the LTC and QD probes and the miRNA biomarkers is 
based on RNA/DNA base pairing and stacking and was described above. In brief, the 
duplexed miRNA sensor contained a single QD605 with two short DNA strands (QD-
DNAs) which were specific to two miRNAs miRNA-20a and miRNA-20b, and two LTC-
DNA probes where miRNAs and QD-DNAs could combine in the order shown in Figure 
4.13. Only in the presence of miRNAs, the hybridization of miRNAs and their respective 
LTC-DNAs can stabilize the binding between the short QD-DNAs and LTC-DNAs and 
lead to LTC-to-QD FRET. The QD applied in our system was a commercial QD-
streptavidin conjugate where the streptavidin covalently attached to the inner 
amphiphilic coating without a PEG linker, and this provided more freedom for the 
coassembly of other biomolecules to the QD. Terminally modifying DNA with a 
polyhistidine (His6) sequence can allow for its rapid self-assembly to the QDs via metal-
affinity coordination, and more importantly, it provides more efficient FRET due to the 
direct attachment of polyhistidine to the inorganic surface of QD compared to 
streptavidin-biotin (sAv-biot) assembly and lead to distinguishable excited-state decay 
lifetime of QD for time-gated measurement. Without preferences, the sAv-biot and His6 
assemblies were chosen for the miRNA-20a and miRNA-20b sensors, respectively.  
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Figure 4.13. The duplexed miRNA sensor contained a single QD605 with two short DNA strands 
(QD-DNAs) which were specific to two miRNAs miRNA-20a and miRNA-20b, and two LTC-DNA 
probes where miRNAs and QD-DNAs could bind in the order shown in the left figure. Only in the 
presence of miRNAs, the hybridization of miRNAs and their respective LTC-DNAs can stabilize 
the binding between the short QD-DNAs and LTC-DNAs and lead to LTC-to-QD FRET. The QD 
of miRNA-20b sensor decays much faster than the QD of miRNA-20a sensor and shows 
distinguishable decay curves, which allows the temporal duplexed detections (applying different 
time-gated windows) of miRNA-20a and miRNA-20b.   
Single sensor performance 
We first tested the performance of the FRET assays in single miRNA detection, where 
all samples contained a single probe (QD-DNA and LTC-DNA) at constant 
concentrations and different amounts of miRNAs. As shown in the PL decay curves of 
the QD detection channels (Figure 4.14), the long-lifetime parts of the decay curves 
strongly increased with increasing miRNA concentrations due to the FRET from LTC to 
QD. As was expected from different distances of LTC-to-QD with two assembly 
chemistries, the FRET efficiency of miRNA-20b sensor (      is ca. 70% based on His6 
assembly) were higher than that of miRNA-20a sensor (      is ca. 50% based on sAv-
biot assembly) as shown in Table 4.3. A detailed time-resolved study was performed to 
estimate the LTC-to-QD FRET efficiencies and donor-to-acceptor distances of two 
sensors, and after trying different exponential decay time fits on the PL decay curves in 
the LTC-donor and QD-acceptor channels, finally we chose 2-exponential and 3-
exponential fits in the LTC and QD channels of miRNA-20a sensor, and 3-exponential 
and 4-exponential fits in the LTC and QD channels of miRNA-20b sensor, respectively 
(Appendix 7.3.3). A detailed introduction of how to deal with the decay lifetime and 
FRET efficiency can be found in reference [40].  
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Figure 4.14. The PL decay curves of the QD detection channels. Top left: miRNA-20a sensor 
with miRNA-20a target; top right: miRNA-20a sensor with miRNA-20b target, bottom left: 
miRNA-20b sensor with miRNA-20a target, bottom right: miRNA-20b sensor with miRNA-20b 
target. The long-lifetime parts of the decay curves strongly increase with increasing 
concentrations of their respective miRNAs (black: 0 nM; red: 2 nM; blue: 4 nM; magenta: 6 nM; 
green: 8 nM; dark blue: 10 nM; violet: 15 nM; purple: 20 nM; wine: 25 nM) for both sensors, 
however, the two sensors provide distinguishable decay curves where the QD of miRNA-20b 
sensor decays much faster than the QD of miRNA-20a sensor does. Control experiments with 
only LTC-DNA and only QD-DNA, showed the background of LTC PL (spectral crosstalk in the 
QD detection channels) and directly excited QD PL. The blue boxes present two time-gated 
windows applied for following temporal multiplexing. 
Table 4.3. FRET efficiencies and calculated donor to acceptor distances of two sensors. A details 
decay time fitting data were shown in Appendix 7.3.3.  
Sensor miRNA-20a miRNA-20b 
Attachment sAv-biotin histidine 
Fitting r (nm)       r (nm)       
Donor (corr.) 10.3 25% 7.5 70% 
Acceptor (corr.) 8.5 52% 7.3 73% 
 
The fact that the QD of miRNA-20b sensor decayed much faster than the QD of miRNA-
20a sensor and showed distinguishable decay curves, allowed for a temporally duplexed 
detection of miRNA-20a and miRNA-20b, because PL intensities could be determined 
from different time-gated windows of the decay curves. To fully investigate the 
possibility of temporal duplexing of miRNA-20a and miRNA-20b, miRNA concentration-
dependent measurements of the FRET ratios in two different time-gated windows (TGi 
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and TGii) for all combinations of single miRNA sensors and miRNA targets were 
performed to estimate the optical and biological crosstalk in miRNA-20a and miRNA-
20b sensors. The TG PL detections (PL intensity integrated from 0.1 to 1.0 ms after the 
excitation pulse for TGi and from 4.0 to 8.0 ms for TGii) were collected from the lifetime 
decay curves in QD and LTC detection channels to efficiently distinguish the FRET-
sensitized QDs and the FRET-quenched LTC and to allow us to perform ratiometric 
measurements, in which Equation 4.1 was applied to calculate the FRET ratio (FR).  
The FRET ratio increment (   , subtract the FRET ratio by the value from the sample 
without miRNA) of the two sensors in both TGi and TGii windows increased with 
increasing concentrations of their respective fully matched miRNA targets, which were 
caused by QD FRET-sensitization from the LTC donors, and got saturated after 20 nM 
due to the saturation of the QD-DNA and LTC-DNA probes by the miRNAs. The 
distinguishable QD decay curves of the two miRNA sensors provided different increases 
of FRET ratios in two TG windows for both miRNAs. MiRNA-20a gave obvious increases 
of FRET ratios in both TG windows, while miRNA-20b gave obvious increases of FRET 
ratios in TGi window, and only minor contribution in TGii window. 
 
Figure 4.15. Performance evaluation of the single miRNA assays. The graphs show the FRET 
ratio increments as a function of miRNA concentration (black: miRNA-20a, red: miRNA-20b) 
with two miRNA sensors and in two time-gated windows.  Top left: miRNA-20a sensor in TGi; 
top right: miRNA-20a sensor in TGii; bottom left: miRNA-20b sensor in TGi; bottom right: 
miRNA-20b sensor in TGii. MiRNA-20a gave obvious increases of FRET ratios in both TG 
windows, while miRNA-20b only gave obvious increases of FRET ratios in TGi window, and a 
minor contribution in TGii window.  
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A small biological crosstalk came from the sequence similarity of miRNA-20a and 
miRNA-20b (two mismatches among the whole sequences), and, as was demonstrated 
before and shown in Figure 4.15, the specificities got greatly improved by optimizing 
the directions of the probes, where the mismatch of miRNA-20a and miRNA-20b greatly 
blocked the stacking effect when located just at the nick of QD-DNA and miRNA and 
only showed a minor contribution in the FRET ratios with miRNA-20b and miRNA-20a 
sensor, respectively. 
Multiplexed sensor performance 
Encouraged by the excellent performance of the single sensor assays and the 
distinguishable increases of FRET ratios with two miRNAs in both TG windows, we 
proceeded to an optimization for duplexed miRNAs detection, where all probes and 
different amounts of the two miRNA targets were present into a single sample. We 
therefore prepared three different assays. The first assay contained two miRNAs at 
increasing concentrations from 2 to 10 nM (the linear dynamic range). The other two 
assays contained the same increasing concentrations but only one of the miRNAs. When 
only miRNA-20a or miRNA-20b were present in the samples, the assays showed similar 
results to the single sensor assays, in which both of them provide increased but different 
FRET ratios in two time-gated windows (Figure 4.16). More importantly, the FRET 
ratios of the samples when both miRNA-20a and miRNA-20b were present overlaid 
almost perfectly with the FRET ratios calculated as a sum of the samples when only one 
of the miRNA-20a and miRNA-20b was present (Figure 4.16), which meant we could 
simply deconstruct (Appendix 7.3.4) the contributions of miRNA-20a and miRNA-20b 
in two TG windows and achieved temporal duplexed determination of miRNA-20a and 
miRNA-20b. Limits of detection (LODs) were estimated as the     values on the 
calibration curves (black data points in Figure 4.16 B and red data points in Figure 
4.16 A for miRNA-20a and miRNA-20b, respectively) calculated from the     of samples 
without miRNA plus three times their standard deviation (n = 10). The LODs were 0.43 
nM and 0.88 nM for miRNA-20a and miRNA-20b, respectively. 
To finally evaluate our homogeneous duplexed miRNA detection technology, we 
challenged the assays with varying concentrations of the different miRNAs (as found in 
real samples). We therefore prepared 16 samples with different concentrations of 
miRNA-20a and miRNA-20b. The FRET ratio calibration curves of miRNA-20a and 
miRNA-20b were determined by using the FRET ratios of Samples 1 to 6 (only miRNA-
20a were present in the samples) and Sample 11 to 16 (where only miRNA-20b were 
present in the samples), respectively. The mathematic treatment of calculating the 
concentrations of miRNA-20a and miRNA-20b by using the different calibration curves 
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is detailed in the Appendix 7.3.4. As shown in Figure 4.17, all samples with varying 
concentrations of miRNA-20a and miRNA-20b could be detected with very high 
precision at low nM concentrations.  
 
Figure 4.16. Duplexed miRNA assays for the detection of miRNA-20a and miRNA-20b. FRET 
ratio increment (   ) in TGi window (left) and in TGii window (right). All assays contain two 
sensors at constant concentrations and different miRNAs at varying concentrations. Black 
squares: miRNA-20a alone; red dots: miRNA-20b alone; blue upward triangles: two miRNAs; 
purple downward triangles: calculated sum of the values of miRNA-20a alone and miRNA-20b 
alone.  
 
Figure 4.17. Duplexed homogeneous miRNA assay results for samples with different miRNA 
concentrations between 0 nM and 10 nM. Black: miRNA-20a; red: miRNA-20b. The lines 
represent known concentrations.  
4.4. Conclusion 
We have developed two rapid and sensitive multiplexed miRNAs assays. The first one is 
based on time-gated FRET from one LTC to multiple QDs with different PL wavelengths, 
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which was referred to as spectral multiplexing, and the second one is based on time-
gated FRET from one LTC to one single color QD, which was referred to as temporal 
multiplexing. The spectral-multiplexed detection was realized by efficient separation of 
the emitted lights from different QDs using optical bandpass filters. Benefiting from the 
narrow emission bands of QDs, no complicated optical crosstalk correction was needed to 
achieve multiplexing. The temporally multiplexed detection was achieved by appling 
multiple time-gated windows, and a simple matrix-based deconstruction of the 
contribution of two miRNAs in two time-gated windows was developed. The multiplexed 
assays exploited the unique properties of QD nanocrystals and demonstrated their 
applicability in multiplexed diagnostics. Time-gated FRET measurements have been 
used to get rid of the background signals from the autofluorescence of the biological 
matrix and the direct excitation of the QDs. We have demonstrated for the first time 
that time-gated measurements can be used to perform temporal multiplexing.    
The specificity to distinguish extremly similar miRNAs sequences miRNA-20a and 
miRNA-20b benefited from the biological recognition principle: stacking effect, which 
was mostly blocked by a mismatched adjacent nucleotide, and the blocking was so 
efficient that no enzymes were needed to improve the specificity. Another big advantage 
with only nucleic acid hybridization (without enzymatic reactions) being involved in the 
assay was that only short incubation time (30 min) was needed thanks to the fast 
kinetics of nucleic acid binding. The real-time LTC-to-QD FRET led to homogeneous 
detection where no washing or separation steps were required. The short incubation 
time together with the mix-and-measure feature of FRET measurements have big 
advantages of inhibiting the contamination of the miRNAs samples from open air and 
experimental reagents or tubes. 
The spectral-multiplexed assay can selectively detect three different miRNAs from a 
single 150 µL sample with detection limits down ca. 0.06 nM for single sensor assays 
and ca. 0.2 nM for triplexed assays. The assays worked at room temperature and 7.5 
seconds of measurement were required to selectively quantify three different miRNAs at 
varying concentrations. The temporal-multiplexed assay can selectively detect two 
different miRNAs from a single 150 µL sample with detection limits ca. 1 nM for 
duplexed assays. The assay can simulteneously detect two miRNAs based on FRET from 
one single LTC to one single QD, and a single optical bandpass filter for the QD 
detection channel was needed (a real “killing two birds with one stone” measurement). 
Immediate applicability to diagnostic applications was demonstrated by sensitive 
multiplexed measurements in samples that contained 10 % serum. The homogeneous 
and sensitive multiple miRNA tests present important complementary techniques to 
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existing detection approaches that offer ultra-high sensitivity (e.g., PCR) or high 
throughput (e.g., microarrays) but very complicated technologies, and they provided the 
unique potential for rapid miRNA clinical diagnostics. 
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5. Amplified DNA/RNA Assay 
5.1. Introduction 
In the previous chapter, we have shown two multiplexed miRNA assays based on 
spectrally or temporally multiplexed FRET from LTC-to-QD, however, to achieve 
simplicity, rapidity, selectivity and multiplexing at the same time, we have to 
compromise on the relative low sensitivities, which are often not sufficient to detect 
extremely low miRNA concentrations. To detect directly the extracellular miRNAs 
circulating in the blood (or plasma/serum), amplification technologies are used to 
amplify the target or the signal. For a robust, reproducible, precise, and simple miRNA 
amplification strategy a linear and low-temperature (e.g., 37 °C) isothermal 
amplification technology is required. Target-primed rolling circle amplification (RCA) 
isothermally generates long ssDNA with a tandem sequence, where targets can be 
amplified 10,000-fold in a few hours. An increasing number of RCA amplified DNA or 
RNA assays have been developed, most of which are based on fluorescence detection 
[188–198].  
This work is to integrate time-gated FRET biosensing into target-primed RCA for 
multiplexed and highly sensitive homogeneous miRNA detection. Using the amplified 
tandem repeats of the miRNA-specific RCA product (RCP) will allow for an integration 
of many miRNA-specific donor-acceptor FRET pairs at tunable donor-acceptor distances, 
which, in turn, will give rise to temporal multiplexing. The technology combines ultra-
high sensitivity and multiplexing of several different miRNAs in a rapid-detection, 
homogeneous assay format. 
We first investigated the donor and acceptor distance dependence of LTC-to-dye FRET 
efficiency using different lengths of dsDNAs, and found an excellent match between the 
estimated distances (based on the defined structure of dsDNAs) and the measured 
distances (based on the relationship of FRET efficiency and distance), and thus, we 
could control the FRET efficiency by control of the distance of donor and acceptor 
fluorophores.  Then we present a homogeneous and highly sensitive detection of single-
stranded DNA (ssDNA) in a single small-volume sample. After the generation of RCA 
products, LTC labeled oligonucleotides and organic dye Cy5.5 labeled oligonucleotides 
(according to RCA products) hybridized with certain locations of RCA products and the 
detection was based on time-gated FRET from LTC to Cy5.5. We performed a systematic 
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optimization of the assay components (e.g., padlock probe concentration, DNA ligases, 
polymerase reaction time and LTC and Cy5.5 probes concentrations) and could greatly 
improve the limit of detection of the ssDNA which was down to fM. 
5.2. Materials and methods 
5.2.1. Materials 
Lumi4-Tb-NHS was provided by Lumiphore, Inc. All oligonucleotides were purchased 
from Eurogentec. Non-modified oligonucleotides were purified with cartridge gold 
desalting method. Phosphate oligonucleotides were purified with polyacrylamide gel 
electrophoresis. All other modified oligonucleotides were purified with HPLC. All 
sequences and modifications of nucleic acids used in this study are summarized in 
Table 5.1. Tris(hydroxymethyl)-aminomethane, HEPES and (NH4)2SO4 were purchased 
from Sigma-Aldrich. NaCl, MgCl2 and KCl were purchased from Duchefa (The 
Netherlands). T4 DNA ligase was purchased from Fermentas. Taq DNA ligase was 
purchased from New England Biolabs, Inc.. Phi29 polymerase, ATP and dNTP mix were 
purchased from Thermo Fisher Scientific. All chemicals were used as received. Water 
was purified by Purelab Option-Q equipped with bio-filter (ELGA Labwater Veolia 
water ST1, Antony, France) to produce nuclease free water. 
5.2.2. LTC-DNA conjugates  
LTC-DNA conjugates were obtained by mixing Lumi4-Tb-NHS (lyophilized product 
dissolved to 8 mM in anhydrous DMF) in concentration excess to amino-functionalized 
oligonucleotides in 100 mM carbonate buffer at pH 9.0. The mixtures were incubated 
while rotating at 30 RPM (Intelli-Mixer, ELMI) overnight at room temperature. The 
LTC-DNA conjugates were purified 3 times by Zeba Spin Desalting Columns (7 kDa 
MWCO). LTC concentrations were determined by absorbance measurements at 340 nm 
using a molar absorptivity of 26,000 M-1cm-1 as provided by the manufacturer. DNA was 
quantified by absorbance measurements at 260 nm. Labeling ratios were determined by 
linear combination of the respective absorbance values of LTC and oligo within the LTC-
oligo conjugates. 
5.2.3. Photophysical properties 
Absorption spectra (Lambda 35 UV/Vis System, PerkinElmer) and emission spectra 
(FluoTime 300, PicoQuant) were recorded in HEPES buffer (100 mM, pH 7.4) and 
purified water for LTC and Cy5.5 samples, respectively. 
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Table 5.1. Oligonucleotide properties 
Probe Sequence 5'-3' Modification 
LTC/DNA 
ratio 
Proof-of-principle   
ssDNA-LTC (10 bps) ATTCGGCATC 5′- C3 amino 1.1 
ssDNA-LTC (13 bps) TAGGATTAACTGA 5′- C3 amino 1.0 
ssDNA-LTC (15 bps) GAAAAATTCGGCATC 5′- C3 amino 1.1 
ssDNA-LTC (20 bps) CTCTTGAAAAATTCGGCATC 5′- C3 amino 0.96  
ssDNA-LTC (25 bps) TCGTGTCTAAAGTCCGTTAGCTCAT 5′- C3 amino 0.82 
ssDNA-Cy5.5 (10 
bps, 15 bps, 20 bps) 
GATGCCGAATTTTTCAAGAG 5′- Cy5.5 / 
ssDNA-Cy5.5 (13 
bps) 
TCAGTTAATCCTA 5′- Cy5.5 / 
ssDNA-Cy5.5 (25 
bps) 
ATGAGCTAACGGACTTTAGACACGA 5′- Cy5.5 / 
RCA FRET   
ssDNA-20a TAAAGTGCTTATAGTGCAGGTAG / / 
ssDNA-20b  CAAAGTGCTCATAGTGCAGGTAG / / 
ssDNA-21  TAGCTTATCAGACTGATGTTGA / / 
padlock-20a 
AAG CAC TTT AAT ATA TGA TGG ACC GCT 
CAA TTA ACT GAA GAT GCC GAA TTT TTC 
AAG AGG AAA TGT CTA CCT GCA CTA T 
5′- 
Phosphorylation 
/ 
padlock-20b 
GAG CAC TTT GAT ATA TGA TGG ACC GCT 
AGG ATT AAC TGA GAT GCC GAA TTT TTC 
AAG AGG AAA TGT CTA CCT GCA CTA T 
5′- 
Phosphorylation 
/ 
padlock-21 
TGA TAA GCT AAT ATA TGA TGG AAT CAA 
GAC AAT ATT GTT GAT GCC GAA TTT TTC 
AAG AGG AAA TGT TCA ACA TCA GTC 
5′- 
Phosphorylation 
/ 
Cy5.5 probe GATGCCGAATTTTTCAAGAG 5′- Cy5.5 / 
20a-LTC  ATTAACTGAA 5′- C6 amino 1.5  
20b-LTC TAGGATTAACTGA 5′- C3 amino 1.0  
21-LTC AATCAAGACAATATTGTT 5′- C6 amino 1.4 
 
5.2.4. Homogeneous FRET assays  
Proof-of-principle FRET assays 
All FRET assays were prepared in hybridization buffer (25mM HEPES buffer, 150mM 
NaCl, 10mM MgCl2, 0.1% BSA, pH7.4) and contained 100 μL of LTC-DNA at constant 
concentrations to which 50 μL of Cy5.5-DNA at different concentrations were added. 
The single sensor assays contained 3 nM of LTC-DNA and increasing concentrations of 
Cy5.5-DNA (from 0.5 nM to 3 nM), and all samples were prepared once. The triplexed 
assays contained three LTC-DNAs (3 nM of each LTC-DNA) and different 
concentrations of the three Cy5.5-DNAs (from 0.5 nM to 3 nM), and all samples were 
prepared once.  
After sample preparation they were incubated in black 96-well microtiter plates for 30 
min at room temperature (22 °C) with an optimal working volume of 150 μL. PL decay 
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curves were acquired on a fluorescence plate reader (Edinburgh Instruments) using 
4000 detection bins of 2 μs integration time and nitrogen laser (MNL 100, LTB 
Lasertechnik Berlin) excitation (337.1 nm, 20 Hz). Optical transmission filter bandpass 
wavelengths were (494±10) nm (Semrock) for the LTC detection channel, (716±20) nm 
(Semrock) for the Cy5.5 detection channel. 
RCA amplified FRET assay 
In a typical target DNA concentration dependant measurement, the ligation mixture 
consisted of 2 Weiss U of T4 DNA ligase, 0.5 nM padlock probe, and an appropriate 
amount of the target DNA in 30 µL ligation buffer (buffer 1, 40 mM Tris-Cl, 10 mM 
MgCl2, 0.5 mM ATP, pH 7.8) and was incubated at 37°C for 1 hr. Then 5 U of phi29 
DNA polymerase and 0.5 mM dNTP being prepared in 60 µL phi29 polymerase buffer 
(buffer 2, 40 mM Tris-Cl, 50 mM KCl, 10 mM MgCl2, 5 mM (NH4)2SO4,  pH 7.5) were 
added and incubated at 37°C for 3 hrs. The polymerization was terminated by 
incubation at 60°C for 10 mins. After that, 60 µL buffer 2 containing 5 nM LTC probe 
and 5 nM Cy5.5 probe was added into the solution and was incubated at room 
temperature (22 °C) for 30 min before measurements. The total reaction volume was 
150 μL and 140 μL of sample was transferred from the tube to black 96-well microtiter 
plate.  
PL decay curves were acquired on a fluorescence plate reader (Edinburgh Instruments) 
using 4000 detection bins of 2 μs integration time and nitrogen laser (MNL 100, LTB 
Lasertechnik Berlin) excitation (337.1 nm, 20 Hz). Optical transmission filter bandpass 
wavelengths were (494±10) nm (Semrock) for the LTC detection channel and (716±20) 
nm (Semrock) for the Cy5.5 detection channel. 
Time-gated (0.1 – 0.9 ms) PL intensity measurements were acquired on a KRYPTOR 
compact plus clinical fluorescence plate reader (Cezanne/Thermo Fisher Scientific) using 
the same LTC and Cy5.5 detection channel bandpass filters as mentioned above. In 
single sensor assays, each measurement consisted of 100 excitation flashes at 20 Hz 
repetition rate (5 s per measurement). For statistical analysis and the estimation of 
LODs all samples were prepared 3 times and measured in triplicates (n = 9) apart from 
the zero-concentration samples (without DNA targets), which were prepared 10 times 
and measured in  triplicates (n = 30).  
5.3. Results and discussions 
5.3.1. Proof-of-principle 
Modulation of energy transfer efficiency in a DNA duplex series 
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FRET results from dipolar coupling between the transition moments of two fluorophores, 
and the energy transfer efficiency depends on the separation between the donor and 
acceptor fluorophores and the relative orientation of their transition dipole vectors. The 
    distance dependence has been verified long time ago [199], but it is not so easy to 
obtain the perfect correlation between the theoretical and experimental data, and this is 
mainly due to the assumption of orientation factor to be constant, which is often not the 
case. LTC possesses multiple emission transition dipole moments (unpolarized emission) 
and therefore a dynamic averaging can be applied for the orientation factor [14]. Even if 
the orientation of the acceptor fluorophore changes, the    ranges from 1/3 to 2/3, which 
is much more confined. So LTC based FRET system is optimal for studying the distance 
dependence of FRET efficiency. In the previous chapter, we have applied different QD 
self-assemblies to control the distance of donor and acceptor, and here we use different 
lengths of dsDNAs to tune the distances. The dsDNA has a defined structure, and for 
instance, the B form DNA is 23.7 Å wide and extends 34 Å per 10 bp of sequence. The 
double helix makes one complete turn about its axis every 10.4-10.5 base pairs in 
solution [200]. If we label the two ends of the dsDNA with LTC and acceptor fluorophore, 
we could relatively easily control and estimate the distance of FRET donor and acceptor. 
We chose an organic dye Cy5.5 as the acceptor fluorophore instead of QD for better 
distance control (cf. Section 2.4.2.). Absorption and PL spectra of LTC donor and Cy5.5 
acceptor are shown in Figure 5.1.  We designed five dsDNAs where the LTC and Cy5.5 
were conjugated on two ends and located in different distances (10 bps, 13 bps, 15 bps, 
20 bps and 25 bps) to study the distance dependence of FRET. 
  
Figure 5.1.  Photophysical properties of the FRET sensor. Left: Absorbance spectra of the probe-
oligos containing LTC-donor (black) and the acceptor dyes Cy5.5 (red). Area-normalized PL 
spectrum of LTC (green) is shown for visualization of donor-acceptor spectral overlap. Förster 
distance was 5.8 nm for LTC-to-Cy5.5 FRET.  Right: PL emission spectra of LTC (green) and 
Cy5.5 (red). Optical transmission filter bandpass wavelengths were (494±10) nm (Semrock) for 
the LTC detection channel and (716±20) nm (Semrock) for the Cy5.5 detection channel. 
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Figure 5.2 shows the PL decay curves of the Cy5.5 and LTC detection channels with 
different lengths of dsDNAs. The long-lifetime parts of the decay curves strongly 
increase with increasing Cy5.5 probe concentrations for all dsDNAs, and furthermore, 
the decay curves show strong distance dependence where the dsDNA with shorter 
length shows much faster decay curves and vice versa. A time-resolved study was 
performed to estimate the LTC-to-Cy5.5 FRET efficiencies and donor-to-acceptor 
distances (Appendix 7.4.1), and FRET efficiencies were calculated by both the donor 
quenching and acceptor sensitization. The large difference in the excited-state lifetimes 
of LTC and Cy5.5 (six orders of magnitude) leads to approximately equal PL decay times 
for FRET-quenched LTC and FRET-sensitized Cy5.5. As a consequence, the decay time 
of LTC donor in the presence of Cy5.5 acceptor (    in Equation 2.7) can be replaced by 
the decay time of Cy5.5 acceptor in the presence of LTC donor (       ) [14], and time-
resolved PL from both LTC and Cy5.5 can be used for FRET analysis. As was mentioned 
in Section 4.3.2, there is a detailed description of LTC-to-QD FRET using time-resolved 
donor quenching and acceptor sensitization analysis in reference [40]. Briefly, the 
measured PL decay curve in both measurement channels contains signals from the 
unquenched donor. In order to estimate the pure FRET decay time for the calculation of 
the donor-acceptor distance the measured PL decay times need to be corrected for the 
free LTC.  
We adapted the method to the LTC-to-Cy5.5 FRET. The analysis of the FRET quenched 
PL decay curves measured in the donor channel is more straightforward, because the 
pure LTC-DNA conjugates exhibit a single-exponential decay and the FRET quenched 
PL decay curves measured in the donor channel can then be fitted with two exponents, 
yielding two decay times      and     .      is the new component derived from FRET 
process and      is contributed by the unquenched LTCs, so only      is used to 
calculate the FRET efficiency.  
For the analysis of the FRET sensitized PL decay curves measured in the acceptor 
channel, the optical crosstalk of LTC in the detection channel of Cy5.5 (Figure 5.2 
middle) still needs to be corrected, though it is very low (cf. Figure 5.1), in order to yield 
the pure FRET sensitized decay time. The quadruple (or less frenquent a triple, 
Appendix 7.4.1) exponential FRET-sensitized Cy5.5 acceptor decay curves was needed 
to perform a good nonlinear least squares fit, with the amplitudes      ,      ,      , 
and       and the decay times     ,     ,     , and     . In order to take into account the 
emission of unquenched donors,      was fixed to     , and the amplitude       was 
fixed to the value according to Equation 5.1, 
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 5.1 
     is the amplitude of the pure LTC decay curve in Cy5.5 detection channel,       and 
      are the amplitudes of LTC decay curves in LTC detection channel, in the presence 
and in the absence of Cy5.5, respectively. 
In order to calculate the average FRET decay time    , the amplitude fractions      , 
     , and       and lifetimes     ,     , and      are taken into account. 
The amplitude fraction       (for  =1–3) can be calculated after Equation 5.2, 
       
     
                         
 5.2 
The amplitudes      (for  =1–3), which is used to calculate the average FRET decay time 
   , must be corrected by the FRET rates         to take into account the FRET 
efficiency-dependent excitation of the acceptors. The corrected amplitude fractions are 
(for  =1–3) calculated according to Equation 5.3, 
      
             
                                               
 5.3 
 The corrected averaged FRET sensitized decay time can then be calculated after 
Equation 5.4, 
                                5.4  
Using this method to consider unquenched LTC contribution in the acceptor channel 
allows the calculation of the pure FRET sensitized decay times and thus the 
determination of donor-acceptor distances. 
Figure 5.3 shows the correlation of the estimated distances (based on the defined 
structure of dsDNAs) and the measured distances (based on the relationship of FRET 
efficiency and donor-to-acceptor distance). The black line is the calculated FRET 
efficiencies for different distances of a donor-acceptor pair with a Förster distance of 
LTC-to-Cy5.5 to be 5.8 nm (based on Equation 2.6). The resulting efficiencies 
calculated from the decay lifetime of the quenched donor and sensitized acceptor (using 
Equation 2.7) are plotted as a function of estimated LTC to Cy5.5 distances, which 
were a summation of the lengths of double helix and the center-to-center distance of 
LTC and Cy5.5. The lengths of the double helix were calculated 0.34 nm per base pair, 
and the center-to-center distance of LTC and Cy5.5 was estimated as 0.9 nm. Overall, 
the values of the FRET efficiency decrease when the lengths of the double helix 
increased, and the estimated and measured FRET effciencies matched very well. We 
should also note that the FRET efficiencies calculated from the acceptor channels and 
the donor channels were very similar for ds DNA with 10 bps, 13 bps, 15 bps and 20 bps, 
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respectively. However, there were obvious differences for dsDNA with 25 bps, and the 
FRET efficiency calculated from the donor channels was much higher than the 
estimated value. As shown in the decay curves of dsDNA with 25 bps (Figure 5.2 
bottom), the pure LTC decays and FRET-quenched or FRET sensitized curves look very 
similar because the long donor-to-acceptor distance leads to a low FRET efficieny and 
therefore very similar decay times of the donor in the presence and in the absence of the 
acceptor. This small difference in unquenched and FRET-sensitized decay times makes 
the decay time fitting method relatively unprecise to distinguish the FRET components 
and the original lifetime of unquenched LTC. However, the weaker Tb background PL in 
the acceptor channel (compared to the donor channel) make fitting in the acceptor 
channel still more precise and a distance value closer to the estimated distance can be 
measured (Figure 5.3). 
 
Figure 5.2. The PL decay curves of the Cy5.5 detection channels (middle) and LTC detection 
channels (right) with different lengths of dsDNAs (10, 13, 15, 20, 25 bps). The long-lifetime parts 
of the decay curves strongly increase with increasing Cy5.5 probe concentrations (red: 1 nM, blue: 
1.5 nM, pink: 2 nM, green: 2.5 nM, dark blue: 3 nM) for all dsDNAs, and furthermore, the decay 
curves show strong distance dependence where the dsDNA with shorter length shows much 
faster decay curves and vice versa. Control experiments with only LTC-DNA, showed the 
background of LTC PL (black curves, spectral crosstalk in the Cy5.5 detection channels). 
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Table 5.2. The resulting efficiencies calculated from the decay times of the quenched donor 
(      of D channel) and sensitized acceptor (      of A channel) are plotted as a function of 
estimated LTC to Cy5.5 distances. The lengths of the double helix were calculated 0.34 nm per 
base pair, and the center-to-center distance of LTC and Cy5.5 was estimated as 1 nm. 
 
Double 
helix 
LTC-to-Cy5.5 
center 
estimated D-A 
distance 
      (A 
channel) 
SD 
      (D 
channel) 
SD 
10 bps 3.4 nm 1 nm 4.4 nm 0.88 0.091 0.93 0.094 
13 bps 4.4 nm 1 nm 5.4 nm 0.61 0.063 0.61 0.063 
15 bps 5.1 nm 1 nm 6.1 nm 0.47 0.050 0.46 0.05 
20 bps 6.8 nm 1 nm 7.8 nm 0.24 0.030 0.19 0.003 
25 bps 8.5 nm 1 nm 9.4 nm 0.15 0.024 0.31 0.036 
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Figure 5.3. The correlation of the estimated distances (based on the defined structure of dsDNAs) 
and the measured distances (based on the relationship of FRET efficiency and donor-to-acceptor 
distance). The black line is the calculated FRET efficiencies for different distances of a donor-
acceptor pair with a Förster distance of LTC-to-Cy5.5 to be 5.8 nm. The red points showed the 
calculated        of acceptor channel, and the green points show the calculated        of donor 
channel, both of them were plotted as a function of estimated LTC to Cy5.5 distances. 
Triplexed DNAs assay 
With the distinguishable decay curves of the sensitized Cy5.5 from different lengths of 
dsDNAs, we could also perform temporal multiplexing based on the principle we 
demonstrated in the previous chapter. We choose three lengths of dsDNA which are10 
bps, 13 bps and 25 bps to show the possibility of temporal multiplexing. In the triplexed 
DNA assay all LTC-DNA probes and different amounts of the Cy5.5-DNA probes were 
present into a single sample. We therefore prepared four different assays. The first three 
assays contained only one of the Cy5.5-DNA probes at increasing concentrations from 1 
nM to 3 nM. The last assay contained the same increasing concentrations of all Cy5.5-
DNA probes. As were shown in Figure 5.4, when only one of the Cy5.5-DNA probes was 
present in the samples, it showed similar decay curves to the single sensor assays and 
when all three Cy5.5-DNA probes were present, the decay curves showed a linear 
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combination of the three decay curves when only one Cy5.5-DNA probe was present. We 
chose three different time-gated windows (TGi: 0.02-1.5 ms, TGii: 2.5-5.0 ms, TGii: 6.0-
8.0 ms) to calculate the FRET ratio (time-gated PL intensities of the Cy5.5 channel were 
divided by that of the LTC channel) of all three systems. Three FRET systems showed 
different contributions in three time-gated windows (Figure 5.5 left). More importantly, 
the FRET ratios of the samples when all three Cy5.5 probes were present overlaid with 
the FRET ratios summation calculated of the samples when only one of the Cy5.5 probes 
was present (Figure 5.5 right), which meant we could simply deconstruct the 
contributions of all Cy5.5 probes in three TG windows and achieved temporal 
multiplexed determinations of all Cy5.5 probes. 
Figure 5.4. The PL decay curves of the Cy5.5 detection channels of the triplexed DNA assay. The 
first three assays contained only one of the Cy5.5-DNA probes at increasing concentrations from 
1 nM to 3 nM (red: 1 nM, blue: 1.5 nM, pink: 2 nM, green: 2.5 nM, dark blue: 3 nM). The last 
assay contained the same increasing concentrations of all Cy5.5-DNA probes. Black curves show 
spectral crosstalk in the Cy5.5 detection channels. 
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Figure 5.5. Triplexed DNA assay. Left: Three FRET systems with different lengths (black 
squares: 10 bps; red circles: 13 bps; blue triangles: 25 bps) showed different contributions in three 
time-gated windows. A: TGi: 0.02-1.5 ms, B: TGii: 2.5-5.0 ms, C: TGiii: 6.0-8.0 ms. Right: The 
FRET ratios of the samples when all three Cy5.5 probes were present (black squares) overlaid 
with the FRET ratios calculated as the mathematic sum of the samples when only one of the 
Cy5.5 probes was present (red circles).  D: TGi: 0.02-1.5 ms, E: TGii: 2.5-5.0 ms, F: TGiii: 6.0-8.0 
ms. 
5.3.2. RCA amplified FRET 
Sensing principle 
The target sequence serves as the primer and after the hybridization with the padlock 
probe, the nick is ligated by DNA or RNA ligase. After adding the polymerase and dNTP, 
the target sequence can be amplified thousands of times in a few hours. After the 
generation of RCA products, LTC labeled oligonucleotides and organic dyes Cy5.5 
labeled oligonucleotides (according to RCA products) hybridized with certain locations of 
RCA products and detection is performed by time-gated FRET from the LTC to Cy5.5. 
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Based on the distance dependance of FRET efficiency from the proof-of-principle study, 
we designed the LTC and Cy5.5 probes to be separated with 10 bps, 13 bps and 18 bps 
sequences for ssDNA/miRNA-20a, ssDNA/miRNA-20b and ssDNA/miRNA-21, 
respectively, to perform temporal multiplexing. 
 
 
Figure 5.6. Time-gated Förster resonance energy transfer based on sequence-specific DNA/RNA-
primed rolling-circle amplification detection. DNA/RNAs serve as the primer and after the 
hybridization with padlock probe, the nick is ligated by DNA/RNA ligase. After adding the 
polymerase and dNTP, the DNA/RNAs can be amplified thousands of times in a few hours, and 
after the generation of RCA products, LTC labeled oligonucleotides and organic dyes Cy5.5 
labeled oligonucleotides according to RCA products will hybridize with certain locations of RCA 
products and the detection is based on time-gated FRET from the LTC to Cy5.5. 
Feasibility of RCA amplified LTC-to-dye FRET 
We worked with exogenous (synthetized) ssDNA first. These exogenous nucleic acids 
were synthetized to have exactly the same sequences as the miRNA cancer biomarker 
targets to be detected in clinical samples. Working on both ssDNA and miRNA has the 
advantage of more versatility for optimization on DNA (lower synthesis costs) and of the 
possibility to directly implement FRET-RCA into sequence-specific DNA target detection, 
which plays an important role in the diagnosis and therapy of genetic diseases, typing 
and tracing sources of infectious agents, forensics, and the detection of single-nucleotide 
polymorphisms (SNP). We therefore performed ‘‘Yes or No’’ test measurements of all 
three ssDNAs. In the ‘‘No’’ measurements, only one of the three padlock probes was 
present in the sample, and in the ‘‘Yes’’ measurements, both the ssDNA and its 
respective padlock probe were present. We had six samples in total, and all of them 
followed the ligation step and polymerisation step, and then their respective LTC probes 
or Cy5.5 probes were added separately to perform FRET. Interestingly, we could see 
some floc in the samples after the generation of RCA products, which strongly suggested 
the process of RCA did happen. We could clearly see the Cy5.5 sensitization and LTC 
quenching in all ‘‘Yes’’ measurements of all ssDNAs (though the heterogeneous solutions 
may not be ideal to perform FRET measurements), and more importantly, the PL decay 
curves of Cy5.5 detection channels showed strong distance dependence where the 
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ssDNA sensor with shorter LTC-to-Cy5.5 distance showed much faster decay curves and 
vice versa (Figure 5.7). Although these decay curves did not follow exactly the same 
way as was shown in the simple dsDNA model (quasi-single-exponential), it was 
expected that they provided similar FRET efficiencies to the simple dsDNA model. The 
multi-exponential decays are due to the coiled structure of RCA products which made 
the LTC and Cy5.5 locating in a various distances (can be shorter or longer than 
presented in Figure 5.6).   
 
Figure 5.7. The red, pink and dark blue curves show the sensitization in PL decay curves of the 
Cy5.5 detection (left) and quenching in PL curves of LTC detection (right) of ssDNA-20a (1 nM), 
ssDNA-20b (1 nM) and ssDNA-21 (1 nM), respectively. The black, blue and green curves show 
the backgrounds from LTC optical crosstalk for when no ssDNAs were present (only padlock-20a, 
padlock-20b and padlock-21 were present, respectively). ssDNA-20a sensor with a 10 bps 
sequence between LTC and Cy5.5 decayed much faster, followed by ssDNA-20b sensor with a 13 
bps sequence and ssDNA-21 sensor with a 18 bps sequence. The final amounts or concentrations 
in 150 µL sample were: 0.2 Weiss U of T4 DNA ligase, 1 nM padlock probe, 5 U of phi29 DNA 
polymerase and 0.2 mM dNTP, 100 nM LTC probe and 100 nM Cy5.5 probe. 2 hrs polymerization 
time.  
Optimization of reaction parameters 
Optimization of the polymerization time, the concentration of the padlock probe and 
LTC and Cy5.5 probes were performed to improve the sensitivity of the RCA FRET 
assay. We used ssDNA-20b as a model to optimize the parameters. We first performed 
the optimization under a fixed concentration of ssDNA-20b at 20 pM, and we varied the 
polymerization times at 2 hrs, 3 hrs and 4 hrs, and we found that from 2 to 3 hrs, the 
FRET sensitization in Cy5.5 detection channel was increasing, and after 3 hrs, it started 
to decrease (Figure 5.8). Although speculative, we think the decrease may come from 
the increased average distance change between LTC and Cy5.5 on the RCA products, 
which can be seen from the different Cy5.5 decay curve at 4 hrs (blue curve in Figure 
5.8). The longer decay at 4 hrs compared to the other two at 2 hrs and 3 hrs maybe a 
result of the inaccessible LTC and Cy5.5 probes to the center of the longer RCA products 
(due to longer polymerization time).    
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Figure 5.8. Polymerization time optimization. The red, pink and dark blue curves show the 
sensitization in PL decay curves of the Cy5.5 (left) and PL quenching of LTC (right) for 2 hrs, 3 
hrs and 4 hrs of polymerization time under the same concentration of ssDNA-20b (20 pM). The 
black, blue and green curves show the backgrounds from LTC optical crosstalk for 2 hrs, 3 hrs 
and 4 hrs of polymerization time when no ssDNA-20b are present. The final amounts or 
concentrations of other components in 150 µL sample were: 2 Weiss U of T4 DNA ligase, 10 nM 
padlock probe, 5 U of phi29 DNA polymerase and 0.2 mM dNTP, 10 nM LTC probe and 10 nM 
Cy5.5 probe. 3 hrs gives the best sensitization in PL decay curves of the Cy5.5 detection, which is 
chosen as the condition for the following measurements. For intercomparison, all curves were 
measured under the same conditions. 
We then varied the concentrations of the padlock probes from 1 nM to 100 nM and found 
that the parameter greatly affected the FRET signals, and the lower amount we apply, 
the higher the FRET sensitization (Figure 5.9 Top). At high concentration the 
possibiltiy increases that the two ends of the padlock probes do not bind to the same 
ssDNA but bind to different ssDNAs and concenquently, the ssDNA-padlock complex 
does not form. As the sensitivity got strongly improved by decreasing the concentration 
of padlock probes, we performed the same optimization with 20 times lower ssDNA 
concentrations, and we varied the concentrations of the padlock probes from 10 pM to 10 
nM with a fixed concentration of ssDNA down to 1 pM, and found the FRET 
sensitization increased from 10 pM to 100 pM, stayed on a plateau from 100 pM to 1 nM, 
and then decreased to background (no FRET sensitization) at 10 nM (Figure 5.9 
Bottom). We finally chose 100 pM of padlock probe to perform the following 
experiments. 
The next parameter was the FRET probes, and we varied the concentrations of both 
LTC and Cy5.5 probes from 2 nM to 50 nM. For intercomparison, all samples were 
measured with approximately the same photon counts in the LTC detection channels 
(with the samples where no  ssDNA-20b were present) by adjusting the laser excitation 
intensity, and we found the  same trend as that of the padlock probe results, where the 
concentrations of the LTC and Cy5.5 probes and the relative FRET sensitization showed 
a negative correlation. By adjusting the laser intensity, Figure 5.10 corresponds to the 
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proportion of introducing LTC-to-Cy5.5 FRET pairs among the total LTC and Cy5.5 
inside the samples. With a constant RCA product level, the lower the concentration of 
LTC and Cy5.5, the higher the fraction of interacting FRET pairs. Even with 2 nM of 
LTC and Cy5.5 probes at 1 pM DNA target and 100 pM padlock concentration, the limit 
was most probably not reached. However, taking into account the instrumental setting 
(detection sensitivity), we finally chose 2 nM of LTC and Cy5.5 probes to perform the 
following experiments. 
 
Figure 5.9. Padlock probe optimization. Top: The red, pink and dark blue curves show the 
sensitization in PL decay curves of the Cy5.5 (left) and PL quenching of LTC (right)  of 1 nM, 10 
nM and 100 nM padlock probe under the same concentration of ssDNA-20b (20 pM). The black, 
blue and green curves show the backgrounds from LTC optical crosstalk of 1 nM, 10 nM and 100 
nM padlock probe when no ssDNA-20b are present. Bottom: The red, pink, dark blue and purple 
curves show the sensitization in PL decay curves of the Cy5.5 detection of 10 pM, 100 pM, 1 nM 
and 10 nM padlock probe under the same concentration of ssDNA-20b (1 pM). The black, blue, 
green and violet curves show the backgrounds from LTC optical crosstalk of 10 pM, 100 pM, 1 
nM and 10 nM padlock probe when no ssDNA-20b are present. The final amounts or 
concentrations of other components in 150 µL sample were: 2 Weiss U of T4 DNA ligase, 5 U of 
phi29 DNA polymerase and 0.2 mM dNTP, 10 nM LTC probe and 10 nM Cy5.5 probe. 100 pM 
padlock probe gives the best sensitization in PL decay curves of the Cy5.5 detection, which is 
chosen as the condition for the following measurements. For intercomparison, all curves were 
measured under the same conditions. 
98 
 
  
Figure 5.10. LTC and Cy5.5 probes optimizations. The red, pink, dark blue, purple and dark 
yellow curves show the sensitization in PL decay curves of the Cy5.5 detection of 2 nM, 5 nM, 10 
nM, 20 nM, and 50 nM LTC probe and Cy5.5 probe under the same concentration of ssDNA-20b 
(1 pM). The black, blue, green, violet and brown curves show the backgrounds from LTC optical 
crosstalk of 2 nM, 5 nM, 10 nM, 20 nM, and 50 nM LTC probe and Cy5.5 probe when no ssDNA-
20b is present. 2 nM LTC probe and 2 nM Cy5.5 probe give the best sensitization in PL decay 
curves of the Cy5.5 detection, which is chosen as the condition in following measurements. For 
intercomparison, all curves were measured with approximately the same LTC channel counts (no 
ssDNA-20b are present) by adjusting the laser intensity. 
Specificity 
In the previous chapter, we have shown multiplexed miRNA detections based on 
stacking effects and achieved very high specificity with two very similar miRNAs mir-
20a and mir-20b. The high specificity came from the terminal mismatches, which very 
nicely blocked the stacking effect. Here, we used the specificity of the ligases to 
distinguish internal mismatches. We compared the specificities of two DNA ligases, 
namely T4 DNA ligase and Taq DNA ligase. According to the provider’s (New England 
Biolab) website, T4 DNA ligase catalyzes the formation of a phosphodiester bond 
between juxtaposed 5' phosphate and 3' hydroxyl termini in duplex DNA or RNA. This 
enzyme will join blunt end and cohesive end termini as well as repair single stranded 
nicks in duplex DNA and some DNA/RNA hybrids. Taq DNA Ligase catalyzes the 
formation of a phosphodiester bond between juxtaposed 5´ phosphate and 3´ hydroxyl 
termini of two adjacent oligonucleotides, which are hybridized to a complementary 
target DNA. The ligation will occur only if the oligonucleotides are perfectly paired to 
the complementary target DNA and have no gaps between them. So T4 DNA ligase 
cannot distinguish a single mismatch while Taq DNA ligase can. In the specificity test 
measurements, we mixed the ssDNA-20b probe (the padlock-20b, LTC-20b and Cy5.5-
20b) with ssDNA-20b and ssDNA-20a targets separately, and we performed the RCA 
FRET assays with both DNA ligases mentioned above. As shown in Figure 5.11, with 
T4 DNA ligase, the ssDNA-20b probe could not distinguish ssDNA-20b and ssDNA-20a 
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as it provided very similar FRET sensitization decay curves for both ssDNAs. However, 
the Taq DNA ligase showed very impressive specificity to distinguish the mismatches 
between the ssDNA-20b probe and ssDNA-20a target, as there was negligible FRET 
sensitization of ssDNA-20a. To selectively detect very similar DNA sequences, a ligase 
with a high specificity, like Taq DNA ligase, should be used.      
  
Figure 5.11. PL decay curves of the Cy5.5 detection channels in specificity test measurement 
based on two DNA ligases. A constant concentrations of the ssDNA-20b probes with different 
concentrations of ssDNA-20b and ssDNA-20a targets (red: 0.1 pM, blue: 0.2 pM, pink: 0.5 pM, 
green: 1 pM, dark blue: 1 pM) were mixed to perform RCA FRET. With T4 DNA ligase, ssDNA-
20b and ssDNA-20a provided the same FRET sensitization of Cy5.5, while with Taq DNA ligase, 
only ssDNA-20b (fully matched with ssDNA-20b probe) provided FRET sensitization of Cy5.5.  
Single sensor performance 
The performance of the single sensors is shown in Figure 5.12. In these assays the 
samples contained only one padlock probe and one target at increasing concentrations. 
We first performed the ssDNA-20b concentration dependent measurement with 
relatively higher concentrations (sub to low pM range) to show the obvious FRET 
sensitization. As was shown in the PL decay curves from the Cy5.5 detection channels, 
the long lifetime parts, which were due to the energy transfer from LTC to Cy5.5 got 
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strongly increased, and in contrast, the PL decay curves from the LTC detection 
channels got significantly quenched. The FRET ratios increased with increasing miRNA 
concentrations between 0.1 and 2 pM. We then performed assays with lower 
concentrations (fM range) to estimate the limits of detection. For statistical analysis and 
the estimation of LODs all samples were prepared 3 times and measured once on the 
Dreamreader (n = 3)  and in triplicates (n = 9) on the KRYPTOR plate readers, 
respectively, apart from the zero-concentration samples (without ssDNA-20b targets), 
which were prepared 10 times and measured once on the Dreamreader (n = 10)  and in  
triplicates (n = 30) on the KRYPTOR. The limits of detection were 30 fM and 5 fM for 
the assays of Dreamreader and KRYPTOR, respectively, and the lower LOD of 
KRYPTOR was due to an optimized detection setup. 
  
Figure 5.12. Performance evaluation of the relatively higher concentrations of ssDNA-20b under 
the optimized conditions above (0.1 nM padlock probe, 2 Weiss U of T4 DNA ligase, 5 U of phi29 
DNA polymerase, 0.2 mM dNTP, 2 nM LTC and Cy5.5 probes in 150 µL volume). A shows the 
obvious sensitization in the PL decay curves of the Cy5.5 detection channel, in which the long-
lifetime parts of the decay curves strongly increase with increasing ssDNA-20b concentrations 
(black, red and blue: 0, pink: 0.1 pM, green: 0.2 pM, dark blue: 0.5 pM, violet: 1 pM, purple: 2 pM). 
B shows the obvious quenching in the PL decay curves of the LTC detection channel, in which the 
short-lifetime parts of the decay curves correspond to the long-lifetime parts in Cy5.5 channel. C 
shows the FRET ratios (ratios of 0.02 – 8 ms time-gated PL intensities of Cy5.5 and LTC 
collected in the graphs above) as a function of ssDNA-20b concentration. 
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Figure 5.13. Performance evaluation of the relatively lower concentrations of ssDNA-20b (fM 
range, close to LOD) under the optimized conditions above (0.1 nM padlock probe, 2 nM LTC and 
Cy5.5 probes in 150 µL volume). The left graph shows the FRET ratios (ratios of 0.02 – 8 ms 
time-gated PL intensities of Cy5.5 and LTC collected on Dreamreader) as a function of ssDNA-
20b concentration. The right graph shows the FRET ratios (ratios of 0.1 – 0.9 ms time-gated PL 
intensities of Cy5.5 and LTC collected on KRYPTOR) as a function of ssDNA-20b concentration. 
We should note that, the target-primed RCA amplified FRET is an ongoing project till 
date. The single sensor statistical assays have been performed with T4 DNA ligase, and 
we also need to estimate the sensitivity of using Taq DNA ligase (the prelimineary 
result has shown the sensitivity of using Taq DNA ligase is higher than that of T4 DNA 
ligase). After the assessment of the single sensor of ssDNA-20b, the next step is to 
investigate the other two ssDNAs either simply transfering the parameters of ssDNA 
single sensor assay or performing similar optimizations for them. Considering the very 
promising sensitivity of ssDNA-20b detection and the distinguishable PL decay curves 
in the Cy5.5 detection channels of all three ssDNA sensors, we believe that a 
multiplexed, extremely sensitive and homogenous DNA/RNA assay will be accomplished 
in the near future.  
5.4. Conclusion  
We first presented a more straightforward way to control FRET efficiencies. We 
achieved this by investigating the donor and acceptor distance dependence of LTC-to-
dye FRET efficiency using different lengths of dsDNAs, and found an excellent match 
between the estimated distances (based on the defined structure of dsDNAs) and the 
measured distances (based on the relationship of FRET efficiency and distance), and 
thus, we could control the FRET efficiency by controlling the distance of donor and 
acceptor fluorophores. We then demonstrated a temporal triplexed DNA assay based on 
FRET from one single LTC to one single organic dye by applying multiple time-gated 
windows.  
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We have developed a target-primed RCA amplified FRET assay where we integrated the 
power of isothermal nucleic acid amplification for ultra-sensitive detection with the 
versatility of FRET for multiplexed and homogeneous optical biosensing. We first tested 
the feasibility of RCA amplified LTC-to-dye FRET to separately detect three ssDNAs 
(miRNA analogies), and showed increased FRET signals for all three ssDNAs, and more 
importantly, the PL decay curves of Cy5.5 detection channels showed strong distance 
dependence which is very promising for future simulteneous temporal multiplexing. 
Then we performed a systematic optimization of the assay parameters and achieved 
greatly improved sensitivity and specificity. Finally we showed that the homogeneous 
assay worked at low temperature on a clinically approved fluorescence plate reader 
system with detection limits down to 5 fM and with high specificity of distinguishing 
single base pair mismatches and did not require any washing or separation steps. 
Considering the very promising sensitivity of ssDNA-20b detection and the 
distinguishable PL decay curves in the Cy5.5 detection channels of all three ssDNA 
sensors, we believe that a multiplexed, highly sensitive and homogenous DNA/RNA 
assay will be available in the near future. 
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6. Summary and Outlook 
6.1. Summary  
An individual summary of each study is provided in the conclusion sections of each 
chapter, and no repeated discussion is necessary here. In this part, the common 
characteristics of all techniques developed in this work and their comparison are 
highlighted. 
The work has been focused on developing multiplexed biosensors based on time-resolved 
FRET from LTC to organic dyes or QDs. I presented several new techniques to 
simultaneously and multiplexed detect biomarkers such as cancer related protein 
biomarkers (human epidermal growth factor receptors) or miRNAs biomarkers (miRNA-
20a, miRNA-20b and miRNA-21) with very low limits of detection. We have used 
different strategies to achieve multiplexed detection, such as spectral-multiplexed 
detection based on different emission spectra of different QDs, and temporal-
multiplexed detection based on distinguishable decaytimes of the same LTC-to-QD or 
LTC-to-dye FRET pairs. The work is not only an applied research that can be used in 
clinical diagnostics but also a fundamental research of time-resolved FRET, which opens 
new dimensions of multiplexed detection. 
From the fundamental reasearch point of view, although time-resovled or time-gated 
measurements have long been used in vitro diagnostics, they have been mainly used to 
avoid the background signals such as the autofluorescence of the biological matrix. 
Unfortunately, time domain has not been strongly explored before as a multiplexed 
domain for quantification. In this work, we have shown for the first time multiplexed 
assays using different time-gated windows to collect the PL intensities, and the 
contributions of different analytes in different time-gated windows were deconstructed 
by a simple matrix calculation. More promisingly, the different lifetimes or PL decay 
curves were obtained from the same FRET pair but with different donor-to-acceptor 
distances. We achieve the controllable distances of LTC-to-QD and LTC-to-dye by two 
different strategies. Due to the defined structure of dsDNA and the site-specific 
modifications available for nucleic acids, it is more straightforward to locate physically 
small molecules such as LTC and dyes and control their distances, and we have shown 
an excellent match between the distances calculated based on the structural feature of 
dsDNA and the measured distances by FRET. However, we have also found that the 
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strategy was not easily transferred to control the distance of LTC-to-QD FRET pairs 
(defined from the LTC to the centra of QD) due to the physically larger sizes of QDs 
(data not shown in this work).  Alternatively, we showed the possibility of tuning the 
LTC-to-QD distances by applying different QD assemblies, namely, sAv-biotin assembly 
and polyhistidine-metal coordination. Biotin or polyhistidine modified DNA provided 
access to different layers of QDs, and thus provided different FRET efficiencies, which 
could be used for temporal multiplexing. 
From the applied research point of view, all of the different assays were homogeneous, 
neither washing steps nor separation steps were needed, even with the amplified assay. 
All assays were designed to be detected on a clinically approved fluorescence plate 
reader system, which allows the analysts to perform direct clinical application without 
introducing new equipments. The two biological models we chose were very challenging. 
The two protein biomarkers come from the same cell membrane receptor family, and two 
of the three miRNAs share almost the same sequences, both of which set high demands 
for the specificity of the assays. We suffered from the biological crosstalk of one of the 
antibodies involved (which should had been avoided at the first place), but luckily, we 
could quantify the effects of the crosstalk and achieve quantification of both antigens 
with satisfying precision. To fullfil the needs of a highly specific miRNAs detection, we 
have achieved terminal single-nucleotide polymorphism distinction based on the 
stacking effects and internal single-nucleotide polymorphism distinction through 
implementing ligase based nucleic acid ligation. As the highly demanding assays were 
successfully performed, these immunoassay based protein detecting techniques and 
hybridization based miRNA detecting techniques should be easily transferable to other 
protein biomarkers or miRNAs biomarkers or even DNA biomarkers. We should note 
that, in the two miRNA assays based on LTC-to-QD FRET (Chapter 4), to achieve 
simplicity, rapidity, selectivity and multiplexing at the same time, we have to 
compromise on the relative low sensitivities (LODs in sub-nM range), which were often 
not sufficient to detect extremely low miRNA concentrations. But in the last amplified 
DNA/RNA FRET assay, we have shown very promising preliminary results with ssDNA 
detection limit to be a few fM (five orders of magnitude lower than before). As the target-
primed RCA amplified FRET is an ongoing project till date, next we present the future 
direction and the perspective. 
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6.2. Outlook 
The temporal multiplexing we demonstrated in this work was only a prime example, 
and this new detecting dimension definitely needs to be fully explored and investigated. 
We proposed a verbal definition of the temporal multiplexing capacity as the number of 
analytes, which can be precisely detected with a single FRET pair, is strongly depending 
on the number of distinct PL decay curves we could get from the single FRET pair, 
which is then determined by the number of different FRET donor to acceptor distances 
that fall into the 0.5 - 2 times Förster  distance range. We have performed triplexed 
assays in proof-of-principle (Section 5.3.1), but the multiplexing capacity is not limited 
to three, and this needs to be figured out in future investigations.   
Considering the different PL decay curves of the sensitized QDs we obtained from the 
different antibody-based protein immunoassays, temporal multiplexing can also be 
applied to FRET immunoassays. Combining spectral and temporal multiplexing 
together (spectral-temporal multiplexing) will then greatly increase the number of 
biomarkers detectable in a single sample (spectral multiplexing capacity multiplied by 
temporal multiplexing capacity). 
More ambitiously, with the powerful target-primed RCA amplified FRET, direct 
quantification of multiple different miRNAs from a single human plasma sample, 
without laborious preparation and separation steps and the need for sophisticated 
equipment and analysis, has the potential for a paradigm shift in clinical diagnostics of 
miRNA, because it combines the simplicity of a homogeneous immunoassay, the 
multiplexing capability of microarrays, the sensitivity of qRT-PCR, and the throughput 
capacity of next generation sequencing within one single diagnostic tool. 
    
106 
 
7. Appendix 
7.1. Abbreviations 
BSA bovine serum albumin 
cDNA complementary DNA 
ChA acceptor channel 
ChD donor channel 
DHLA dihydrolipoic acid 
DNA deoxyribonucleic acid 
dNTP deoxynucleotide 
dsDNA double strands DNA 
EGFR epidermal growth factor receptor 
ELISA enzyme-linked immunosorbent assay 
Fab fragmented antigen-binding 
FDA Food and Drug Administration 
FLIM fluorescence lifetime imaging  
FP fluorescent protein 
FRET Förster resonance energy transfer 
FWHM full-width-at-half-maximum 
HER2 human epidermal growth factor receptor 2 
His6 hexahistidine 
HPLC high performance liquid chromatography 
IR infrared  
Ln lanthanides 
LOD limit of detection 
LTC lanthanide terbium complex 
mAb monocolonal antibody 
MCS multichannel scaling  
MEM maximum entropy method 
miRNA miRNA 
MWCO molecular weight cut-off 
NBCS newborn calf serum 
NGS next generation sequencing  
NHS N-hydroxysuccinimide 
NIR near infrared 
NMR nuclear magnetic resonance 
NP nanoparticle 
NSCLC non-small-cell lung cancer  
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PEG poly(ethylene glycol) 
PL photoluminescence 
PMT photomultiplier tube 
POCT point-of-care testing 
QD quantum dot 
qRT-PCR quantitative reverse transcription-polymerase chain reaction 
RCA rolling circle amplification 
ref. reference 
RNA ribonucleic acid 
SATA N-succinimidyl S-acetylthioacetate 
sAv streptavidin 
sdAb single domain antibody 
SDS-PAGE sodium dodecyl sulfate polyacrylamide gel electrophoresis  
SNP single-nucleotide polymorphism 
ssDNA single strand DNA 
STR short tandem repeats  
TCSPC time-correlated single-photon counting 
TEM transmission electron microscopy 
TG time-gated 
Tm melting temperature 
TPSA total prostate specic antigen 
TR time-resolved 
UC upconversion  
UCNP upconversion nanoparticle 
UV ultraviolet 
Vis visible 
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7.2. Multiplexed Protein Assay 
7.2.1. Antibody fragmentation SDS-PAGE 
Fragmentation of EGFR antibody Matuzumab 
 
Figure 7.1. Matuzumab Fab SDS-PAGE certification image. 1:PSS 233 IgG1 (another full size 
antibody as a reference); 2:Matuzumab fragments after generation of fragmentation; 3:PSS 233 
IgG1; 4:Matuzumab fragments after purification and buffer exchange; 5:Protein A Column 
Elution 1; 6:Protein A Column Elution 2; 7:Protein A Column Elution 3 (1 and 2: reducing 
loading buffer and boiling; 3-7: no reducing loading buffer and boiling) 
Fragmentation of HER2 antibody Pertuzumab 
 
Figure 7.2. Pertuzumab Fab SDS-PAGE certification image. 1:Pertuzumab IgG1; 2:Pertuzumab 
Fab  fragments after generation; 3:Pertuzumab IgG1; 4:Pertuzumab Fab fragments after 
purification and buffer exchange; 5:Protein A Column Elution 1; 6:Protein A Column Elution 2; 
7:Protein A Column Elution 3 (1-2: reducing loading buffer and boiling; 3-7: non reducing loading 
buffer and boiling)  
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7.2.2. LTC and QD bioconjugation protocols 
Labeling 11A4 with L4-maleimide 
(For other antibodies concerning L4Tb-NHS labelings, no reduction or Tb 
charging steps are needed.) 
________________________________________________________________________________ 
Reduction of 11A4-Cysteine-tag 
Some sulfhydryl-containing molecules may oxidize in solution and form disulfide bonds, which 
cannot react with maleimides. Disulfide bonds can be reduced to produce free sulfhydryls. After 
reduction, most reducing reagents must be removed before conjugation. 
1. Bring 11A4-Cysteine-tag solution (1.33 mg/mL) into reducing buffer (50 mM sodium phosphate, 
150  mM NaCl, pH=6.5) 
using Amicon 0.5 3 K spin column: 
- prewet with 500 µL reducing buffer 
- shortly vortex the 11A4-Cysteine-tag (in PBS) + spin down - ca. 90 µL in tube 
- discard carbonate buffer from spin column 
- fill in ca. 90 µL of 11A4-Cysteine-tag + 310 µL reducing buffer 
- preparing counter balance 
 
-> Eppendorf centrifuge: 5424 R 
 settings: rcf (g-number): 14000; T = 20 °C; fast mode; time: (2+2+2+2) min 
- 2 times refill of reducing buffer, time: 8 min 
 
- recovery: settings: rcf (g-number): 1000; T = 20 °C; fast mode; time: 2 min 
Finally, 120 μg 11A4-Cysteine-tag in 120 μL reducing buffer 
2. Reduce Cysteine-tag sample by addition of 0.6 μL 1M TCEP (final concentration of TCEP is 10 
mM)  
 
- shortly vortex 
- Intelli Mixer -> prewetting tubewalls by rotating the tube 
  -> sample in alu foil 
  -> program F5 - 25 rpm  
- incubation time: 30 min 
________________________________________________________________________________ 
Conjugation 
1. Exchange with labeling buffer (50mM sodium phosphate, 150 mM NaCl, pH=7.4), where VHH 
concentration is preferably close to 1 mg/ml.  
using Amicon 0.5 3 K spin column: 
- prewet with 500 µL labeling buffer 
- shortly vortex the 11A4-Cysteine-tag (reduced) + spin down - ca. 120 µL in tube 
- discard labeling buffer from spin column 
- fill in ca. 120 µL of 11A4-Cysteine-tag + 280 µL labeling buffer 
- preparing counter balance 
 
-> Eppendorf centrifuge: 5424 R 
 settings: rcf (g-number): 14000; T = 20 °C; fast mode; time: 8 min  
- 2 times refill of labeling buffer 
 
- recovery: settings: rcf (g-number): 1000; T = 20 °C; fast mode; time: 2 min 
Finally, 11A4-Cysteine-tag in 96 μL labeling buffer 
 
Absorbance measurement  
 
-> BMG reader - L-Vis plate 
 settings: 100 flashes; 0.5 s pos. delay; res. 1.0 nm; scan 220 - 1000 nm 
- reducing or labeling buffer for blank -> same spots for reducing buffer exchange FT 1-3, labeling 
buffer exchange FT 1-3 and 11A4-Cysteine-tag (after labeling buffer exchange) 
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Result: no obvious lose of VHH in the flow through, and concentration of 11A4-Cysteine-tag 
(reduced) is 0.73 mg/mL 
 
2. 70 μg 11A4-Cysteine-tag in 96 μL labeling buffer + 2.31 µL L4-maleimide (in DMF, 8 mM) -> 
in 1.5 mL Eppendorf-tube 
concentration of 11A4-Cysteine-tag in conjugation solution: 0.73 mg/mL -> reaction ratio L4-
maleimide/VHH = 4/1 
 
- shortly vortex 
- Intelli Mixer -> prewetting tubewalls by rotating the tube 
  -> sample in alu foil 
  -> program F1 - 25 rpm  
- incubation time: 3 h 
________________________________________________________________________________ 
Purification: 
 
-> Thermo Scientific Heraeus MegaFuge 40 R 
 settings: g-number: 4000; T = 4°C; swing bucket; Acc/Dcc 9 
 
using Amicon 4 3 K spin column: 
- prewet with 1 mL 100 mM TRIS/Cl pH 7.4 
- discard TRIS/Cl buffer from spin column 
- fill in ca. 100 µL of (11A4-Cysteine-tag) – (L4-maleimide) + 3.9 mL TRIS/Cl buffer 
- preparing counter balance 
- spin-time for one Flow through : 23 min  
- 3 times refill with TRIS/Cl buffer 
- total Flow through number: 4 
 
-> final sample volume: ~ 490 µL for (11A4-Cysteine-tag) – (L4-maleimide) 
________________________________________________________________________________ 
Characterization: 
Absorbance measurement: 
 
-> PerkinElmer reader 
settings: scan 800 - 200 nm; res. 1.0 nm; speed 120 nm/min; lamp change at 326 nm 
  
- 5 times TRIS/Cl buffer for blank -> sample of (11A4-Cysteine-tag) – (L4-maleimide) and Flow 
through 1 to 4 
________________________________________________________________________________ 
Tb3+ charging 
 
4:1 ratio of TbCl3 to (11A4-Cysteine-tag) – (L4-maleimide) 
 
- Intelli Mixer -> prewetting tubewalls by rotating the tube 
  -> sample in alu foil 
  -> program F1 - 25 rpm  
- incubation time: 1 h 
________________________________________________________________________________ 
Storage 
11A4-Tb in 100 mM TRIS/Cl pH 7.4 in 4 °C 
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EgB4 labeling with eQD605 and eQD650  
(The protocol is all suitable for 18A12 random labeling, and for other antibody 
labelings, no SATA step was needed) 
________________________________________________________________________________ 
Material Preparation  
Reaction Buffer:  Prepare 250 mL of PBS: 0.1M phosphate, 0.15M NaCl, pH 7.3.  
Protein Solution: EgB4 110 μg, dissolve in 116 μL in Reaction Buffer.  
Deacetylation Solution: 0.5M Hydroxylamine in PBS, pH 7.3. Dissolve 0.435 g 
hydroxylamine•HCl in 10 mL Reaction Buffer. Add ultrapure water to a final volume of 12.5 mL 
and adjust pH to 7.4 with NaOH. (prepared before usage) 
________________________________________________________________________________ 
Reaction of Antibody with SATA 
1.  Immediately before reaction, dissolve 2.8 mg of SATA in 0.22 mL of DMSO (results in 55 mM 
solution).  
2. Combine 116 μL (110 μg) of EgB4 Solution with 0.6 µL of the SATA solution. (5:1 molar ratio of 
SATA to VHH) Mix contents and incubate reaction at room temperature for 30 minutes.  
Note: The level of sulfhydryl incorporation may be altered by using different molar ratios of 
SATA to protein. This default reaction uses 60 nmol Protein and 550 nmol SATA, a 9:1 molar 
ratio of SATA to protein. More complete acylation of all primary amino groups will occur when 
larger molar excesses of SATA are used; however, higher levels of acylation correspond to greater 
risk of protein inactivation. Increase or decrease the amount of SATA in the reaction by adding 
more or less than 10 µL of the SATA solution per mL of Protein Solution. 
Purifying Acylated Protein from Excess Reagent and By-Products (this part is 
modified with Zeba spin desalting column)  
A.  Protein Desalting Spin Column Preparation  
1.  Remove column’s bottom closure and loosen cap (do not remove cap).  
2.  Place column in a 2.0mL collection tube. Centrifuge at 1500 × g for 1 minute to remove storage 
solution.  
3.  Place a mark on the side of the column where the compacted resin is slanted upward. Place 
column in the  
microcentrifuge with the mark facing outward in all subsequent centrifugation steps.  
4.  Add 300µL of reaction buffer on top of the resin bed. Centrifuge at 1500 × g for 1 minute to 
remove buffer.  
5.  Repeat Step 4 two to three additional times, discarding buffer from the collection tube.   
  
B.  Sample Loading  
1.  Place column in a new collection tube, remove cap and apply 100 µL of sample to the top of the 
compact resin bed.  
2.  Centrifuge at 1500 × g for 2 minutes to collect the sample. Discard desalting column after use.  
Note: At this point, the modified protein may be stored indefinitely for later deacetylation and 
generation of sulfhydryl groups.  
 
Absorbance measurement of EgB4-SATA 
 
-> BMG reader - L-Vis plate 
 settings: 200 flashes; 0.2 s pos. delay; res. 1.0 nm; scan 220 - 1000 nm 
- Reaction buffer for blank -> EgB4-SATA 
________________________________________________________________________________ 
 
Deacetylate SATA-Modified Protein to Generate Sulfhydryl Groups  
1.  Combine 0.115 mL of SATA-modified (acetylated) protein (ac.78 μg) with 11.5 µL of the 
Deacetylation Solution.  
2.  Mix contents and incubate reaction for 2 hours at room temperature.  
3. Use a desalting column to purify the sulfhydryl-modified protein from the Hydroxylamine in 
the Deacetylation Solution. Desalt into Reaction buffer, pH 7.4 using the same procedure 
above.  
   
Absorbance measurement of EgB4-SH 
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-> BMG reader - L-Vis plate 
 settings: 200 flashes; 0.2 s pos. delay; res. 1.0 nm; scan 220 - 1000 nm 
- 1 x PBS buffer for blank -> EgB4-SH 
________________________________________________________________________________ 
Preparation EgB4 solution for conjugation 
Labeling of eQD605 or eQD650 to EgB4 in 1xPBS buffer pH 7.4 
 
Conjugation with eQD605 or eQD650: 
 
- heating up water bath to 60°C 
- add certain concentration of EgB4 filled in 1.5 mL Eppendorf tube 
- using 220 µL conjugation buffer for reconstitution of eQD605 vial; 110 µL conjugation buffer for 
reconstitution of eQD650 vial 
- gently shaking 
- put in water bath for 15 s -> red clear solution 
  Volume conc. QD605 VHH/QD Quencher 
EgB4 100 μL 
0.3 
mg/mL 
25 μL 27:1 0.25 μL 
Control 100 µL 0 25 µL 
 
0.25 μL 
  Volume conc. QD650 VHH/QD Quencher 
EgB4 100 μL 
0.3 
mg/mL 
25 μL 27:1 0.25 μL 
Control 100 µL 0 25 µL 
 
0.25 μL 
 
- shortly vortex 
 
- Intelli Mixer -> prewetting tubewalls by rotating the tube 
  -> sample in alu foil 
  -> program F1 - 25 rpm (remix every 30 min) 
Incubation time: 6 h  
Quenching: 
 
- add certain quencher solution 
- shortly vortex for 2 s 
- mixing with Intelle Mixer for 10 min -> same settings as for conjugation 
________________________________________________________________________________ 
Purification: 
 
-> Thermo Scientific Heraeus MegaFuge 40 R 
 settings: g-number: 1000; T = 23°C; swing bucket; Acc/Dcc 9 
 
using Amicon 4 100 K spin column: 
- prewet with 1 mL 100 mM Na-tetraborate buffer pH 8.5 (borate buffer) 
- discard borate buffer from spin column 
- fill in ca. 125 µL of EgB4-eQD605, EgB4-eQD650, bare-eQD605 and bare-eQD650 + 1.0 mL 
purification buffer 
- preparing counter balance 
- total spin-time for one Flow through : 8 min (one time) 150 μL left 
- 2 times refill with purification buffer 
- total Flow through number: 3 
- wash the spin column membrane with 150 µL purification buffer 
________________________________________________________________________________ 
Characterization: 
Absorbance measurement: 
-> PerkinElmer reader 
PL emission and lifetime measurement: 
-> FT300 
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7.2.3. LTC and QD bioconjugates concentrations overview 
EGFR single domain antibody conjugates 
QD conjugates 
sdAb QD sdAb [µM] QD [µM] sdAb /QD 
EGFR - EgB4 (R) eQD650 2.6 0.14 18.1 
EGFR - EgB4 (R) eQD605 5.3 0.24 22.0 
LTC conjugates 
sdAb LTC sdAb [µM] LTC [µM] LTC/sdAb 
EGFR - EgA1 L4-NHS 8.9 19.7 2.2 
EGFR antibody conjugates 
QD conjugates 
Ab QD Ab [µM] QD [µM] Ab /QD 
EGFR - Matuzumab eQD650 1.9 0.29 6.5 
EGFR - Matuzumab Fab eQD650 7.5 0.21 35.9 
EGFR - Cetuximab eQD650 0.8 0.19 4.3 
EGFR - Matuzumab eQD605 1.9 0.52 3.6 
EGFR - Matuzumab Fab eQD605 5.9 0.42 14.1 
EGFR - Cetuximab eQD605 0.9 0.27 3.2 
LTC conjugates 
Ab LTC Ab [µM] LTC [µM] LTC/Ab 
EGFR - Matuzumab L4-NHS 2.0 8.1 4.1 
EGFR - Cetuximab L4-NHS 1.5 11.4 7.7 
HER2 single domain antibody conjugates 
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QD conjugates 
sdAb QD sdAb [µM] QD [µM] sdAb /QD 
HER2 - 18A12 (O) eQD650 3.2 0.16 19.7 
HER2 - 18A12 (R) eQD650 1.8 0.10 17.3 
HER2 - 18A12 (O) eQD605 1.7 0.17 9.8 
HER2 - 18A12 (R) eQD605 0.9 0.29 3.1 
LTC conjugates 
sdAb LTC sdAb [µM] LTC [µM] LTC/sdAb 
HER2 - 11A4 L4-Maleimide 8.4 11.7 1.4 
HER2 antibody conjugates 
QD conjugates 
Ab QD Ab [µM] QD [µM] Ab /QD 
HER2 - Pertuzumab eQD650 2.4 0.30 8.1 
HER2 - Pertuzumab Fab eQD650 7.0 0.41 17.0 
HER2 - Pertuzumab eQD605 1.6 0.61 2.5 
HER2 - Pertuzumab Fab eQD605 1.5 0.44 3.4 
LTC conjugates 
Ab LTC Ab [µM] LTC [µM] LTC/Ab 
HER2 - Trastuzumab L4-NHS 0.9 11.5 13.5 
HER2 - Pertuzumab L4-NHS 1.3 11.2 8.9 
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7.3. Multiplexed MiRNA assay 
7.3.1. LTC-DNA conjugation protocol  
Labeling reporter 20a with L4Tb-NHS  
(a typical protocol, suitable for all other DNAs used in this work) 
________________________________________________________________________________ 
Conjugation: 
7.9 µL Carbonate buffer pH 9.0 + 10 µL reporter 20a (100 μM) + 2.1 µL L4Tb-NHS (in DMF, 6 
mM) -> in 0.5 mL Eppendorf-tube 
concentration of reporter 20a in conjugation solution: 50 μM -> reaction ratio LTC/ reporter 20a = 
12/1 
________________________________________________________________________________ 
- shortly vortex 
- Intelli Mixer -> prewetting tubewalls by rotating the tube 
  -> sample in alu foil 
  -> program F1 - 30 rpm  
- incubation time: over night 
________________________________________________________________________________ 
Purification: 
Purification buffer: 100 mM HEPES, pH 7.4 
A. Desalting Spin Column Preparation  
1.  Remove column’s bottom closure and loosen cap (do not remove cap).  
2.  Place column in a 2.0 mL collection tube. Centrifuge at 1500 × g for 1 minute to remove 
storage solution.  
3.  Place a mark on the side of the column where the compacted resin is slanted upward. Place 
column in the microcentrifuge with the mark facing outward in all subsequent centrifugation 
steps.  
4.  Add 300 µL of purification buffer on top of the resin bed. Centrifuge at 1500 × g for 1 minute 
to remove buffer.  
5.  Repeat Step 4 two to three additional times, discarding buffer from the collection tube.   
  
B.  Sample Loading  
1.  Place column in a new collection tube, remove cap and apply 100 µL of sample (20 µL sample 
plus 80 µL purification buffer) to the top of the compact resin bed.  
2.  Centrifuge at 1500 × g for 2 minutes to collect the sample. Discard desalting column after use.  
Repeat A and B two more times to fully separate free LTC from reporter 20a-LTC sample 
(checked with UV table) 
_________________________________________ 
Characterization: 
Absorbance measurement: 
-> PerkinElmer reader 
PL emission and lifetime measurement: 
-> FT300 
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7.3.2. Mathematical model of spectral crosstalk correction 
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Figure 7.3. The FRET ratio of pure miRNA-21 (brown curve in A) increases in the presence of 
miRNA-20a (red curve in A) or miRNA-20b (dark-yellow curve in A). This increase is linearly 
dependent on the concentrations of miRNA-20a and miRNA-20b but also of miRNA-21. Therefore 
the FRET ratio contribution of constant concentrations of miRNA-20a and miRNA-20b increases 
with increasing miRNA-21 concentrations (B).  
 
Figure 7.3 A shows the increase of the FRET ratio of miRNA-21 when constant 
concentrations of miRNA-20a or miRNA-20b are present in the sample. This FRET ratio 
increase is not a simple constant intensity offset on top of the pure miRNA-21 FRET 
ratio curve (brown curve in Figure 7.3 A) but an offset that linearly increases with 
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miRNA-21 concentration. This means that the miRNA-20a and miRNA-20b 
concentration-dependent linearly increasing FRET ratio offsets at low miRNA-21 
concentrations (e.g., u20a and u20b) have a smaller slope than the ones at high miRNA-21 
concentrations (e.g., v20a and v20b), as shown by the equations in Figure 7.3 B. Therefore 
the mathematical correction model must take into account the concentrations of miRNA-
20a, miRNA-20b, and miRNA-21. 
To define the mathematical correction model we used the FRET ratio calibration curves 
(in the QD705 detection channel) of i) samples containing only miRNA-21 (brown curve 
in Figure 2 C or Figure 7.3 A), ii) samples containing miRNA-21 and 1 nM miRNA-
20a (red curve in Figure 7.3A), and iii) samples containing miRNA-21 and 1 nM miRNA-
20b (dark-yellow curve in Figure 7.3 A). Note that the curves in Figure 7.3 are only 
qualitative and are not the real calibration curves but serve for explanation of the 
mathematical model. For the real values that were used for the mathematical correction 
model several concentrations between 1 and 10 nM of miRNA-20a and miRNA-20b were 
applied to verify the linear concentration-dependence of the FRET offsets. Due to 
normalization of the correction model on 1 nM concentrations of miRNA-20a and 
miRNA-20b all concentrations in the model below are given in nM. 
The FRET ratio (FR) offsets of miRNA-20a (red curve in Figure 7.3 B) and miRNA-20b 
(dark-yellow curve in Figure 7.3 B) are: 
(1) FR20a = z20a  c21 + u20a 
(2) FR20b = z20b  c21 + u20b 
c21 is the concentration of miRNA-21, z20a and z20b are the slopes, and u20a and u20b the 
ordinate intercepts of the linear equations. 
u20a and u20b can be calculated using the concentrations of miRNA-20a (c20a) and miRNA-
20b (c20b), which are quantified in the detection channels of QD655 and QD605 (Figure 
4.9 A and 4.9 B), and the FRET ratio values at zero concentration (ordinate intercepts) 
of the different calibration curves shown in Figure 7.3 A:  
(3) u20a = (b20a - b21) c20a  
(4) u20b = (b20b - b21) c20b 
z20a and z20b can be calculated using the zero (ordinate intercepts) and 10 nM FRET ratio 
values of the different calibration curves shown in Figure 7.3 B:  
(5) z20a = (v20a - u20a) / 10 
(6) z20b = (v20b - u20b) / 10  
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v20a and v20b can be calculated using the concentrations of miRNA-20a (c20a) and miRNA-
20b (c20b) and the 10 nM FRET ratio values of the different calibration curves shown in 
Figure 7.3 A: 
(7) v20a = (d20a - d21) c20a 
(8) v20b = (d20b - d21) c20b 
with 
(9) d21 = 10k21 + b21 
Using equations 3, 4, 7, 8, and 9 in equations 5 and 6 results in: 
(5a) z20a = c20a [(d20a - 10k21 - b20a) / 10] 
(6a) z20b = c20b [(d20b - 10k21 - b20b) / 10] 
Using equations 3, 4, 5a, and 6a in equations 1 and 2 results in: 
(1a) FR20a = c21 c20a [(d20a - 10k21 - b20a) / 10] + c20a (b20a - b21)  
(2a) FR20a = c21 c20b [(d20b - 10k21 - b20b) / 10] + c20b (b20b - b21) 
The FRET ratio curve (in the QD705 detection channel) equation containing all 
contributions from miRNA-21, miRNA-20a, and miRNA-20b is then: 
(10) FR = c21 k21 + b21  +  c21 c20a [(d20a - 10k21 - b20a) / 10] + c20a (b20a - b21)  +  c21 c20b [(d20b - 
10k21 - b20b) / 10] + c20b (b20b - b21) 
In this equation FR is the measured FRET ratio from the QD705 detection channel and 
therefore all constants and variables apart from c21 are known.   
 
Solving equation 10 for the desired concentration of miRNA-21 (c21) leads to: 
(11)[miRNA-21] = c21 = [FR - b21 - c20a (b20a - b21) - c20b (b20b - b21)] / [k21 + c20a [(d20a - 10k21 
- b20a) / 10 + c20b [(d20b - 10k21 - b20b) / 10]] 
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Figure 7.4. FRET ratio calibration curves for the miRNAs 20a (left), 20b (middle), and 21 (right) 
measured in the different detection channels for samples in buffer. Due to small differences of 
the curves with only a single (black data points) or all three (red data points) miRNAs present in 
the samples an average of the two linear fits was used as final calibration curve for the triplexed 
determination of varying miRNA concentrations in buffer.    
 
 
 
 
 
 
 
Figure 7.5. FRET ratio calibration curves for the miRNAs 20a (left), 20b (middle), and 21 (right) 
measured in the different detection channels for samples containing 10 % serum. Due to small 
differences of the curves with only a single (black data points) or all three (red data points) 
miRNAs present in the samples an average of the two linear fits was used as final calibration 
curve for the triplexed determination of varying miRNA concentrations in samples containing 10 % 
serum.
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7.3.3. Decay time fitting of temporal multiplexed assay 
 
Donor Channel R0 = 8.6 nm 8.6 Fitted from 0.02 to 8 ms  
# mir-20a 
  
                        
 
1 LTC alone D in the absence of A (mono-exponential)   
2 10 2100 0.25 216 0.06 1.00 
3 15 2300 0.18 262 0.08 1.00 
4 20 1900 0.32 282 0.08 1.00 
5 25 2100 0.25 376 0.11 1.00 
average 2-5 2100 0.25     1.00 
distance r (nm) 10.3 10.3   fraction: 100% 
 
   
3.9% 13.2% 
  
0.0% 
 
 
   
fixed 
          # mir-20a 
  
            
  
  
              
  1 LTC alone 
  
2800 3586 1.00 
  
2800 
  2 10 
  
2800 3132 0.94 
  
2750 0.00 2100 0.25 
  3 15 
  
2800 3081 0.92 
  
2760 0.00 2300 0.18 
  4 20 
  
2800 3187 0.92 
  
2730 0.00 1900 0.32 
  5 25 
  
2800 3087 0.89 
  
2720 0.00 2100 0.25 
  average 2-5 
  
2800     
  
    2100 0.25 
  distance r (nm) 
  
>>R0 
    
  
 
10.3 10.3 
  
 
          
3.9% 13.2% 
  R0 is the Fo rster distance (donor−acceptor distance of 50% FRET efficiency) for LTC-QD-pair bioconjugate calculated as R0 = 0.02108 (κ2 ΦTb n−4 J)1/6 nm, with the FRET orientation factor κ2 = 2/3, the 
refractive index n = 1.35, and the overlap integral J = ∫ FLTC εQD λ4 dλ (from 450 to 700 nm with the area-normalized LTC emission spectrum FLTC and the QD molar absorptivity spectra εQD; cf. Figure S1). 
Distance values from the FRET analysis are given for the decay time fits in the LTC-donor (D) and QD-acceptor (A) channels, respectively. 
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Acceptor Channel R0 = 8.6 nm 8.6 Fitted from 0.2 to 8 ms  
    # mir-20a 
 
    
                                
                               
2 10 330 0.88 376 0.32 0.00267 0.10   1400 0.50 443 0.38 0.00036 0.90 
3 15 340 0.88 367 0.32 0.00258 0.10   1400 0.50 442 0.38 0.00036 0.90 
4 20 380 0.86 471 0.29 0.00227 0.08   1500 0.46 732 0.45 0.00031 0.92 
5 25 400 0.86 473 0.28 0.00214 0.08   1500 0.46 785 0.47 0.00031 0.92 
average 2-5 363 0.87       0.091   1450 0.48       0.909 
distance r 6.3 6.3 
  
fraction: 9% 
 
8.7 8.7 
  
fraction: 91% 
relSD(tau) 
  
4.6% 10.2% 
   
7.0% 
 
2.0% 10.7% 
   
0.7% 
 
   
fixed 
                  # mir-20a 
 
 
            
   
                
         2 10   
 
2800 357 0.303 
   
1480 0.0000 1291 0.54 
         3 15   
 
2800 354 0.305 
   
1490 0.0000 1291 0.54 
         4 20   
 
2800 418 0.258 
   
1510 0.0000 1410 0.50 
         5 25   
 
2800 418 0.249 
   
1510 0.0000 1412 0.50 
         average 2-5   
 
2800     
    
  1351 0.52 
         distance r 
  
>>R0 
       
8.5 8.5 
         
 
     
  
     
2.6% 10.6% 
           
122 
 
Donor Channel R0 = 8.6 nm 8.6 Fitted from 0.02 to 8 ms  
# mir-20b 
 
                        
 
                        
1 LTC alone                     
2 10 31 0.99 442 0.10 0.55 1700 0.39 356 0.08 0.45 
3 15 40 0.99 260 0.06 0.42 1700 0.39 359 0.09 0.58 
4 20 55 0.98 232 0.06 0.47 1500 0.46 260 0.06 0.53 
5 25 42 0.99 367 0.08 0.53 1500 0.46 324 0.07 0.47 
average 2-5 40 0.99     0.49 1600 0.44     0.51 
distance r (nm) 4.2 4.3   fraction: 49% 9.0 8.9   fraction: 51% 
 
  
12.4% 10.4% 
  
6.1% 
 
3.6% 11.1% 
  
6.0% 
 
   
fixed 
         # mir-20b 
  
            
  
  
              
 1 LTC alone 
  
2800 4171 1.00 
  
2800 
 2 10 
  
2800 3531 0.82 
  
2430 0.00 780 0.72 
 3 15 
  
2800 3523 0.85 
  
2530 0.00 1000 0.64 
 4 20 
  
2800 3703 0.88 
  
2570 0.00 820 0.71 
 5 25 
  
2800 3680 0.84 
  
2470 0.00 730 0.74 
 average 2-5 
  
2800     
  
    830 0.70 
 distance r (nm) 
  
>>R0 
    
  
 
7.4 7.5 
 
 
          
7.1% 10.5% 
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Acceptor Channel R0 = 8.6 nm 8.6 Fitted from 0.2 to 8 ms  
    
# mir-20b 
 
                               
 
                                
                               
2 10             340 0.88 1466 0.51 0.00258 0.27   930 0.67 1127 0.39 0.00072 0.73 
3 15 89 0.97 1202 0.31 0.0109 0.049 410 0.85 1441 0.37 0.00208 0.31   1000 0.64 923 0.24 0.00064 0.64 
4 20 45 0.98 7323 0.70 0.0219 0.121 350 0.88 1620 0.15 0.00250 0.23   940 0.66 1258 0.12 0.00071 0.64 
5 25 120 0.96 1096 0.27 0.0080 0.053 420 0.85 1550 0.38 0.00202 0.29   990 0.65 1113 0.27 0.00065 0.65 
average 2-5 85 0.97       0.074 380 0.86       0.276   965 0.66       0.668 
distance r 4.8 4.8   
fraction: 7% 6.3 6.3   
fraction: 28% 
 
7.7 7.7   
fraction: 67% 
relSD(tau) 
 
22.3% 10.8% relSD(r)  
  
27.3% 
 
5.4% 10.3% 
   
6.0% 
 
1.8% 10.4% 
   
3.3% 
 
   
fixed 
                  
# mir-20b 
 
 
            
   
                
         2 10   
 
2800 309 0.215 
   
1140 0.0000 773 0.72 
         3 15   
 
2800 302 0.124 
   
770 0.0000 773 0.72 
         4 20   
 
2800 319 0.036 
   
300 0.0000 693 0.75 
         5 25   
 
2800 315 0.077 
   
680 0.0000 777 0.72 
         average 2-5   
 
2800     
    
  754 0.73 
         
distance r   
>>R0 
       
7.3 7.3 
         
 
     
  
     
2.7% 10.3% 
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7.3.4. Temporal multiplexed assay matrix 
Figure 7.6. The FRET ratio increment (FR) of miRNA-20a (black) and miRNA-20b (red) in TGi (A) 
and TGii (B). 
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 ,     
 ,     
 ,      
  represent the slopes of four calibration curves when only one of the two 
miRNAs is present in TGi and TGii. For instance,     
  is the slope of the calibration curve of 
miRNA-20a in TGi, et cetera.      and      is the concentration of miRNA-20a or miRNA-20b, 
respectively,     ,      is the FRET ratio increment in TGi and TGii when both miRNA-20a and 
miRNA-20b are present. 
      
125 
 
7.4. Amplified DNA/RNA Assay 
7.4.1. Decay time fitting 
10 bps dsDNA 
Donor Channel R0 = 5.8 nm 5.8 Fitted from 0.02 to 8 ms 
   # Cy5.5 
  
                        
1 0 
     
2 0.5 47 0.98 444 0.05 1.00 
3 1.0 150 0.94 667 0.09 1.00 
4 1.5 150 0.94 1068 0.13 1.00 
5 2.0 170 0.93 1241 0.15 1.00 
6 2.5 180 0.93 1315 0.17 1.00 
7 3.0 190 0.92 1708 0.20 1.00 
average 2-7 150 0.94 
  
1.00 
distance r (nm) 3.7 3.7  
fraction: 100% 
 
   
14.1% 10.5% 
  
0.0% 
 
   
fixed 
         
# Cy5.5 
  
            
  
  
             
 1 0 
  
2400 7675 1.00 
  
2400 
 2 0.5 
  
2400 8129 0.95 
  
 
    3 1.0 
  
2400 6707 0.91 
  
2200 0.00 150 0.94 
 4 1.5 
  
2400 7392 0.87 
  
2120 0.00 150 0.94 
 5 2.0 
  
2400 6801 0.85 
  
2060 0.00 170 0.93 
 6 2.5 
  
2400 6479 0.83 
  
2030 0.00 180 0.93 
 7 3.0 
  
2400 6801 0.80 
  
1960 0.00 190 0.92 
 average 2-7 
  
2400 
  
  
  
170 0.93 
 
distance r (nm) 
  
>>R0 
    
  3.8 3.8 
 
 
          
4.3% 10.2% 
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10 bps dsDNA 
Acceptor Channel R0 = 5.8 nm 5.8 
Fitted from 0.05 to 8 
ms 
          # Cy5.5 
 
                               
 
                                
                               
1 0.0 
                   
2 0.5 
      
160 0.93 2776 0.89 0.00583 0.73 
 
470 0.80 294 0.09 0.00171 0.27 
3 1.0 97 0.96 2276 0.38 0.0099 0.19 210 0.91 3507 0.59 0.00435 0.68 
 
750 0.69 137 0.02 0.00092 0.13 
4 1.5 97 0.96 3918 0.44 0.0099 0.22 220 0.91 4870 0.54 0.00413 0.66 
 
800 0.67 169 0.02 0.00083 0.11 
5 2.0 99 0.96 4250 0.41 0.0097 0.21 220 0.91 5793 0.56 0.00413 0.68 
 
800 0.67 194 0.02 0.00083 0.11 
6 2.5 110 0.95 5298 0.48 0.0087 0.27 230 0.90 5533 0.50 0.00393 0.85 
 
870 0.64 178 0.02 0.00073 0.15 
7 3.0 120 0.95 6967 0.51 0.0079 0.31 230 0.90 6552 0.48 0.00393 0.85 
 
900 0.63 211 0.02 0.00069 0.15 
average 2-
7 
105 0.96 
   
0.241 212 0.91 
   
0.742 
 
765 0.68 
   
0.153 
distance r 3.5 3.5   
fraction: 24% 3.9 3.9   
fraction: 74% 
 
5.1 5.1   
fraction: 15% 
relSD(tau) 
        
5.1% 10.2% 
   
4.8% 
 
8.2% 10.6% 
   
15.3% 
 
   
fixed fixed 
                 # Cy5.5 
 
 
            
   
     
          
         1 0.0 
  
2400 40 1.000 
   
2400 0.0000 
         2 0.5 
  
2400 42 0.014 
   
220 0.0000 242 0.90 
         3 1.0 
  
2400 35 0.006 
   
190 0.0000 256 0.89 
         4 1.5 
  
2400 38 0.004 
   
190 0.0000 259 0.89 
         5 2.0 
  
2400 35 0.003 
   
190 0.0000 259 0.89 
         6 2.5 
  
2400 34 0.003 
   
190 0.0000 354 0.85 
         7 3.0 
  
2400 35 0.003 
   
190 0.0000 371 0.85 
         average 2-
7 
  
2400 
  
    
 
290 0.88 
         
distance r   
>>R0 
       
4.2 4.2 
         
 
           
7.9% 10.3% 
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13 bps dsDNA 
Donor Channel R0 = 5.8 nm 5.8 Fitted from 0.02 to 8 ms 
   # Cy5.5 
  
                        
1 0 
     
2 0.5 1100 0.61 908 0.13 1.00 
3 1.0 1000 0.64 1812 0.27 1.00 
4 1.5 1100 0.61 2419 0.36 1.00 
5 2.0 1100 0.61 3278 0.51 1.00 
6 2.5 1100 0.61 3793 0.57 1.00 
7 3.0 1100 0.61 5006 0.61 1.00 
average 2-7 1080 0.61 
  
1.00 
distance r (nm) 5.4 5.4  
fraction: 100% 
 
   
1.5% 10.4% 
  
0.0% 
 
   
fixed 
         
# Cy5.5 
  
            
  
  
             
 1 0 
  
2800 7091 1.00 
  
2800 
 2 0.5 
  
2800 6069 0.87 
  
 
    3 1.0 
  
2800 5003 0.73 
  
2320 0.00 1000 0.64 
 4 1.5 
  
2800 4238 0.64 
  
2180 0.00 1100 0.61 
 5 2.0 
  
2800 3205 0.49 
  
1940 0.00 1100 0.61 
 6 2.5 
  
2800 2818 0.43 
  
1820 0.00 1100 0.61 
 7 3.0 
  
2800 3205 0.39 
  
1760 0.00 1100 0.61 
 average 2-7 
  
2800 
  
  
  
1080 0.61 
 
distance r (nm) 
  
>>R0 
    
  5.4 5.4 
 
 
          
1.7% 10.4% 
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13 bps dsDNA 
Acceptor Channel R0 = 5.8 nm 5.8 Fitted from 0.05 to 8 ms 
          # Cy5.5 
 
                               
 
                                
                               
1 0.0 
                   
2 0.5 
      
580 0.79 712 0.30 0.00137 0.14 
 
1200 0.57 1565 0.66 0.00048 0.86 
3 1.0 280 0.90 460 0.10 0.0032 0.02 1000 0.64 3771 0.81 0.00064 0.78 
 
1700 0.39 345 0.07 0.00023 0.20 
4 1.5 180 0.94 498 0.08 0.0052 0.01 960 0.66 5018 0.78 0.00068 0.72 
 
1500 0.46 838 0.13 0.00031 0.27 
5 2.0 330 0.88 566 0.07 0.0027 0.02 1000 0.64 7484 0.88 0.00064 0.84 
 
1800 0.36 399 0.05 0.00020 0.15 
6 2.5 
      
890 0.68 6598 0.68 0.00077 0.54 
 
1300 0.54 3017 0.31 0.00041 0.46 
7 3.0 
      
1000 0.64 12203 0.97 0.00064 0.89 
 
2000 0.29 319 0.03 0.00014 0.11 
average 2-
7 
263 0.91 
   
0.015 905 0.68 
   
0.653 
 
1583 0.43 
   
0.340 
distance r 4.0 4.0   
fraction: 1% 5.1 5.1   
fraction: 65% 
 
6.1 6.1   
fraction: 34% 
relSD(tau) 
        
7.4% 10.5% 
   
17.6% 
 
7.9% 11.5% 
   
34.2% 
 
   
fixed fixed 
                 # Cy5.5 
 
 
            
   
     
          
         1 0.0 
  
2600 123 1.000 
   
2600 0.0000 
         2 0.5 
  
2600 106 0.044 
   
1080 0.0000 1115 0.60 
         3 1.0 
  
2600 87 0.019 
   
1010 0.0000 1126 0.60 
         4 1.5 
  
2600 74 0.011 
   
990 0.0000 1097 0.61 
         5 2.0 
  
2600 56 0.007 
   
1000 0.0000 1106 0.61 
         6 2.5 
  
2600 49 0.005 
   
1030 0.0000 1078 0.61 
         7 3.0 
  
2600 56 0.004 
   
1030 0.0000 1105 0.61 
         average 2-
7 
  
2600 
  
    
 
1105 0.61 
         
distance r   
>>R0 
       
5.4 5.4 
         
 
           
0.6% 10.4% 
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15 bps dsDNA 
Donor Channel R0 = 5.8 nm 5.8 Fitted from 0.02 to 8 ms 
   # Cy5.5 
  
                        
1 0 
     
2 0.5 1600 0.43 1022 0.24 1.00 
3 1.0 1600 0.43 1023 0.28 1.00 
4 1.5 1500 0.46 1469 0.41 1.00 
5 2.0 1500 0.46 1863 0.53 1.00 
6 2.5 1500 0.46 2028 0.69 1.00 
7 3.0 1500 0.46 2795 0.63 1.00 
average 2-7 1530 0.45 
  
1.00 
distance r (nm) 6.0 6.0  
fraction: 100% 
 
   
1.4% 10.8% 
  
0.0% 
 
   
fixed 
         
# Cy5.5 
  
            
  
  
             
 1 0 
  
2800 3790 1.00 
  
2800 
 2 0.5 
  
2800 3246 0.76 
  
 
    3 1.0 
  
2800 2673 0.72 
  
2470 0.00 1600 0.43 
 4 1.5 
  
2800 2144 0.59 
  
2270 0.00 1500 0.46 
 5 2.0 
  
2800 1651 0.47 
  
2110 0.00 1500 0.46 
 6 2.5 
  
2800 903 0.31 
  
1900 0.00 1500 0.46 
 7 3.0 
  
2800 1651 0.37 
  
1980 0.00 1500 0.46 
 average 2-7 
  
2800 
  
  
  
1520 0.46 
 
distance r (nm) 
  
>>R0 
    
  6.0 6.0 
 
 
          
1.2% 10.7% 
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15 bps dsDNA 
Acceptor Channel R0 = 5.8 nm 5.8 Fitted from 0.05 to 8 ms 
          # Cy5.5 
 
                               
 
                                
                               
1 0.0 
                   
2 0.5 88 0.97 72 0.09 0.0110 0.00 890 0.68 111 0.14 0.00077 0.07 
 
1600 0.43 542 0.70 0.00027 0.93 
3 1.0 25 0.99 613 0.32 0.0396 0.00 760 0.73 160 0.08 0.00096 0.04 
 
1500 0.46 1111 0.58 0.00031 0.95 
4 1.5 56 0.98 132 0.06 0.0175 0.00 910 0.68 337 0.16 0.00074 0.08 
 
1500 0.46 1561 0.76 0.00031 0.92 
5 2.0 52 0.98 170 0.07 0.0189 0.00 1200 0.57 1332 0.52 0.00048 0.38 
 
1700 0.39 1055 0.41 0.00023 0.62 
6 2.5 
      
1100 0.61 1055 0.33 0.00055 0.20 
 
1600 0.43 2097 0.66 0.00027 0.80 
7 3.0 
      
1300 0.54 2199 0.60 0.00041 0.46 
 
1700 0.39 1437 0.39 0.00023 0.54 
average 2-
7 
55 0.98 
   
0.002 1027 0.63 
   
0.205 
 
1600 0.43 
   
0.793 
distance r 3.0 3.0   
fraction: 0% 5.3 5.3   
fraction: 21% 
 
6.1 6.1   
fraction: 79% 
relSD(tau) 
        
8.2% 10.7% 
   
35.2% 
 
2.3% 10.9% 
   
9.0% 
 
   
fixed fixed 
                 # Cy5.5 
 
 
            
   
     
          
         1 0.0 
  
2700 62 1.000 
   
2700 0.0000 
         2 0.5 
  
2700 53 0.068 
   
1430 0.0000 1548 0.45 
         3 1.0 
  
2700 44 0.023 
   
1000 0.0000 1461 0.48 
         4 1.5 
  
2700 35 0.017 
   
1330 0.0000 1449 0.48 
         5 2.0 
  
2700 27 0.010 
   
1340 0.0000 1508 0.46 
         6 2.5 
  
2700 15 0.005 
   
1440 0.0000 1502 0.46 
         7 3.0 
  
2700 27 0.007 
   
1470 0.0000 1515 0.46 
         average 2-
7 
  
2700 
  
    
 
1497 0.47 
         
distance r   
>>R0 
       
5.9 5.9 
         
 
           
1.0% 10.7% 
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20 bps dsDNA 
Donor Channel R0 = 5.8 nm 5.8 Fitted from 0.02 to 8 ms 
   # Cy5.5 
  
                        
1 0 
     
2 0.5 
 
 
   
3 1.0 2300 0.18 1047 0.28 1.00 
4 1.5 2300 0.18 1523 0.41 1.00 
5 2.0 2200 0.21 1842 0.50 1.00 
6 2.5 2300 0.18 2279 0.63 1.00 
7 3.0 2200 0.21 2645 0.59 1.00 
average 2-7 2260 0.19 
  
1.00 
distance r (nm) 7.4 7.4  
fraction: 100% 
 
   
1.0% 13.7% 
  
0.0% 
 
   
fixed 
         
# Cy5.5 
  
            
  
  
             
 1 0 
  
2800 3776 1.00 
  
2800 
 2 0.5 
  
   
  
 
    3 1.0 
  
2800 2697 0.72 
  
2660 0.00 2300 0.18 
 4 1.5 
  
2800 2159 0.59 
  
2590 0.00 2300 0.18 
 5 2.0 
  
2800 1824 0.50 
  
2500 0.00 2200 0.21 
 6 2.5 
  
2800 1350 0.37 
  
2490 0.00 2300 0.18 
 7 3.0 
  
2800 1824 0.41 
  
2440 0.00 2200 0.21 
 average 2-7 
  
2800 
  
  
  
2260 0.19 
 
distance r (nm) 
  
>>R0 
    
  7.4 7.4 
 
 
          
1.0% 13.7% 
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20 bps dsDNA 
Acceptor Channel R0 = 5.8 nm 5.8 Fitted from 0.05 to 8 ms 
          # Cy5.5 
 
                               
 
                                
                               
1 0.0 
                   
2 0.5 
                   
3 1.0 68 0.98 100 0.19 0.0143 0.00 460 0.84 38 0.07 0.00182 0.01 
 
2000 0.29 265 0.50 0.00014 0.99 
4 1.5 
      
260 0.91 105 0.16 0.00349 0.01 
 
2100 0.25 440 0.68 0.00012 0.99 
5 2.0 48 0.98 292 0.27 0.0205 0.00 600 0.79 88 0.08 0.00131 0.01 
 
2200 0.21 599 0.56 0.00010 0.99 
6 2.5 60 0.98 209 0.19 0.0163 0.00 530 0.81 100 0.09 0.00153 0.01 
 
2200 0.21 757 0.67 0.00010 0.99 
7 3.0 45 0.98 334 0.23 0.0219 0.00 800 0.71 117 0.08 0.00089 0.01 
 
2200 0.21 916 0.63 0.00010 0.98 
average 2-
7 
55 0.98 
   
0.002 530 0.81 
   
0.010 
 
2140 0.24 
   
0.988 
distance r 3.0 3.0   
fraction: 0% 4.6 4.6   
fraction: 1% 
 
7.1 7.1   
fraction: 99% 
relSD(tau) 
        
15.2% 10.6% 
   
9.1% 
 
1.7% 12.8% 
   
0.1% 
 
   
fixed fixed 
                 # Cy5.5 
 
 
            
   
     
          
         1 0.0 
  
2800 182 1.000 
   
2800 0.0000 
         2 0.5 
  
   
    
  
          3 1.0 
  
2800 130 0.244 
   
1720 0.0000 1976 0.29 
         4 1.5 
  
2800 104 0.160 
   
1910 0.0000 2085 0.26 
         5 2.0 
  
2800 88 0.082 
   
1530 0.0000 2178 0.22 
         6 2.5 
  
2800 65 0.058 
   
1690 0.0000 2183 0.22 
         7 3.0 
  
2800 88 0.061 
   
1630 0.0000 2177 0.22 
         average 2-
7 
  
2800 
  
    
 
2120 0.24 
         
distance r   
>>R0 
       
7.0 7.0 
         
 
           
1.7% 12.7% 
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25 bps dsDNA 
Donor Channel R0 = 5.8 nm 5.8 Fitted from 0.02 to 8 ms 
   # Cy5.5 
  
                        
1 0 
     
2 0.5 
 
 
   
3 1.0 1900 0.32 319 0.09 1.00 
4 1.5 2000 0.29 398 0.11 1.00 
5 2.0 1900 0.32 438 0.12 1.00 
6 2.5 1900 0.32 510 0.15 1.00 
7 3.0 1900 0.32 648 0.17 1.00 
average 2-7 1920 0.31 
  
1.00 
distance r (nm) 6.6 6.6  
fraction: 100% 
 
   
1.0% 11.5% 
  
0.0% 
 
   
fixed 
         
# Cy5.5 
  
            
  
  
             
 1 0 
  
2800 3661 1.00 
  
2800 
 2 0.5 
  
   
  
 
    3 1.0 
  
2800 3253 0.91 
  
2720 0.00 1900 0.32 
 4 1.5 
  
2800 3081 0.89 
  
2710 0.00 2000 0.29 
 5 2.0 
  
2800 3091 0.88 
  
2690 0.00 1900 0.32 
 6 2.5 
  
2800 2985 0.85 
  
2670 0.00 1900 0.32 
 7 3.0 
  
2800 3091 0.83 
  
2640 0.00 1900 0.32 
 average 2-7 
  
2800 
  
  
  
1920 0.31 
 
distance r (nm) 
  
>>R0 
    
  6.6 6.6 
 
 
          
1.0% 11.5% 
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25 bps dsDNA 
Acceptor Channel R0 = 5.8 nm 5.8 Fitted from 0.05 to 8 ms 
          # Cy5.5 
 
                               
 
                                
                               
1 0.0 
                   
2 0.5 
                   
3 1.0 65 0.98 339 0.61 0.0150 0.01 460 0.84 71 0.13 0.00182 0.02 
 
2400 0.14 96 0.17 0.00006 0.96 
4 1.5 78 0.97 393 0.60 0.0125 0.01 590 0.79 95 0.14 0.00134 0.02 
 
2500 0.11 121 0.18 0.00004 0.97 
5 2.0 70 0.98 527 0.60 0.0139 0.01 500 0.82 136 0.15 0.00164 0.02 
 
2500 0.11 170 0.19 0.00004 0.97 
6 2.5 64 0.98 684 0.62 0.0153 0.01 440 0.84 158 0.14 0.00192 0.02 
 
2400 0.14 211 0.19 0.00006 0.97 
7 3.0 72 0.97 567 0.55 0.0135 0.01 520 0.81 153 0.15 0.00157 0.02 
 
2500 0.11 256 0.25 0.00004 0.98 
average 2-
7 
70 0.98 
   
0.010 502 0.82 
   
0.021 
 
2460 0.12 
   
0.968 
distance r 3.1 3.1   
fraction: 1% 4.5 4.5   
fraction: 2% 
 
8.1 8.1   
fraction: 97% 
relSD(tau) 
        
4.8% 10.3% 
   
6.3% 
 
0.9% 17.9% 
   
0.2% 
 
   
fixed fixed 
                 # Cy5.5 
 
 
            
   
     
          
         1 0.0 
  
2800 59 1.000 
   
2800 0.0000 
         2 0.5 
  
   
    
  
          3 1.0 
  
2800 52 0.094 
   
770 0.0000 2323 0.17 
         4 1.5 
  
2800 50 0.075 
   
800 0.0000 2428 0.13 
         5 2.0 
  
2800 50 0.056 
   
760 0.0000 2437 0.13 
         6 2.5 
  
2800 48 0.044 
   
690 0.0000 2328 0.17 
         7 3.0 
  
2800 50 0.049 
   
880 0.0000 2452 0.12 
         average 2-
7 
  
2800 
  
    
 
2393 0.15 
         
distance r   
>>R0 
       
7.8 7.8 
         
 
           
1.1% 16.0% 
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9. Synthèse en français  
« Vous pouvez faire correspondre une transfusion sanguine à un groupe sanguin – ce fut 
une découverte importante. Et si faire correspondre un traitement contre le cancer à 
notre code génétique était aussi simple, aussi standard ? Et si déterminer la dose 
adéquate d’un médicament était aussi simple que prendre notre température ? » 
Barack Obama, 30 janvier 2015 
Le dessein dépeint ci-dessus est souhaitable et enthousiasmant, mais néanmoins peu 
simple à mettre en œuvre. Qu’est-ce que le code génétique ? Quelle est la relation entre 
le cancer et le code génétique ? Comment choisir un traitement efficace ? Après 
l’achèvement du Human Genome Project en 2003, il est possible de répondre à la 
première question, cependant la façon dont le code génétique affecte le développement 
d’un cancer reste un problème qui n’a pas été complètement résolu. D’autre part, de 
nouvelles études « -omiques » telles la protéomique, la transcriptomique et la 
métabolomique doivent également être prises en compte. Les nouvelles exigences du 
diagnostic clinique et de la thérapeutique, particulièrement en diagnostic au chevet du 
patient et en médecine de précision – un grand défi pour les scientifiques, les analystes 
et les cliniciens, mais hautement bénéfique pour les patients – ont conduit à une 
demande croissante d’analyses multiplexées et avec un rendement important d’un grand 
nombre de biomolécules (protéines, acides nucléiques, métabolites) au sein d’un 
échantillon unique. Une détection multiplexée de biomarqueurs potentiels ne permet 
pas seulement d’atteindre une très grande précision en termes de diagnostic clinique, 
mais fournit également de plus amples informations dans le cadre du développement 
d’une médecine de précision. Les applications basées sur le transfert d’énergie par 
résonance de type Förster (FRET pour Förster Resonance Energy Transfer) sont parmi 
les techniques les plus prometteuses en regroupant quasiment toutes les exigences d’un 
diagnostic multiplexé, rapide et simple. La technique de FRET acquiert sa popularité 
dans le domaine du diagnostic grâce à la forte dépendance en distance dans les distances 
de travail des interactions biomoléculaires, qui sont de l’ordre de 1 à 20 nm. Le FRET 
est un concept spectroscopique qui peut être vu comme un processus de désactivation 
additionnel d’une molécule excitée (donneur FRET), depuis lequel l’énergie résonante 
est transférée de façon non radiative à l’état fondamental d’une molécule (accepteur 
FRET). Quand deux molécules à reconnaissance de cible différentes sont conjuguées 
avec des fluorophores donneur et accepteur de FRET respectivement, la présence de la 
cible aboutit à la proximité du donneur et de l’accepteur FRET impliquant un 
changement mesurable dans les propriétés photophysiques de la paire de FRET. La plus 
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grande majorité des essais basés sur le FRET sont homogènes par nature et sont 
souvent aussi simples que « mélange et mesure », ce qui a accéléré leur diffusion dans 
les diagnostics cliniques. La Section 2.1 présente le contexte nécessaire pour la 
compréhension du FRET et un cours aperçu des applications basées sur le FRET. 
En raison du nombre croissant d’applications du FRET, de nombreux fluorophores 
différents ont été utilisés en tant que donneur FRET, d’accepteur FRET ou les deux. 
Parmi les choix quasiment illimités de donneurs FRET, le FRET basé sur le complexe 
lanthanide de terbium (LTC pour Lanthanide Terbium Complex) comme donneur 
d’énergie a de nombreux avantages uniques pour la détection biomoléculaire 
multiplexée. Le LTC appartient à la famille des complexes de lanthanides, et en raison 
des transitions intraconfigurationnelles f-f interdites des ions lanthanides centraux 
(forme commune de Ln3+), les complexes de lanthanides présentent des propriétés 
photophysiques distinctes des autres fluorophores, comme les bandes d’émission 
caractéristiques multiples et étroites, et des durées de vie des états excités extrêmement 
longues, qui peuvent aller jusqu’à quelques millisecondes. Le LTC est le choix optimal 
en tant que donneur FRET parmi les membres de la famille des complexes de 
lanthanides. Outre les grandes distances de FRET permettant un FRET efficace, et des 
durées de vie des états excités extrêmement longues, qui permettent la réalisation de 
mesures résolues en temps (Section 2.2.4), un avantage caractéristique de l’utilisation 
du LTC en tant que donneur FRET est la capacité de multiplexage. Les quatre bandes 
d’émission principales du Tb sont bien mieux séparées et donc plus adaptées au 
multiplexage spectral; la durée de vie longue et distinguable des accepteurs sensibilisés 
due à différentes efficacités de FRET assure un grand potentiel pour le multiplexage 
temporel. 
Les caractéristiques photophysiques du LTC offrent de prometteuses capacités de 
multiplexage en tant que donneur FRET, néanmoins, des accepteurs FRET 
parfaitement adaptés aux deux configurations multiplexées (multiplexages spectral et 
temporel) constituent les autres facteurs clés. Les QDs sont des nanocristaux 
semiconducteurs confinant les excitons dans les trois dimensions de l’espace. En raison 
de l’effet de confinement quantique, la photoluminescence (PL) des QDs peut être 
accordée en fonction de leur taille, ce qui signifie que l’on peut synthétiser une série de 
QDs de tailles et donc d’émissions différentes. Des profils d’émission étroits et 
symétriques avec une largeur à mi-hauteur (FWHM pour Full Width at Half Maximum) 
d’environ 25-35 nm peuvent être obtenus avec des QDs de grande qualité. Cette 
caractéristique des QDs est très appropriée pour le multiplexage spectral du fait des 
interférences optiques (optical crosstalk) particulièrement réduites parmi les différents 
canaux de détection (en utilisant des filtres optiques passe – bande pour la séparation de 
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la lumière). Comparée aux colorants organiques traditionnels, l’application des QDs 
dans la biodétection basée sur le FRET apporte bien d’autres avantages dans le cadre du 
défi de nouveaux diagnostics, notamment une grande brillance, une remarquable 
photostabilité et un important décalage de Stokes effectif. Coupler le LTC aux QDs dans 
un modèle de FRET permet de tirer avantage des deux côtés. Des études récentes 
menées dans notre groupe ainsi que dans d’autres équipes montrent que les essais de 
FRET du Tb aux QDs peuvent remplir les conditions nécessaires pour des tests 
diagnostiques, même dans des milieux difficiles comme le sérum ou le plasma, et le 
FRET multiplexé entre le LTC et différents QDs a été démontré pour détecter de 
multiples biomolécules, basé sur le multiplexage spectral, et du FRET allant du Tb 
jusqu’à cinq QDs a déjà été réalisé. 
Pour le multiplexage spectral, les colorants organiques traditionnels constituent 
rarement le meilleur choix. Du fait des interférences optiques manifestes des différents 
colorants causées par leurs larges profils d’émission, une correction est toujours 
nécessaire afin d’obtenir un multiplexage efficace. Cependant, ces colorants organiques 
présentent des propriétés physiques prometteuses pour la réalisation de multiplexage 
temporel. En raison de leurs petites tailles, la plupart des colorants organiques offrent 
un unique site actif pour la conjugaison à des biomolécules, et surtout ils peuvent être 
assimilés à des points lorsqu’on estime la distance entre le donneur et l’accepteur FRET. 
Des distances du donneur à l’accepteur FRET correctement estimées et contrôlables 
peuvent alors être obtenues dans des systèmes biologiques pour la détection multiplexée 
temporelle. L’origine des propriétés photophysiques des sondes photoluminescentes 
utilisées dans ces travaux en tant que donneur et accepteurs FRET, notamment les 
LTCs (Section 2.2), les QDs (Section 2.3) et les colorants organiques (Section 2.4.) sont 
brièvement expliqués, ainsi que leurs avantages et leurs limitations dans différentes 
applications basées sur le FRET. 
Dans ce travail, je me suis focalisée sur deux classes de biomarqueurs particulièrement 
importantes : les biomarqueurs protéiques et les biomarqueurs microARN (miARN). Les 
biomarqueurs protéiques sont utilisés depuis longtemps en diagnostic tant en recherche 
clinique qu’en application clinique. Les protéines circulantes biomarqueurs du cancer 
sont celles dérivant d’une tumeur et circulant dans le sang par voie de sécrétion. Nous 
avons choisi la famille des récepteurs de facteurs de croissance épidermique comme 
modèle pour investiguer l’applicabilité du FRET multiplexé dans les immuno-essais. 
Comparés aux protéines, les miARNs constituent un membre bien plus récent de la 
famille de biomarqueurs, mais ils ont montré un fort potentiel en tant que biomarqueurs 
de nouvelle génération. Plus de 2500 miARNs ont été trouvés chez l’Homme, et ils sont 
fortement impliqués dans le contrôle de l’expression des gènes par interaction avec des 
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ARN messagers cibles. L’homéostasie physiologique des cellules et des tissus est 
maintenue par une régulation complexe ; par conséquent une dérégulation des miARNs 
peut conduire à des maladies comme des cancers ou des maladies cardiovasculaires. Les 
miARNs circulant apparaissent comme étant très stables et ont montré des spectres 
d’expression caractéristiques de types de cancers spécifiques ou de stades de la maladie. 
Un bref aperçu du développement des biomarqueurs et de l’importance des 
biomarqueurs protéiques et des biomarqueurs miARNs ainsi que leurs techniques de 
détection est présenté en Section 2.5. 
A la suite du contexte de ces travaux, trois études individuelles sont présentées. Chaque 
chapitre est constitué d’une introduction, d’une section matériaux et procédés, d’une 
partie résultats et discussion, et d’une conclusion. 
La première étude présente un essai duplexé de deux récepteurs du facteur de 
croissance épidermique EGFR et HER2 basé sur du FRET résolu en temps du LTC vers 
deux QDs commerciaux. L’anticorps présente une liaison spécifique à l’antigène ainsi 
qu’une forte affinité, cependant il peut être moins pratique du point de vue du FRET du 
fait des grandes dimensions du complexe anticorps-antigène-anticorps résultant. Le 
FRET peut se faire avec d’autres anticorps avec les mêmes spécificités mais des tailles 
réduites. Le fragment de liaison à l’antigène (Fab pour Fragment antigen-binding) est 
une région de l’anticorps composée d’un domaine constant et d’un domaine variable sur 
chacune des chaînes lourde et légère, qui détermine la spécificité de la liaison à 
l’antigène. Les fragments Fab peuvent être générés en laboratoire par clivage de 
l’anticorps par une enzyme. Un anticorps à domaine unique (sdAb pour single-domain 
antibody) est un fragment d’anticorps consistant en un domaine d’anticorps 
monomérique unique et variable, ce qui constitue le plus petit anticorps disponible à ce 
jour. Pour être utilisés dans une configuration de FRET, deux anticorps se liant à 
différents épitopes de l’antigène sont conjugués avec le LTC et un QD respectivement. 
Différentes méthodes de bioconjugaison covalente comme le couplage entre un ester N-
hydroxysuccinimide et une amine primaire, ou celui entre un groupement maleimide et 
un groupement thiol/cystéine ont été réalisées et comparées. En tirant parti de la facilité 
de la manipulation des modifications terminales des sdAb, on peut créer, grâce à des 
techniques de biologie moléculaire standard, des anticorps présentant des cystéines, et 
ainsi réaliser un marquage orienté et le comparer à des marquages aléatoires. Une 
caractérisation spectroscopique détaillée des conjugués de LTC et de QD a été réalisée 
avant et après la conjugaison avec différents types d’anticorps (mAb, Fab et sdAb) en 
utilisant la spectroscopie d’absorption UV/Vis stationnaire et la spectroscopie de 
luminescence stationnaire et résolue en temps afin d’estimer le nombre d’anticorps par 
luminophore et de vérifier toute altération des propriétés photophysiques due à la 
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conjugaison de la biomolécule. En réalisant l’investigation systématique des différents 
immuno-essais de FRET basés sur toutes les sortes d’anticorps et sur deux QDs à des 
longueurs d’onde d’émission différentes (nanocristaux eFluor 605/650), nous avons 
trouvé que différents paramètres – la taille des anticorps, leur orientation sur les QDs – 
affectent les performances des mesures de FRET et nous suggérons qu’ils soient pris en 
compte lors de l’élaboration des immuno-essais basés sur le FRET. Nous montrons 
également des résultats prometteurs pour un essai duplexé simultané de EGFR et de 
HER2. Les essais homogènes présentent des limites de détection sub-nM (quelques 
ng/mL) pour EGFR et HER2 dans des échantillons de 50 μL et ont été conçus pour des 
applications sur un lecteur de microplaques à fluorescence agréé dans le cadre du 
diagnostic clinique. 
Dans la seconde étude, j’ai dans un premier temps appliqué l’essai de FRET multiplexé 
spectral (un seul type de LTC vers plusieurs QDs) à la détection de miARN. Du fait de la 
longueur très courte des miARNs, il n’est pas judicieux d’utiliser une hybridation 
traditionnelle en sandwich (qui est similaire à l’immuno-essai présenté ci-dessus, où 
deux anticorps différents conjugués au LTC ou à un QD sont liés à différents épitopes 
d’un unique antigène) ; il est préférable que le miARN soit reconnu par une sonde ADN 
unique. Le principe de reconnaissance des sondes LTC et QD et des biomarqueurs 
miARN est basé sur l’appariement et l’empilement des bases d’ARN/ADN. Le senseur 
miARN unique contenait un QD unique avec un brin d’ADN court (QD-ADN, 7-8 bases) 
et un LTC avec un brin d’ADN plus long (LTC-ADN, 30-31 bases), et QD-ADN pouvait 
se lier spécifiquement à une partie du LTC-ADN avec métastabilité, ce qui signifie que 
la liaison entre eux n’était pas stable sous certaines conditions (température ambiante 
par exemple). Quand la cible miARN était présente, elle se liait spécifiquement à l’autre 
partie du LTC-ADN, et l’hybridation du miARN et du LTC-ADN pouvait stabiliser la 
liaison entre le QD-ADN court et le LTC-ADN basé sur l’ « effet d’empilement », et 
mener à la proximité entre le LTC et le QD pour faire du FRET. En ce qui concerne 
l’essai multiplexé de miARNs, j’ai conçu trois LTC-ADNs spécifiques des trois miARNs 
et conjugué trois QDs commerciaux, QD605, QD655 and QD705 (Qdot 605/655/705 
ITK™ Streptavidin Conjugate Kits), avec trois ADNs courts, respectivement. De façon à 
démontrer l’entière capacité de multiplexage de notre essai, nous avons détecté les trois 
miARNs hsa-miR-20a-5p (miRNA-20a, mir-20a), hsa-miR-20b-5p (miRNA-20b, mir-20b) 
et hsa-miR-21-5p (miRNA-21, mir-21), dont deux contiennent seulement deux 
mésappariements. L’effet d’empilement a montré une très grande capacité à distinguer 
les mésappariements terminaux entre miRNA-20a et miRNA-20b. L’essai multiplexé ne 
nécessitait pas d’étape de lavage ou de séparation ni l’addition d’enzymes, et comme 
seules des hybridations simples étaient impliquées, l’essai pouvait être réalisé en 30 min 
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d’incubation. Nous avons également effectué des mesures multiplexées précises de ces 
miARNs à des concentrations variables, et démontré la faisabilité de l’adaptation de la 
technologie aux examens au chevet du patient (POCT pour point-of-care testing) dans 
un tampon contenant 10% de sérum. Le second senseur multiplexé est une version 
améliorée du premier, et nous avons démontré pour la première fois avec succès un essai 
de miARN en FRET multiplexé d’un LTC à un QD unique. Nous avons accompli ceci en 
appliquant différents auto-assemblages de QD pour contrôler les distances entre 
donneur et accepteur FRET et pour obtenir des courbes de décroissance de PL 
distinguables. Le QD que nous avons utilisé dans ces systèmes était le même conjugué 
commercial QD-streptavidine que dans le précédent senseur, où la streptavidine était 
attachée de façon covalente au revêtement intérieur amphiphile sans ligand au PEG, ce 
qui permettait plus de liberté pour le co-assemblage d’autres biomolécules aux QDs. 
L’ADN avec une terminaison modifiée avec une séquence de poly-histidine (His6) permet 
son auto-assemblage rapide au QD via une coordination d’affinité au métal, et de façon 
plus importante, implique un FRET plus efficace dû à l’attachement direct de la poly-
histidine à la surface inorganique du QD comparé à l’assemblage streptavidine-biotine 
(sAv-biot) et conduit à une décroissance de durée de vie de l’état excité du QD 
distinguable pour le multiplexage temporel. L’ADN modifié pour présenter soit une 
biotine terminale, soit une séquence peptidylique oligo-histidine a été assemblé à une 
streptavidine / un QD amphiphilique et a servi de molécule de capture du QD pour 
s’approcher du LTC. Deux fenêtres de détection temporelle (0,1-1 ms et 4-8 ms) ont été 
utilisées pour collecter les contributions distinctes de deux miARNs dans ces deux 
fenêtres. Une méthode rapide et homogène pour détecter miRNA-20a et miRNA-20b de 
façon sensible et hautement sélective dans un échantillon unique de 150 μL a été 
réalisée basée sur le FRET d’un LTC unique vers un QD unique. Nous avons réalisé un 
multiplexage à la fois spectral et temporel basé sur le FRET du LTC vers un QD. 
Dans la troisième étude, j’ai d’abord démontré un moyen plus direct de contrôler 
l’efficacité de FRET en investiguant la dépendance de la distance entre donneur et 
accepteur de l’efficacité de FRET du LTC à Cy5.5 en utilisant différentes longueurs de 
dsDNAs, et j’ai obtenu une excellente correspondance entre les distances estimées 
(basées sur la structure définie des dsDNAs) et les distances mesurées (basées sur la 
relation entre efficacité de FRET et distance) ; ainsi, nous avons pu contrôler 
simplement l’efficacité de FRET en contrôlant la distance entre les fluorophores donneur 
et accepteur. Grâce aux courbes de décroissance distinctes des colorants sensibilisés 
depuis différentes longueurs de dsDNAs, nous avons pu réaliser du multiplexage 
temporel. Nous l’avons ensuite intégré dans une amplification par cercle roulant (RCA 
pour rolling circle amplification) amorcée par cible pour la détection homogène en 
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multiplexage temporel hautement sensible de ssDNA. La RCA génère de façon 
isotherme de longs ssDNAs avec une séquence en tandem utilisant des précurseurs 
aléatoires, une ADN-polymérase et un modèle d’amplification circulaire formé en 
joignant les extrémités 5’-PO4 et 3’-OH d’une sonde pré-circulaire utilisant l’acide 
nucléique cible comme modèles de jonction. Les cibles peuvent être amplifiées 10000 fois 
en quelques heures en utilisant la RCA. Après la formation de produits de RCA, les 
oligonucléotides marqués au LTC et ceux marqués au Cy5.5 (selon les produits de RCA) 
s’hybrident avec certains endroits des produits de RCA et la détection est basée sur le 
FRET résolu en temps du LTC au Cy5.5. En se fondant sur la dépendance en distance 
de l’efficacité de FRET, nous avons conçu les sondes LTC et Cy5.5 de façon à ce qu’elles 
soient séparées de séquences de 10, 13 et 18 paires de bases pour ssDNA/miRNA-20a, 
ssDNA/miRNA-20b et ssDNA/miRNA-21 respectivement, afin de réaliser du 
multiplexage temporel. L’amplification isotherme de la RCA permet une température de 
travail constante et basse (≤37°C). Cet essai de FRET amplifié ne nécessitait pas non 
plus d’étapes de lavage ou de séparation et assurait une détection FRET-RCA homogène 
du ssDNA (analogue au miARN) avec une limite de détection de quelques fM. 
Un résumé des résultats obtenus et des conclusions, de même qu’une perspective des 
développements futurs sont donnés dans le dernier chapitre. L’appendice consiste en la 
liste des abréviations, les protocoles détaillés de bioconjugaison, le modèle de correction 
mathématique, les tables d’ajustement des courbes de décroissance, les informations 
graphiques complémentaires et la bibliograpie.  
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épidermique) ou de microARNs (hsa-miR-20a-
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très faibles limites de détection. J’ai utilisé 
différentes stratégies afin d’obtenir des 
détections multiplexées telles la détection 
multiplexée spectrale basée sur les différents 
spectres d’émission de différents luminophores, 
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les durées de vie distinctes des états excités des 
luminophores. Ces travaux ne sont pas 
seulement une recherche appliquée qui peut être 
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Abstract: The new mission of clinical 
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and high throughput analyses of large numbers 
of biomolecules within a single sample. The 
thesis focuses on developing multiplexed 
biosensors based on time-resolved Förster 
resonance energy transfer from lanthanide 
complexes to organic dyes or quantum dots. I 
present several new techniques to 
simultaneously and multiplexed detect cancer 
related protein biomarkers (human epidermal 
growth factor receptor) or microRNAs (hsa- 
miR-20a-5p, 
hsa-miR-20b-5p and hsa-miR-21-5p) with very 
low limits of detections. I have used different 
strategies to achieve multiplexed detections 
such as spectral multiplexed detection based on 
different emission spectra of different 
luminophores, and temporal multiplexed 
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an applied research that can be used in clinical 
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